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from companion animals and potential reservoirs of antibacterial resistance in 
humans. 
 
 
Andrea Catherine Scott  -  May 2018 
 
Abstract 
 
Antimicrobial resistance (AMR) is a multifactorial and complex issue, affecting 
healthcare worldwide. This is an escalating concern, highlighted by European and 
International bodies. AMR is not only a concern in human health but also animal 
health.  The close interface between people, pets, food production animals and the 
environment exemplifies the importance that these two areas of health should not 
be considered as independent factions.  Pseudomonas aeruginosa is a formidable 
pathogen due to its innate resistance making it naturally insensitive to many classes 
of antimicrobials, alongside its ability to acquire further resistance mechanisms.  P. 
aeruginosa in the veterinary setting is a clinically relevant pathogen often 
associated with disease.   
 
In this project, I determined the susceptibility of a set of veterinary clinical P. 
aeruginosa isolates (n=24) to polymyxin antibiotics, colistin (polymyxin E) and 
polymyxin B, by broth micro dilution and showed that the MICs for polymyxin B to 
be significantly higher than in a panel of human P. aeruginosa isolates (n= 37). 
Resistance to other antibiotics used in human medicine was low but higher levels of 
resistance were detected to ticarcillin (21%), and also to marbofloxacin (21%) and 
enrofloxacin (33%), these being two widely used veterinary antibiotics.  Using the 
array tube typing method, the P. aeruginosa veterinary isolates were found to be 
distributed throughout the P. aeruginosa population, with shared array types from 
human infections such as keratitis and respiratory infections.  Using whole genome 
sequencing on a limited subset of isolates, the veterinary isolates were generally 
clustered within the main P. aeruginosa population; however one isolate, did not 
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cluster with any other previously sequenced isolate. The genome sequencing also 
revealed that isolates had mutations in genes associated with polymyxin resistance 
and other antimicrobial resistance-related genes.  These findings may suggest that 
treating animal infections with antimicrobials could lead to resistance in isolates 
capable of causing human infections.   
 
The prevalence of resistance to beta-lactams, aminoglycosides and 
fluoroquinolones in isolates from companion animals particularly in P. aeruginosa is 
a relatively understudied area.  Here, the resistance characteristics of a set of P. 
aeruginosa isolates from companion animals (n=106), collected, at the Veterinary 
Diagnostic laboratory (VDL) at the Small Animal Teaching Hospital, Leahurst 
(University of Liverpool, UK) was investigated.  Several resistance genes including 
those relating to ESBLs (blaTEM, blaSHV and blaOXA) and those relating to 
fluroquinolone resistance (qnr) were identified.  In particular the identification of 
qnrA and qnrB genes in P.aeruginosa isolates of companion animal origin is a novel 
finding with no known reports to current date in the UK.  Of the 8 confirmed 
sequenced positive amplicons they comprised 7 different isolates all canine in 
origin.  Multidrug resistance was also demonstrated among some isolates.  
These findings further support the likelihood that companion animals are an 
understudied source of antimicrobial resistant P. aeruginosa isolates, and merit 
sustained surveillance of the veterinary niche as a potential reservoir for resistant, 
clinically-relevant bacteria. 
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Chapter 1 : Introduction 
 
1.1 Pseudomonas aeruginosa  
 
P. aeruginosa features and habitats 
Pseudomonas aeruginosa is a Gram negative rod shaped aerobic bacterium that is 
motile with a single polar flagella and can act as an opportunistic pathogen.  Key 
features of the bacterium are listed in Table 1.1 P. aeruginosa is metabolically 
versatile and can grow both aerobically and as a facultative anaerobe, in addition to 
utilising other metabolic systems (such as those using nitrate or benzoate) thus 
contributing to its ability to be both ubiquitous and opportunistic in nature.  These 
factors also explain the organisms’ presence in numerous environments, including 
within natural water sources such as lakes and marshes, in soil and also within both 
the hospital and community environments (Khan & Cerniglia, 1994).  P. aeruginosa 
may be isolated from hospital respiratory ventilator equipment, antiseptics, sinks 
and cleaning equipment  (Trautmann et al, 2008; Trautmann et al, 2005).  In the 
non-hospital environment reservoirs have been reported in recreational water 
venues such as poorly maintained swimming pools, hot tubs, whirlpools, spas 
(Ratnam, 1986) and also in contact lens cleaning solution, (Dutta et al, 2012; Kaye et 
al., 2017) soil and vegetables (Correa et al, 1991; Deredjian et al., 2014; Green et al, 
1974; Khan & Cerniglia, 1994; Mena et al., 2008; Youenou et al, 2014).  
 
Table 1.1 Key features of P. aeruginosa features  
 
Description Gram negative rod shaped aerobic bacterium that is motile with a single polar 
flagella and can act as an opportunistic pathogen 
 
Diversity Found in diverse environments including water (Cabral, 2010), soil, sewage 
(Slekovec et al., 2012) and also humans, animals and plants  
 
Form Found in planktonic forms or biofilms (O’Tool et al, 2000) 
 
Colony types Variable, smooth or mucoid in appearance; 
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Wild-type isolates found naturally from soil or water frequently produce a small, 
rough colony. Clinical isolates are usually either a large, smooth colony type with 
flat edges and elevated appearance. Or, they may have a mucoid appearance, 
this colony type being associated with the over production of the polysaccharide 
alginate and are typically found in those samples from the respiratory and 
urinary tract (Cole et al, 2014; Distefano, 2015). 
 
Pigment production P. aeruginosa can produce a variety of pigments; Pyocyanin a blue coloured 
phenzine pigment; 
Pyoverdine a siderophore, involved in iron metabolism, it is a yellow-green 
brightly fluroscent pigment; 
Pyorubin a red brown pigment; 
Pyomelanin a brown pigment, melanin like compound synthesized from tyrosine. 
(Lau et al 2004) 
 
 
P. aeruginosa genome 
P. aeruginosa has a comparatively large genome of approximately 6.3 million base 
pairs (Mbp) (referred to in Figure 1.1). It is known to consist of a main conserved 
core genome and variable accessory segment (Stover C-K., et al 2000). It has been 
estimated that approximately 10% of its genome varies from strain to strain (Ozer 
et al 2014) and is thus referred to as the accessory genome. Genetic elements 
within the accessory genome of P. aeruginosa have been associated with 
differences in virulence and antibiotic resistance (Kung et al , 2010; Ozer et al., 
2014).  Virulence factors associated with P. aeruginosa include flagella, adhesion 
and extracellular proteins, or secondary metabolites that have proteolytic/cytotoxic 
activity (such as exotoxin A, elastase, proteases, pyocyanin, hemolysins) (Driscoll et 
al, 2007).  The known virulence factors of P. aeruginosa are reported in Table 1.2. 
 
P. aeruginosa infection process and virulence  
The P. aeruginosa infection process consists of three stages; bacterial adhesion and 
colonization; local invasion; and disseminated systemic disease (Strateva & Mitov, 
2011). The colonization phase, primarily involves the cell-associated virulence 
factors (Table 1.2). The infectious stage (which may then develop to either an acute 
infection or a chronic infection) is characterized by the production of extracellular 
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virulence factors.  In acute infections high production of these factors are typical, 
whereas inchronic infections lower amounts of these determinants are produced 
(Strateva & Mitov, 2011). 
 
P. aeruginosa virulence factors and quorum sensing 
The virulence of P. aerurginosa depends on a varied number of both cell-associated 
and extracellular factors (Table 1.2).  The majority of P. aeruginosa infections are 
both invasive and toxinogenic.  Many of the extracellular virulence factors 
(proteases, exotoxin A, pyocyanin, siderophores, haemolysins) are controlled by 
quorum sensing (QS).  This is a cell-to-cell signaling system that enables the bacteria 
to produce these factors in a coordinated, cell-density-dependent manner and 
overwhelm the host defense mechanisms during acute infection. The QS system can 
also contribute to biofilm formation and so may participate in the pathogenesis of 
chronic infection.  Two-component sensor kinases such as RetS, LadS and GacS are 
also recognized as controlling the production of virulence factors as well as the 
switch from acute to chronic infection (Jimenez et al., 2012). 
As mentioned, the production of many of the virulence factors is regulated by 
quorum sensing (QS), a bacterial cell-to-cell communication mechanism.  There 
exists two well defined QS systems in P. aeruginosa, the las and rhl systems 
(Pearson et al 1997; Pesci et al., 1997) although two other system have also been 
identified (pqs and iqs).  These rely on auto-inducer signal molecules (n N-acyl 
homoserine lactone molecules, or other molecules whose production depends on S-
adenosylmethionine as a substrate).  Auto-inducers are produced in the cell and 
freely diffuse across the inner and outer membranes.  These molecules accumulate 
in the environment as the bacterial population density increases, and bacteria track 
this information and collectively alter gene expression. QS controls genes that direct 
activities that are beneficial when performed by groups of bacteria acting in 
synchrony. The term “fitness” is used to describe this ability to adjust metabolism to 
suit the environmental conditions, in order to survive and grow (Beceiro et al., 
2013; Millan et al., 2015).  Processes controlled by QS include bioluminescence, 
sporulation, competence, antibiotic production, biofilm formation, and virulence 
factor secretion (Ruparell et al., 2016; Karatuna & Yagci, 2010) 
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Figure 1.1 P.aeruginosa (PA01) genome sequence (Pseudomonas Genome 
Database 
Table 1.2 Summary of the Virulence Determinants of Pathogenic Pseudomonas 
aeruginosa   Table adapted from (Strateva & Mitov, 2011) 
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Virulence Factors Cell 
associated 
factors 
Extra cellular 
factors 
Adhesins 
Type IV pili (N-methyl-phenylalanine pili) 
Polysaccharide capsule (glycocalyx) 
Alginate slime (biofilm) 
Carbohydrate-binding 
Proteins (lectins) 
 
 





 
 
Adhesion Facilitation 
Neuraminidase (sialidase) 
 
 

 
Invasins 
Elastases (LasB and LasA) 
Alkaline protease 
Haemolysins (phospholipase and rhamnolipid) 
Cytotoxin (leukocidin) 
Siderophores and siderophore uptake systems 
Pyocyanin diffusible pigment 
 
  







 
Motility/chemotaxis 
Flagella (swimming motility) 
Retractile pili (twitching motility) 
 
 


 
Toxinogenesis 
Exotoxin A 
Lipopolysaccharide (endotoxin) 
LecA and LecB lectins  
Type III effector cytotoxins (ExoS, ExoU, ExoT, 
ExoY) 
Enterotoxin 
 
 



 
 






 
Antiphagocytic surface properties 
Capsules, slime layers 
Lipopolysaccharide 
Biofilm  
 
 



 
 

 
Defense against serum bactericidal reaction 
Slime layers, capsules, biofilm 
Lipopolysaccharide 
 


 
 

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Protease enzymes 
 
 
 
Defense against immune responses 
Capsules, slime layers, biofilm 
Protease enzymes 
 
 

 
 


 
Genetic attributes 
Genetic exchange by transduction and 
conjugation 
Inherent (natural) drug resistance 
R factors and drug resistance plasmids 
 
 
N/A 
 
N/A 
Ecological criteria 
Adaptability to minimal nutritional requirements 
Metabolic diversity 
Widespread occurrence in a variety of habitats 
 
 
N/A 
 
N/A 
 
 
1.2  P. aeruginosa infections in humans  
 
Introduction  
P. aeruginosa is rarely the primary cause of infections in healthy individuals.  
However, as an opportunistic pathogen it is a known cause of disease in the 
immune-compromised host (for example in severe burns, cystic fibrosis, diabetes 
mellitus, cancer patients).  P. aeruginosa is a serious pathogen in hospitals (Shorr 
2009), accounting for approximately 10% of all such infections in most European 
Union hospitals.  According to the Centre for Disease Control and Prevention (CDC) 
of the United States, P. aeruginosa is the fourth most commonly-isolated 
nosocomial pathogen, responsible for 10.1% of all hospital acquired infections 
(HAIs) (Centre for Disease Control and Prevention, 2013).  This is similar to that 
reported in European hospitals (De Bentzmann & Plésiat, 2011). In the CDC 
Antibiotic Resistant Threats in US Report of 2013, approximately 13% of hospital 
acquired P. aeruginosa infections were multidrug resistant (Centre for Disease 
Control and Prevention, 2013).  P. aeruginosa is a cause of severe hospital-acquired 
(nosocomial) infections such as pneumonia (ventilator associated, VAP) and is 
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involved in the etiology of several diseases including bronchopneumonia, ocular, 
burn and wound infections, bacteremia, endocarditis and meningitis.  The organism 
most commonly affects the lower respiratory system in humans and is an important 
respiratory pathogen in patients with cystic fibrosis (CF) and also other chronic lung 
diseases such as non-CF bronchiectasis and severe chronic obstructive pulmonary 
disease (COPD) (Govan et al, 2007). 
 
P. aeruginosa is a known cause of bacteraemia and this is associated with significant 
mortality and morbidity.  Mortality rates within the first 3-5 days of the onset of 
bacteremia are high and fifty percent of isolates are resistant to the standard 
antibiotics used in empirical treatment.  Poorer clinical outcomes have also been 
demonstrated with pneumonia caused by infections due to P. aeruginosa due to 
associated multidrug resistance of the organism (Tam et al., 2010).  P. aeruginosa is 
reported as the most common Gram-negative pathogen causing nosocomial 
pneumonia in the United States, and it is frequently implicated in hospital-acquired 
urinary tract and bloodstream infections (Peleg et al, 2010; Mehrad et al, 2015) 
 
 
 
Specific P. aeruginosa human infections including some epidemiology and 
prevalences 
  
Bacteremia 
A UK government (UKGov, 2017) Public Health England (PHE) Infection Surveillance 
report looking at bloodstream infections showed that the overall rate of 
Pseudomonas as 6.2 per 100,000 population (July 2015) which was an 11% decrease 
from 2007 (the analyses of this report were based on data relating to diagnoses of 
Pseudomonas spp. and Stenotrophomonas spp. bacteramia 2007 – 2014 in England, 
Wales and Northern Ireland.  The most frequently identified Pseudomonas species 
in blood isolates in 2014, according to the same surveillance report, was P. 
aeruginosa at 81%. The proportion of which were reported as resistant to one of 
the key antimicrobials in 2014 remained steady or increased slightly compared to 
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2013.  A steady increase in reported resistance of Pseudomonas isolates to 
piperacillin/tazobactam was observed reported 2010-2014 from 7%-10%. In 
England, dual resistance to ciprofloxacin and ceftazidime was reported in 2% of 
Pseudomonas spp. bacteraemia.  Imipenem resistance increased the most from 13% 
of isolates in 2013 to 16% isolates in 2014.  In 2014 the proportion of resistant 
Pseudomonas spp. bacteraemia isolates reported was 10% piperacillin/tazobactam, 
11% ciprofloxacin, 7% ceftazidime, 10% meropenem, 16% imipenem and 4% 
gentamicin.  
Comparatively, a US study (Larru et al., 2016) evaluated the epidemiology and 
antimicrobial resistance of bloodstream infections occurring during an 11-year 
period in a large, tertiary care children's hospital in the United States and found 
20% of these infections to be ESKAPE (includes P. aeruginosa) pathogen in origin. 
No clinically significant increases in ceftazidime-resistant P. aeruginosa were 
observed during the study, although MRSA rates did increase over time (Larru et al., 
2016). 
 
 
Keratitis   
In humans P. aeruginosa is a known problem in contact lens wearers, were it can be 
a common cause of ulcerative keratitis (Stapleton et al, 1995). Ulcerative keratitis is 
a rare, but potentially serious, complication of cosmetic contact lens wear.  It has 
the potential to affect vision and cause blindness (Austin et al, 2017; Zegans et al., 
2016).  There are several different types of microbes that colonize lenses and can 
lead to infection and inflammation, but one of the most common causes of 
microbial keratitis remains P. aeruginosa. Its ability to produce proteases, to either 
invade or kill corneal cells, and to coordinate expression of virulence factors via 
quorum-sensing have been shown to be important during microbial keratitis. 
Another important factor that contributes to the destruction of the cornea during 
microbial keratitis is excessive activation of the host defense system. P. aeruginosa 
can activate several pathways of the immune system and activation often involves 
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receptors on the corneal epithelial cells called toll-like receptors (Hazlett, 2004; 
Willcox, 2007).  P. aeruginosa has a tendency to adhere to the contact lens surface 
and is transferred over scratched corneal epithelium penetrating the cornea's 
deeper layers and leading corneal ulcers. Permanent blindness can be caused by a 
severe infection. The lens, ocular environment, and storage case may offer an 
appropriate survival niche for the organism to adhere to and colonize lens materials 
during wear and storage (Hedayati, et al 2015). 
 
A 2015 retrospective case control study (Vazirani et al, 2015) looked at ninety 
episodes of P. aeruginosa keratitis from a tertiary care eye institution from 2007 -
2014 (23 multi-drug resistant as cases and 67 episodes drug-sensitive as controls).  
Antimicrobial resistance in the MDR P.aeruginosa keratitis isolates lowest for both 
colistin and imipenem at 56.52% each. Complications (such as corneal perforation, 
cyanoacrylate glue application and keratoplasty) were more common in when 
infections involved MDR isolate. Studies report that various factors, such as the use 
of ocular lubricant, a compromised ocular surface, and bandage contact lens are 
associated with MDR (multi-drug resistant) P. aeruginosa keratitis. An addition, 
preservative-free lubricant ointment may act as a source or reservoir of infection in 
this condition (Vazirani et al., 2015).  A 2015 study by (Hedayati et al., 2015) looked 
at contact lens wearers in Iran with 26 patients at a hospital from 2012-2013. With 
a low number (8 samples) of the scraped ulcers being reported as sterile, and of the 
positive cultures, 80% isolated P. aeruginosa.  In this particular study 84% of the 
microorganism cases were sensitive to ciprofloxacin, while imipenem, meropenem, 
and ceftazidime were the second most effective antibiotics (susceptibilities tested 
by disc diffusion method). The percentage of isolates sensitive to imipenem, were 
somewhat higher in this study. Colistin susceptibility here was not tested however.  
Fernandes et al (Fernandes et al 2016) specifically looked at extensively and pan 
drug resistant P. aeruginosa keratitis.  In their study (of 15 eyes from 13 different 
patients, at an Eye Institute in India 2009-2013) 40% were sensitive only to 
imipenem, 20% to colistin, 13.3% to neomycin and 6.7% each to imipenem and 
colistin, impienem and ceftazidime and azithromycin respectively (susceptibilities 
tested by disc diffusion method).  The imipenem resistance in this study was higher 
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but it specifically looked at those isolates that were MDR from the Opthalmology 
Microbiology Unit.  By comparison a larger UK study (in the area of Kent) over a ten 
year period to 2008 (Shalchi et al, 2011) looked at corneal scrapings isolate 
sensitivity to chloramphenicol, cefuroxime, gentamicin and ciprofloxacin.  This was 
determined by microdilution (using Microscan System).  The study assessed 476 
scrapes from 440 patients.  Bacterial keratitis accounted for 162 isolates (94.2%), of 
which 99 (61.1%) were Gram-negative. There was a general increase in the number 
of Gram-negative isolates with time.  Testing showed widespread Gram-negative 
resistance to chloramphenicol (74.1%), with reducing sensitivity over the time 
frame of the study. There was 97.3% sensitivity to combination gentamicin and 
cefuroxime, and 94.4% sensitivity to ciprofloxacin.  
 
Cystic Fibrosis 
In patients with CF, P. aeruginosa is the major pathogen and is the major cause of 
morbidity and mortality (Hirsch & Tam, 2011; Tam et al., 2010).  It has a high 
prevalence and once established, a chronic infection with mucoid strains almost 
inevitably occurs. Treatment strategies may involve controlling infection or 
attempting to eradicate the organism in the early stages of infection. Inhaled 
antibiotics are a mainstay of maintenance therapy while intravenous antibiotics are 
usually required if pulmonary exacerbations develop.  
Good hygiene measures are important in prevention and to limit cross-infection in 
patients.  A large variety of P. aeruginosa strains are seen to infect CF patients and it 
is common for the same clone type to persist in the airways of CF patients (Marvig 
et al 2014) (Johansen et al, 2008).  P. aeruginosa populations within the lung in 
infected CF patients are highly diverse and dynamic and extreme diversification 
within a specific strain type during a chronic infection has been observed (Ashish et 
al, 2012; Hogardt & Heesemann, 2010).  There may be impaired mucociliary 
clearance or dysfunction of antibacterial peptides, increased availability of bacterial 
receptors, reduced ingestion of pathogens by CF cells and impaired defences 
(related to low levels of molecules such as nitric oxide or glutathione).  Conversion 
to mucoid colony types and the formation of biofilms are successful mechanisms by 
which the organism then enhances its survival and avoids host defences in the 
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established infection. 
 
 
1.3 Circulating P. aeruginosa strain types in humans and diversity of the population 
structure 
 
The genome of P. aeruginosa is large and complex and its size ranges from 5.2-
7Mbp.  It is known to consist of a main core genome and a variable accessory 
segment.  The core genome demonstrates low variability of nucleotide divergence 
(0.5%) and multiple alleles at a few loci that are subject to diversifying selection 
(Wiehlmann et al., 2007; Smith et al., 2005).  The accessory portion of the genome 
constitutes genomic islands and islets that are highly variable (Kung et al., 2010).  
Typing of particular traits allows identification of bacterial isolates to the strain 
level.  MLST (multilocus sequence typing) is a typing scheme that uses sequence 
data of DNA fragments of seven housekeeping genes (Wiehlmann et al., 2007).  
MLST represents the genetic diversity of the 7 genes, which are all confined to the 
core genome.  MLST databases are published for multiple species of bacteria 
including P. aeruginosa.  The P.aeruginosa isolate that was first sequenced was 
PA01, a reference strain widely used in laboratories and research studies (Curran at 
al., 2004).  This strain is 6.3Mbp and contains 5570 predicted open reading frames.  
The P. aeruginosa genome contains a large number of genes predicted to encode 
outer membrane proteins involved in adhesion, motility, antibiotic efflux, virulence 
factors, export and environmental sensing by two-component systems.  There are 
also a large number of genes encoding transport systems and enzymes involved in 
nutrient uptake and metabolism (Stover et al., 2000).  The large genome allows P. 
aeruginosa to be highly adaptable to many different environments and can utilize a 
variety of carbon sources. 
A great number of other P.aeruginosa isolates have also subsequently been genome 
sequenced allowing important comparative genomic studies (Mathee et al., 2008; 
Roy et al., 2010; Valot et al., 2015; Winstanley et al., 2009).  P. aeruginosa has a 
non-clonal structure but a few sequence types are widely distributed and frequently 
encountered (Woodford et al., 2011) .  These are referred to as clones.  Some are 
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thought to be significant in the spread of resistance (Oliver et al., 2015).   
Importantly the accessory genome is a source of genes encoding virulence factors 
and resistance to multiple classes of antibiotics (Ballarini et al., 2012; Kos et al., 
2015; Kung et al., 2010; Talbot et al., 2006; Wiehlmann et al., 2007). 
A panmictic population has been suggested for the population structure of P. 
aeruginosa from a number of studies (Denamur, 1993; Picard et al., 1994).  
Panmictic populations are characterised by extreme genetic diversity, whereby each 
clinical isolate can be genetically distinct from another. Wiehlmann et al 
(Wiehlmann et al., 2007) assessed 240 P. aeruginosa strains using DNA array tube 
assay and reported that the majority of strains belonged to a few dominant clones 
widespread in disease and environmental habitats.  Overall the P. aeruginosa 
population structure is considered non-clonal, that clinical isolates are 
indistinguishable from environmental isolates, and that there are no specific clones 
with a specific habitat (disease) selection (Pirnay et al., 2009).  However, the study 
reported the emergence, spread and persistence of multidrug resistant clones in 
hospitals, predominantly in those wards such as intensive care units, whereby a 
high antibiotic selection pressure may exist.  Two serotypes, O11 and O12, are 
highly associated with these epidemic strains (Farmer et al, 1982). Typing of these 
strains supported a heterogeneous population in serotype O11 but those of 
serotype O12 often appeared to lack significant diversity.  There is also the 
emergence of a number of ‘transmissible’ CF clones in P. aeruginosa, these have 
been reported across the world (Scott & Pitt, 2004; Syrmis et al., 2004) and may 
indicate the development of specific clones that have adapted to the CF airway 
environment and have the ability to spread within CF patient populations 
(Fothergill, et al., 2012).  A study by Pirnay et al in 2009 (Pirnay et al., 2009) carried 
out work to provide a reference evolutionary framework and to position the 
emergent P. aeruginosa clones in the global population structure.  The collection 
consisted of 328 unrelated isolates (collected over the last 125 years from 69 
localities in 30 countries on 5 continents).  They included isolates from diverse 
clinical (both human and animal) and environmental habitats.  Pirnay et al (Pirnay et 
al., 2009) confirmed from their data the non-clonal epidemic population structure 
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of P. aeruginosa.  Their findings also indicated that there are no widespread CF 
epidemic clones. They suggested that ‘CF strains are part of a successful and 
ubiquitous core lineage that have infected CF patients from the natural 
environment and spread through short to medium range transmission between 
patients in CF clinics and holiday and rehabilitation camps’.  They also reported of 
the worldwide spread and persistence of the MDR clone O12. Inferring that the 
excessive use of antibiotics has caused a worldwide preferential selection for 
multiple resistant or pan-resistant P. aeruginosa strains (Pirnay et al., 2009; 
Fothergill, et al., 2012).  
It had generally been thought that individual CF patients acquired their infections 
separately and harboured their own individual strain that were non transferable 
between patients. However, Cheng et al (Cheng et al., 1996) reported the 
development of a drug resistant strain in a CF children’s ward in Liverpool centre 
and spread among patients, termed the Liverpool Epidemic Strain (Al-Aloul et al., 
2004; Ashish et al., 2012; Fothergill et al., 2012). Other epidemic strains have since 
been reported in Manchester (A. M. Jones et al., 2001) and Midlands (Scott & Pitt, 
2004) CF centers and worldwide (Aaron et al., 2014; Leão et al, 2010; Parkins et al., 
2014). 
 
The LES has a number of characteristic features which include transmissibility and 
superinfection, that is it has the ability to superinfect patients previously chronically 
infected with a different strain of P. aeruginosa (McCallum et al., 2001).  It has also 
been reported to cause respiratory infections of both non-CF parents of the same 
CF patient (McCallum et al, 2002).  In addition to this a report in 2008 indicated that 
the LES has also been associated with transmission to a pet cat (Mohan et al., 2008). 
It has also been documented that LES isolates are significantly more antibiotic 
resistant than other P. aeruginosa CF isolates and that resistance in LES isolates is 
more likely to develop over time (Ashish et al., 2012; Salunkhe et al., 2005). 
 
LES is known to be associated with increased morbidity and mortality (Al-Aloul et 
al., 2004), increased resistance to antibiotics (Ashish et al., 2012) ,the ability to 
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superinfect patients already harbouring their unique strains of P. aeruginosa 
(McCallum et al., 2001) and overproduction of important virulence factors 
(Fothergill et al, 2012; Fothergill et al., 2007) 
 
Due to the high transmissibility of the LES, Midlands and Manchester strains a policy 
of microbiological surveillance for monitoring P. aeruginosa cross-infection of these 
particular strains is in place.  Along with the introduction of new infection control 
measures in CF centres.  Although much study and surveillance continues regarding 
these genotypes in human population little is known of their dispersion among the 
animal P. aeruginosa population.  
 
 
 
Table 1.3 Summary of the antibacterial classes and the route of administration 
commonly used in management of CF P. aeruginosa lung infections.  Table 
adapted from (Kanj & Kanafani, 2011). 
 
Antibacterial Classes   
 
Antibacterials and Route of administration commonly used in 
management of CF 
 
Antipseudomonal 
penicillins 
Ticarcillin administered iv.  
 
Beta-Lactam/Beta-
Lactamase Inhibitor 
Combinations 
Ticarcillin-clavulanate and piperacillin- tazobactam administered iv. 
 
Inhaled antibiotics may be used in the treatment of P. aeruginosa 
pneumonia in particular CF patients, those used include colistin, 
tobramycin and beta lactams,    
 
Cephalosporins Cephalosporins considered good treatment of choice because of their 
good activity and narrow spectrum of activity as compared to 
carbapenems so Useful if isolate is susceptible  ie Ceftazidime and 
cefepime administered iv. 
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Monobactams Monobactams such as Aztreonam dosed iv.  P. aeruginosa isolates that 
produce metallo-beta lactamases may be susceptible to aztreonam. 
 
Carbapenems  Carbapenems such as meropenem, imipenem, doripenem administered 
iv.  The various carbapenems have different levels of activity against 
Pseudomonas isolates. In vitro studies have, doripenem, like other 
carbapenems, has minimal activity against metallo-β-lactamase–
producing Pseudomonas isolates compared with other carbapenems. 
Whether these in vitro differences among carbapenems translate into 
clinical out- come differences has not yet been determined. 
Carbapenems are usually used in the empirical treatment of suspected 
Pseudomonas species infections or when a polymicrobial infection is 
considered a possibility. In view of their broad spectrum of activity and 
the inherent risk of selecting for MDR organisms including P aeruginosa 
and Acinetobacter species, antibiotic therapy should be de-escalated 
when possible based on culture results.  
 
Fluroquinolones Fluroquinolones such as ciprofloxacin and levofloxacin dosed iv. 
Polymyxins Colistin (polymyxinE) The increasing rates of MDR Pseudomonas 
isolates have prompted clinicians to turn to agents such as the 
polymyxins that had previously fallen out of favour as a result of their 
adverse effects (namely nephrotoxicity).  The polymyxins are often used 
as a salvage therapy when therapeutic choices are seriously limited.   
Inhaled antibiotics may be used in the treatment of P. aeruginosa 
pneumonia in particular CF patients, those used include colistin. 
 
Aminoglycosides Inhaled antibiotics may be used in the treatment of P. aeruginosa 
pneumonia in particular CF patients, those used include tobramycin.    
 
Other Antibacterials 
(Combination therapy) 
Other antibacterials are generally not recommended for monotherapy 
due to their high propensity to induce drug resistance.  
They may be considered used usually in combination therapy with 
other anti pseudomonal agents such as aminoglycosides, amikacin, 
gentamycin, tobramycin or rifampicin. 
 
(Kanj & Kanafani, 2011) 
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1.4 Limited antimicrobial treatment options in treatment of P. aeruginosa infections 
in humans 
 
P. aeruginosa is one of the so-named ESKAPE pathogens by the IDSA (Infectious 
Diseases Society of America) and is categorized by the CDC as a serious level of 
threat.  These are significant antibiotic resistant threats for varying reasons 
including a reduced availability of therapeutic options.  P. aeruginosa is now 
detailed on the WHO urgent list for priority pathogens for reasearch and 
development of new antibiotics (WHO Feb 2017).  ESKAPE pathogens are 
highlighted as being of ever-growing relevance to antimicrobial chemotherapy in 
future years (Boucher et al., 2009; Santajit & Indrawattana, 2016; Zilahi et al, 2016).   
P. aeruginosa presents a serious therapeutic challenge for treatment of both 
community-acquired and nosocomial infections, and selection of the appropriate 
antibiotic to initiate therapy is essential to improve the clinical outcome.  
Unfortunately, selection of the most appropriate antibiotic is complicated by the 
ability of P. aeruginosa to develop resistance to multiple classes of antibacterial 
agents, even during the course of treating an infection. Epidemiological outcome 
studies have shown that infections caused by drug-resistant P. aeruginosa are 
associated with significant increases in morbidity, mortality, need for surgical 
intervention, length of hospital stay and chronic care, and overall cost of treating 
the infection. Even more problematic is the development of resistance during the 
course of therapy, a complication which has been shown to double the length of 
hospitalization and overall cost of patient care. P. aeruginosa can develop 
resistance to antibacterials either through the acquisition of resistance genes on 
mobile genetic elements (i.e., plasmids) or through mutational processes that alter 
the expression and/or function of chromosomally encoded mechanisms. Both 
strategies for developing drug resistance can severely limit the therapeutic options 
for treatment of serious infections (Cosgrove, 2006). 
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Antimicrobial resistance 
Treatment of infectious diseases becomes more challenging particularly with the 
ability of bacteria to rapidly mutate and adapt.  This is apparent in P. aeruginosa, in 
particular with its ability to develop a MDR  (defined as non susceptibility to at least 
one agent in three or more antimicrobial categories) (Magiorakos et al., 2012) 
phenotype and also the potential passage of resistance mechanisms on mobile 
genetic elements.  Most notably with P. aeruginosa its ability to rapidly develop 
resistance to multiple classes of antibiotics during the course of treating a patient 
further complicates the challenge (Lister et al., 2009). 
P. aeruginosa is a bacterium that possess a great and varied armory in its defences.  
Among others; mediator activation via endotoxin release, exotoxins and enzymatic 
products, designed to evade host defences, and chromosomal and plasmid-
mediated antibiotic resistance factors (El Solh & Alhajhusain, 2009).  A multidrug-
resistant phenotype can arise in P. aeruginosa through the acquisition of multiple 
imported resistance mechanisms on mobile genetic elements, a combination of 
imported and chromosomally encoded resistance mechanisms, accumulation of 
multiple chromosomal changes over time, and/or a single mutational event leading 
to the overexpression of a multidrug resistance mechanism (such as an efflux pump) 
(Lister et al 2009). Examples of specific gene mutations include ciprofloxacin 
resistance being associated with a mutation in gyrA (Cambau et al., 1995; Lomholt 
& Kilian, 2003) and mutations to topoisomerases II and IV that confer 
fluoroquinolone resistance.  The up-regulation of MexAB-OprM is known to 
compromise the fluoroquinolones, penicillins, cephalosporins, and, to some degree, 
meropenem (not imipenem).  It also enhances resistance to many other drugs that 
lack useful anti-pseudomonal activity.  Up-regulation of other efflux systems, such 
as MexCD-OprJ and MexEF-OprN, confers resistance to fluoroquinolones and some 
β-lactams.  The up-regulation of MexXY-OprM also affects aminoglycosides 
(Hocquet et al., 2006; Morita et al, 2013). There are mutations in genes encoding 
key regulators for example, mexT and ampR. Together, the traits affected by these 
mutations have been termed ‘pathoadaptive’ traits (Winstanley et al, 2016). 
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As observed in chronic CF patients P. aeruginosa exhibits phenotypic diversity, often 
characterized by the appearance of different colony morphology types.  These may 
include mucoid (hyperalginate producers), and small colony variants (Sousa & 
Pereira, 2014).  The small colony variants are typically slow growing and may exhibit 
higher levels of resistance.  They may adhere well to surfaces and be involved in 
biofilm formation, which further contributes to treatment challenges.  The 
phenotypic variation of P. aeruginosa isolates of the same genotype can also be 
seen in variation of antibiotic susceptibility profiles amongst isolates within a single 
patient sample. 
 
Hypermutators are known to occur within P. aeruginosa populatons. These are 
bacteria with mutations in their DNA repair or mutation avoidance genes.  
Hypermutators are found at a relatively higher prevalence in CF patients chronically 
infected with P. aeruginosa (Ferroni et al., 2009; Lutz et al., 2013; Maciá et al, 
2005).  They are also found in other chronic lung disease such as severe COPD and 
non-CF bronchiectasis (Parameswaran & Sethi, 2012; Sahuquillo-Arce et al, 2016).  
 
Adaptation during chronic infections  
 
P. aeruginosa evolves from a state of early, recurrent intermittent colonization of 
the airways of patients with CF to a chronic infection state (Folkesson et al., 2012). 
The genetic adaptation of P. aeruginosa in the chronic CF lung involves specific gene 
mutations that can produce beneficial phenotypic changes to enable its persistence 
in the lung. The mutations most commonly observed are those inactivating the 
regulators mucA (alginate biosynthesis), lasR (quorum sensing) and mexZ (regulator 
multidrug-efflux pump MexXY).  Along with those inactivating the DNA mismatch 
repair system (MRS) leading to hyper-mutator genotypes (Feliziani et al., 2010).   
CF infections involving P. aeruginosa are dynamic and see a gradual development 
from an acute early infection to a host-adapted pathogen of chronic infection 
(Sousa et al., 2014).  However, virulence has shown to be reduced in these isolates 
that have become adapted to their niche environment.  Lore, N.I. et al (Lorè et al., 
2012) showed that niche-specific selection in P. aeruginosa reduced its ability to 
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cause acute infections across a range of hosts while maintaining the capacity for 
chronic infection in the CF host (Lorè et al., 2012). 
 
Populations of P. aeruginosa in chronic CF lung infections typically exhibit high 
phenotypic diversity.  As this population diversity is dynamic over time, it makes 
accurate diagnosis and treatment challenging.  This phenotypic diversity includes 
clinically important traits such as antibiotic resistance and toxin production.  In such 
highly diverse populations it is possible for false diagnoses (for example based upon 
antimicrobial susceptibility testing using single/pairs of isolates). Given the already 
limited efficacy of current antibiotics in these chronically infected CF patients, 
research in this area is ongoing to help improve understanding of the evolution of 
bacterial populations during chronic infections especially with the use of affordable 
high throughput genome sequencing (Winstanley et al., 2016). 
 
Chronic P.aeruginosa lung infection is an endobronchiolitis characterized by the 
micro-colony mode of growth (biofilm). The most commonly used anti-
pseudomonal agents (Table 1.3) used are the extended-spectrum penicillins, beta-
lactams, aminoglycosides, cephalosporins, fluoroquinolones and polymxins (Høiby, 
2011).  However, the treatment of infections caused by multi-drug resistant 
organisms is problematic as antibacterial options and the development of new 
drugs for clinical use are limited.  The drug development process is a long process 
with numerous restrictions along the pipeline of antibiotic development.  In 
addition, no new novel agents with efficacy against the Gram negative pathogens in 
particular, have been developed in the last 30 years (Briers & Lavigne., 2015; Coates 
et al., 2011). 
 
 
1.5  P.aeruginosa infections in animals 
 
In the veterinary setting P.aeruginosa can be a cause of disease in a variety of 
different species.  It may be involved in ear, skin, respiratory, urinary, reproductive, 
ocular and wound infections.  Similar to its nature in humans P. aeruginosa is also 
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less common as a primary cause of disease in the healthy animal subject.  In the 
dog, P.aeruginosa is a frequently isolated pathogen in chronic otitis externa and 
otitis media (Morris, 2004; Nuttall & Cole, 2007; Rubin et al., 2008; Steen & 
Paterson, 2012) and may be found in chronic deep pyodermas (Hillier et al, 2006; 
Rubin et al., 2008).  In the canine patient P.aeruginosa related otitis can be 
notoriously difficult to treat and is a painful condition.  In these patients it is often 
that the dog will have another underlying skin issue such as that of allergic skin 
disease, termed atopy (Hillier et al., 2006) whereby the effective skin-barrier 
function has become compromised.  The recommended management of canine 
otitis externa consists of identifying and treating the predisposing factors and 
primary disease.  Ear cleaning, flushing, appropriate topical therapy and if indicated, 
systemic antimicrobial medications (Morris, 2004; Nuttall & Cole., 2007). 
 
A number of other infections involving P.aeruginosa in animals are known and 
reported in the literature, including that of contagious equine metritis (Atherton & 
Pitt., 1982; Ensink et al., 1993) and in chronic equine wounds were the ability of 
P.aeruginosa to form and survive within protective biofilms has been studied 
(Percival et al, 2015; Westgate et al, 2011).  Westgate et al (Westgate et al, 2011) 
reported the first identification of biofilms in chronic wounds of horses. They looked 
at 13 tissues samples from 18 chronic wounds and identified the most common 
bacteria isolated from each wound, one of the most common from skin and wound 
samples was P.aeruginosa (Westgate et al 2008).    
 
There are reports of P. aeruginosa infections affecting chinchillas and the organism 
has been isolated in high numbers in laboratory animals of this species (Wideman, 
2006).  In mink, P.aeruginosa is also a known cause of haemorrhagic pneumonia.  In 
particular, it is an acute and fatal disease in farmed mink (Salomonsen et al., 2013; 
Shimizu et al., 1974; Wilson et al., 2015).  A 2009 study (Pedersen et al., 2009) 
reporting the useage of antimicrobials and occurrence of AMR among bacteria from 
mink found that all the 39 P.aeruginosa samples in their study were sensitive 
gentamicin and colistin (Pedersen et al., 2009).   
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In the veterinary environment P.aeruginosa in also encountered in various eye 
conditions including the non-healing (so called ‘melting’) corneal ulcers and 
bacterial ulcerative keratitis in horses and occasionally dogs (Delgado & Subtil, 
2015; Hindley et al, 2016).  A study by Hindley et al, 2016, looked at bacterial 
isolates, from dogs with keratitis attending two Australian referral practices (2012-
2014).  Positive cultures were obtained from 42 of the 71 ulcers sampled (59%), 
with 45 bacteria isolated. The most commonly isolated bacteria were β-hemolytic 
Streptococcus (14/45, 31%), Pseudomonas (14/45, 31%), and Staphylococcus 
species (8/45, 18%).  P. aeruginosa isolates were resistant to chloramphenicol, 
cephalexin, and fusidic acid; however, >90% were susceptible to ciprofloxacin, 
polymyxin B, and gentamicin.  In comparison, a study of 97 dogs with bacterial 
keratitis identified from teaching hospital medical records at the Universities of 
Tennessee and Florida (1993 to 2003) were reviewed.  The most commonly isolated 
bacteria were Staphylococcus intermedius (29%), beta-hemolytic Streptococcus spp 
(17%), and P. aeruginosa (21%). Here isolates of P. aeruginosa were susceptible to 
tobramycin and gentamicin and had limited resistance to ciprofloxacin and 
enrofloxacin. Among bacterial species isolated, there was no evidence of 
development of increased AMR over time. 
 
In horses, P. aeruginosa is one of the most commonly identified causative 
organisms in ulcerative keratitis.  Keller et al (Keller & Hendrix, 2005) documented 
bacterial isolates and their antimicrobial susceptibilities from horses with ulcerative 
keratitis treated at the University of Tennessee (1993 -2004).  Of the 43 horses, 51 
bacterial isolates were isolated. S. equi ssp. zooepidemicus and P. aeruginosa were 
the most frequently isolated bacterial organisms in equine ulcerative keratitis. No 
significant trends in aminoglycoside or fluoroquinolone resistance were noted 
among these organisms.  A retrospective study by Sauer et al (Sauer et al, 2003) 
looked at all cases of equine bacterial ulcerative keratitis seen at the University of 
Florida's VMTH (1991-2000).  The 65 identified bacterial isolates were subjected to 
sensitivity testing via disc diffusion and of these isolates, P. aeruginosa accounted 
for 14 of the bacterial isolates (22%). A statistically significant increase in resistance 
of P. aeruginosa isolates to the antibiotics gentamicin and tobramycin was found 
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between the isolates from 1992 to 1998 and those from 1999 to 2000 (Sauer et al., 
2003).  
 
P. aeruginosa is reported as a pathogen in mastitis in goats.  A recent study looking 
at this condition in goats (Scaccabarozzi et al., 2015) showed caprine P. aeruginosa 
isolates to be phenotypically diverse, able to cause both transient and chronic 
infections and with both clinical and subclinical manifestations.  P. aeruginosa also 
initiated a more pronounced inflammatory response compared to other pathogens. 
The study showed that the P. aeruginosa was able to persist during the dry period 
through the subsequent lactation, demonstrating the difficult clearance of this 
pathogen from the mammary gland (Scaccabarozzi et al., 2015).  The multidrug 
resistance patterns demonstrated by all of the isolates tested, contributes to the 
difficulty to effectively cure the intra mammary infections. In the study the highest 
levels of resistance were found to be against the most commonly used beta-lactam 
antibiotics.  There was also the suggestion of unique patterns of virulence-related 
phenotypes with certain isolates possibly being better adapted to the udder 
environment. For example an association between hemolysin production and 
swimming motility may infer that some virulence factors would be capable of 
making an isolate more adapted to the goat udder (Scaccabarozzi et al., 2015).   P. 
aeruginosa infections have also been reported in sheep causing mastitis (Wright et 
al., 2015).  This study reported two clonal P. aeruginosa isolates (PSE305 and 
PSE306) from a mastitis infection outbreak, representing distinct colony 
morphology variants with differences in phenotypic characteristics between the 
two clones. 
Examples of infections in animals involving P.aeruginosa are summarized in Table 
1.4. 
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Table 1.4.   Examples of infections in animals involving P. aeruginosa 
 
Species 
 
Examples of infections involving P. 
aeruginosa in animals 
 
Horses - Contagious equine metritis 
- Non healing lower limb wounds 
- Bacterial ulcerative keratitis 
- Non healing corneal ulcers  
 
Goats - Mastitis 
 
Sheep 
 
- Mastitis 
Mink - Haemorrhagic pneumonia 
 
Dogs - Otitis 
- Deep pyodermas 
- Bacterial keratitis 
 
Chinchillas -Pneumonia 
- Septicaemia 
- Enteritis 
- Otitis media and interna 
 
 
 
1.6  Antimicrobial treatments used for P.aeruginosa infections in animals 
 
Sulfonamides were the first antimicrobial to be introduced into food animal 
medicine in the 1940s. The subsequent discoveries and availabilities of newer 
antibiotics in the 1950’s has progressed to the widespread therapeutic usage of 
antibacterials for management of infectious diseases in the majority of food animal 
species.  Antibiotics have also been given to food production animals for growth 
promotion (in animal feeds) and prophylactic medication (Landers et al., 2012). 
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Non-therapeutic use of antibacterials in animals may include use as growth 
promoters (added in low doses to the feed of farm animals, they improve their 
growth performance) or prophylactic/metaphylactic purposes. For instance, an 
animal may be treated with antibiotics post surgery or trauma.  In companion 
animal veterinary medicine, antibiotics are commonly used to control secondary 
bacterial infection (for example during surgical procedures) and managing infection-
promoting disease conditions (such as in urolithiasis).  Also, in herd/flock 
management, whereby they may be given antibiotics if they are at risk of suffering 
an outbreak of infectious disease due to exposure to disease agents or extremely 
unfavorable host or environmental conditions.  In poultry and livestock, mass 
administration of antibiotics is often practiced when transporting or moving young 
animals, during dry-cow therapy in dairy cows, and in preventing respiratory and 
intestinal disease when animals have been subjected to severely stressful 
conditions.  With the emergence of antibiotic resistance, the use of growth 
promoters has been banned on all/or particular classes of antibiotics, with different 
countries having different lists of approved and banned growth promoter 
antibiotics. In 2005, the EU banned antibiotics in animal feed as growth promoters 
(Maron et al, 2013). A number of veterinary bodies currently implement guidelines 
on antibacterial usage and prescribing promoting judicious use and antimicrobial 
stewardship.  For example, those guidelines by the British Small Animal Veterinary 
Society (BSAVA 2017a; BSAVA 2017b) and the British Veterinary Association (BVA 
2017). 
 
In most countries, there are no reliable consumption figures on antimicrobial agents 
administered to pet animals. Most national monitoring programs focus on food 
animals and do not include data on antimicrobial resistance in companion animals. 
Some long-term studies in Europe have described trends in antimicrobial resistance.  
Several countries have national agencies for the purpose of monitoring 
antimicrobial usage and rates of AMR in food animals, food and of people. For 
example; in the USA National Antimicrobial Resistance Monitoring System (NARMS).  
This is a collaborative project of state and local public health departments (FDA, 
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CDC and USDA).  The Canadian Integrated Program for Antimicrobial Resistance 
(CIPARS) in Canada; Observatoire National de Epidémiologie de la Résistance 
Bactérienne aux Antibiotiques (ONERBA) in France and The Danish Integrated 
Antimicrobial Resistance Monitoring and Research Programme (DANMAP) in 
Denmark.  DANMAP monitors sales for humans and animals annually, along with 
rates of AMR in bacteria from people, food animals, and food products.  The 
component that monitors antibiotic usage in veterinary practice is VetStat, which 
collects data from pharmacies, veterinary surgeons and feed mills (Bywater., 2004; 
Chantziaras et al., 2014; Cogliani et al., 2011; Garcia-Migura et al., 2014; DANMAP, 
2014; Bywater, 2004). 
 
 
Polymyxin useage in veterinary species 
 
It is difficult to identify usage of polymyxins within both companion and food 
producing veterinary species as the small animal usage is not well documented. 
In a report of antibiotics most commonly prescribed in animals in Europe (De Briyne 
et al., 2013) a survey of 3004 practitioners from 25 European countries was 
completed.  It showed polymyxins were cited relatively infrequently by practitioners 
for use in cats and dogs, however this was higher in cattle pigs and horses.  
However, polymyxins were reported most in the treatment of diarrhoea in cattle 
and calves (40% frequency of citation of this class of antibiotic for this indication in 
this species).  Polymyxins were also cited frequently as prescribed for diarrhoea 
(including colibacillosis and dysentery) in pigs at 30%.  Colistin is often used in 
control of colibacillosis in poultry and pig production administered in the oral form.  
Resistant isolates are sometimes received from pathogenic cases especially in 
piglets.  Colistin resistance was reported in E.coli and Salmonella enterica of poultry 
and swine (De Briyne et al., 2013). However, in Europe the percentage resistance to 
colistin in E.coli strains isolated from digestive tract microbiota of healthy animals 
remains very low at <1%.   
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A surveillance study of carbapenem-resistant Enterobacteriacea (CRE) isolates from 
a University hospital in Shanghai, China, reported the independent emergence of 
colistin resistance in KPC (Klebsiella pneumonia carbapenemase) producing CRE 
isolates without treatment with colistin (S. Chen et al., 2011).  Wang et al reported 
the IMP-45 (Imipenemase metallo-β-lactamase) producing MDR P.aeruginosa that 
was of canine origin (Y. Wang et al., 2014). This is an important MBL (metallo beta 
lactamase) gene, which can be disseminated horizontally among Gram-negative 
bacteria including major pathogens of humans and animals.  IMP type 
carbapenemases represent one of the most clinically relevant MBL groups in terms 
of epidemiological dissemination. 
 
The main indications for polymyxin useage in the veterinary sector are infections 
caused by Enterobacteriaceae in rabbits, pigs, poultry, cattle, sheep and goats (EMA 
2017a; EMA 2017b).  In addition, colistin is utilised in laying hens and cattle, sheep 
and goats producing milk for human consumption. Most often, colistin products are 
administered orally, as a drench, in feed, in drinking water or through milk replacer 
diets. Combinations of colistin with other antimicrobials are available for group 
treatments of food-producing animals in some European countries. Products for 
parenteral and intra-mammary administration are also available, and Gram-
negative infections in ruminants including endotoxinaemia are claimed indications. 
Polymyxin B is used for systemic treatment of endotoxaemia associated with severe 
colic and other gastrointestinal diseases. Several proprietary forms of colistin and 
polymyxin B are available for topical use in companion animals; prescription eye 
and eardrops are available as colistin alone, or in combination with other 
antimicrobials. Colistin tablets are available for calves for the prevention and 
treatment of neonatal colibacillosis. In some EU Member States, veterinary 
medicinal products containing colistin are not on the market and not used at all 
(ESVAC, 2012). The 2010 and 2011 FDA (FDA, 2017) reports on sales of veterinary 
antimicrobials show no sales of polymyxins, but there are reports of off label use of 
polymyxin B in horses in cases of endotoxemia (Werners et al, 2005).  
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1.7 AMR in P. aeruginosa 
 
Antimicrobial resistance is a multifactorial and complex issue, affecting healthcare 
worldwide and is an escalating concern as a developing public health crisis.  
European and International bodies have highlighted AMR as a global public health 
issue of imperative importance.  The World Health Organisation (WHO), the 
European Centre Disease Prevention and Control (ECDPC) and Infectious Diseases 
Society of America (IDSA) have included within their concerns and priorities, 
emerging antimicrobial resistance mechanisms, surveillance and antibiotic 
stewardship, considering within this, roles of both the veterinary and medical 
communities. AMR is not only a concern in human health but also animal health.  
The close interface between people, pets, food production animals and the 
environment exemplifies the importance that these two areas of health should not 
be considered as entirely independent with regards to AMR.  Adopting a ‘one-
health’ approach in combatting this global problem is of imperative importance in 
understanding and potentially controlling the advances of resistance among the 
microbial population.  P. aeruginosa is one of the so-named ESKAPE pathogens by 
the IDSA and is categorized by the CDC (Centre for Disease Control and Prevention) 
as a serious level of threat.  These are significant antibiotic resistant threats for 
varying reasons including a reduced availability of therapeutic options (Santajit & 
Indrawattana, 2016).  
 
Relevant β-lactams and aminoglycosides remain active against 70%–98% of P. 
aeruginosa isolates in the United States and the United Kingdom (Lister et al., 2009; 
Livermore, 2002). Nevertheless, resistance is more frequent in specific areas, most 
notably, in hospital units for the management of patients with burns or CF, or in 
ICUs. The high levels of aminoglycoside resistance in isolates from patients with CF 
is apparent in both the United Kingdom and the United States (Poole, 2005a), and 
also imipenem resistance among isolates from patients in ICUs. More generally, 
there are higher levels of resistance among isolates from hospitalized patients, 
compared with those from outpatients (da Silva Filho et al, 2001; Mesaros et al., 
2007; Pitt, 2002; Vicente et al., 2013; Winstanley et al 2016). Snapshot surveys 
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performed in 1982, 1993, and 1999 show little increase in resistance among P. 
aeruginosa strains in the United Kingdom (Livermore, 2002); however, resistance to 
ciprofloxacin in particular but, also to piperacillin and gentamicin, has recently risen 
among such strains in the United States. 
 
1.8 Potential for cross-species transmission between humans and animals 
 
The occurrence and risks of P. aeruginosa transmission between animals and 
humans is an area of limited study.  There are a small number of reports in the 
literature of cross transmission between humans and animals.  In 2008 Mohan et al 
(Mohan et al., 2008) documented a case report of a cat being infected by a 
transmissible strain of P.aeruginosa from a CF owner.  The pet cat presented with a 
6wk history of serous nasal discharge and sneezing and required an extensive 
antibiotic treatment course of 6wks marbofloxacin and was found to be harbouring 
the LES of P.aeruginosa.  The owner of the cat was an adult CF patient infected with 
the LES, a known highly transmissible strain of P. aeruginosa and transmission was 
deemed to be from human to animal in this instance.   
 
Conversely, Maeda & Tazumi et al (Tazumi et al., 2009) looked at the potential for 
transmission of bacteria between reptiles and a CF patient but concluded from their 
case study there was no evidence of the CF patient’s reptile collection acting as a 
source of any of his respiratory flora or vice versa.  However, it did highlight 
increased risk of transmission of pathogens to the reptiles in the direct care of CF 
patients.   
 
Animals being a potential source of P.aeruginosa infection to humans is highlighted 
again in the work by Hirakawa et al (Hirakawa et al., 2010).  This study reported that 
P. aeruginosa was isolated at high rates from pet and laboratory chinchillas, with 
typing analysis showing the isolates to be diversified however low antimicrobial 
susceptibility was identified in several isolates.  The isolates in the study were found 
to contain the gene pilL that was previously identified only in highly virulent strains 
of P. aeruginosa (Battle et al, 2008). Thus, it is necessary to take into account the 
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risk of infection from pets or laboratory chinchillas to humans.  This risk can be even 
more relevant in situations whereby pets are within the household of medical 
patients.  A report (Broughton et al, 2010) looking at zoonotic causes of infectious 
peritonitis as complications in peritoneal dialysis patients, raises the importance of 
considering companion animals (or the patients working with animals) as sources of 
these infections.  P. aeruginosa being one of the common causative agents in 
infectious peritonitis of peritoneal dialysis patients.  
 
Other species have also displayed human-bacterial transmission. A report in 2012 
on interspecies transmission between a CF patient and their pet cat revealed 
Bordetella bronchiseptica (BB) being transferred from a kitten to a CF patient 
(Register et al, 2012).  BB was isolated from routine sputum samples of an 11yr old 
stable CF patient.  There had been the recent acquisition of a kitten displaying acute 
respiratory disease.  Genetic characterization of the isolate and comparison with 
other isolates of human and feline origin strongly suggested the kitten was the 
source of infection. Genetic traits of the isolate were consistent with it being of 
feline origin (Register et al., 2012).  There has also been a report of a transplant 
patient developing BB pneumonia from pet dogs (two cases out of 60 patients with 
BB pneumonia contracted from pet dogs) in CF patient lung transplant recipients 
(Ner et al., 2003). For these patients, the infection was fatal. Due to a lack of 
research in this area, it is not known whether such occurences are a rare 
phenomenom or an emerging risk as a route of infection.  Gisel et al (Gisel et al, 
2010) also documented a case of a kidney-pancreas transplant patient who suffered 
postoperative complications requiring further surgery for adhesions and two weeks 
postoperatively the patient developed pneumonia (failing to respond to repeated 
courses of antibiotics). BB was isolated following diagnostics and it was discovered 
that the patient's dogs had recently received a live-attenuated BB intranasal 
vaccination. The patient recovered after 21 days of therapy with doxycycline based 
upon susceptibility testing. However, in this study as polymerase chain reaction 
testing was not performed, comparing the isolated strain to the vaccination strain, 
the association here is presumptive and further confirmation would need to be 
achieved. 
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There are reports of interspecies transmission, whereby studies suggest that pets 
such as cats and dogs may be potential sources for methicillin-resistant 
Staphylococcus aureus (MRSA) infection (Ferreira et al., 2011; Morris et l.,, 2010; 
Morrow et al., 2014; Wang et al., 2008).  A report of a case of MRSA infection in a 
family that involved the pet cat reported the transmission of PVL-positive (Panton 
Valentine leukocidin) MRSA increased virulence bacteria between a symptomatic 
woman and both her asymptomatic family and their healthy pet cat (Wang et al., 
2008). However, it is unclear if the cat was source of patient’s infection or vice 
versa. A further study reported PVL positive MRSA strains with identical resistance 
patterns cultured from recurrent infections in a 51yr old patient, her healthy 
husband, son and pet dog.  Pulsed field gel electrophoresis showed all strains to be 
indistinguishable (Weese et al., 2006).  Furthermore a study in 2009 (Murphy et al., 
2009) documented the high prevalence of concurrent MRSA colonization and 
identification of indistinguishable strains in humans and pet dogs and cats in the 
same household.  Investigations of six situations where MRSA was identified in one 
or more animals in a household or veterinary facility were performed. MRSA was 
isolated from 8 animals (5 dogs and 3 cats) with clinical infections, 1 cat that was in 
contact with 2 infected cats and 14/88 (16%) of household contacts or veterinary 
personnel (Murphy et al., 2009). An indistinguishable MRSA isolate was recovered 
from at least one human that was in contact with each animal case. All isolates 
were classified as Canadian epidemic MRSA-2, the predominant community-
associated MRSA clone in humans in Canada. They concluded that transmission of 
MRSA between humans and animals, in both directions, was suspected (Murphy et 
al., 2009; Weese et al., 2006).  A recent study looking at the carriage of methicillin-
resistant staphylococci between humans and animals on a small farm by Loncaric, 
et al (Loncaric et al., 2016) also reported of carriage of both MRSA and MRCoNS 
(methicillin-resistant coagulase negative staphylococci) among humans and various 
animals within a shared environment. The detection of strains with 
indistinguishable molecular characteristics strongly suggested transmission of these 
MRSA between the various animal species and humans. These studies highlight that 
interspecies transmission of MRSA is possible.  It is therefore likely that pets may be 
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considered as possible household reservoirs that can cause infection and 
reinfection of humans.   
 
The Figure 1.2 (starts p38) details consequences of antimicrobial use in small animal 
veterinary practice and human medicine on exchange of resistant bacteria and 
transfer of resistance genes between pet animals and humans with impact on 
human health and general factors contributing to antimicrobial use and resistance.  
Figure is adapted from (Guardabassi et al.,2002) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Flow chart to show consequences of antimicrobial use in small animal veterinary practice and human medicine on 
exchange of resistant bacteria and transfer of resistance genes between pet animals and humans with impact on human 
health and general factors contributing to antimicrobial use and resistance. 
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Figure 1.3 details some examples of the reservoirs of antibacterial resistance 
involving both humans and animals. 
 
 
 
 
 
  
 
 
Figure 1.3  Diagram to demonstrate the potential reservoirs of antibacterial resistance (blue arrows) 
involving humans and animals and the selection pressures (red arrows). 
 
 
 
 41 
Chapter 2: Materials and Methods 
 
Materials and Methods for Results Chapter 3 - Reservoirs of resistance: polymyxin 
resistance in veterinary-associated isolates of Pseudomonas aeruginosa: 
 
2.1 Bacterial Isolates 
24 P. aeruginosa isolates from 22 companion animal attending Leahurst Veterinary 
Teaching Hospital (UK) in 2012 were collected for this study (Table 2.1).  No prior 
clinical details or antibiotic use for the cases were available.  Human-associated P. 
aeruginosa isolates (Table 2.1).  from a previously published panel were used as a 
comparison (De Soyza et al., 2013). Those isolates from this published panel that 
were of non-human origin (eg. environmental origin) were excluded.  All isolates 
were stored in LB supplemented with glycerol and stored at -80 oC.  When needed, 
bacteria were grown on Columbia agar for 24hrs at 37oC. 
 
 
Table 2.1 Veterinary and human bacterial isolates used in this study 
Strain  or Isolate Description (Origin/Source) Animal/Human Isolate  Reference 
    
1115 P.aeruginosa (Canine testicle/ 
scrotum swab) 
Animal This study 
1114 P.aeruginosa (Canine neck wound 
swab) 
Animal This study 
1107 P.aeruginosa (Canine Bile sample) Animal This study 
1098  P.aeruginosa ( Canine Vaginal 
swab) 
Animal This study 
1095 P.aeruginosa (Canine Buccal 
swab) 
Animal This study 
1090 P.aeruginosa (Canine Skin lesion 
swab) 
Animal This study 
1070  P.aeruginosa (Canine neck swab) Animal This study 
1055 P.aeruginosa (Canine Lip fold 
swab) 
Animal This study 
994 P.aeruginosa ( Canine Right elbow 
swab) 
Animal This study 
984 P.aeruginosa (Canine Right ear 
swab) 
Animal This study 
982 P.aeruginosa (Canine Urine 
sample) 
Animal This study 
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978 P.aeruginosa (Canine Non-Healing 
Wound swab) 
Animal This study 
970 P.aeruginosa (Canine Wound 
swab) 
Animal This study 
969 P.aeruginosa (Canine 
Oropharyngeal tube swab) 
Animal This study 
897 P.aeruginosa ( Canine ear swab) Animal This study 
886-1 &-2 P.aeruginosa (Canine nail pus 
swab) 
Animal This study 
992 P.aeruginosa ( Feline 
Oropharyngeal tube stoma swab) 
Animal This study 
856 P.aeruginosa ( Equine Abdominal 
incision swab) 
Animal This study 
903 P.aeruginosa ( Equine Urine 
sample) 
Animal This study 
823 P.aeruginosa ( Canine Left ear 
swab) 
Animal This study 
811  P.aeruginosa ( Equine nasal swab) Animal This study 
467-L P.aeruginosa (Canine Left Ear 
swab) 
Animal This study 
467-R P.aeruginosa ( Canine Right Ear 
swab) 
Animal This study 
AES-1R (AUST01) Paediatric CF (1992), Melbourne 
Australia 
Human De Soyza et al., 2013 
AUS23 (AUST02) Adult CF (2007), Brisbane 
Australia 
Human De Soyza et al., 2013 
AUS52 (AUST03) Adult CF (2008), Hobart Australia Human De Soyza et al., 2013 
2192 Chronic CF patient, Boston MA Human De Soyza et al., 2013 
AMT 0023-30 (AMT2330) Paediatric CF, Seattle WA Human De Soyza et al., 2013 
AMT 0060-3 (AMT60-3) Paediatric CF, Seattle WA Human De Soyza et al., 2013 
AMT 0060-2 (AMT60-2) Paediatric CF, Seattle WA Human De Soyza et al., 2013 
AMT 0023-34 (AMT2334) Paediatric CF, Seattle WA Human De Soyza et al., 2013 
U018a CF patient, Hobart Australia Human De Soyza et al., 2013 
57P31PA Chronic obstructive pulmonary 
disease, USA 
Human De Soyza et al., 2013 
IST27N CF patient, spontaneous non 
mucoid variant, Lisbon Portugal 
Human De Soyza et al., 2013 
IST27mucoid (IST27muc) CF patient, Lisbon Portugal Human De Soyza et al., 2013 
TB CF10839 (TB) CF, Germany Human De Soyza et al., 2013 
UCBPP-PA14 (PA14) Human burn isolate Human De Soyza et al., 2013 
NH57388A Denmark, CF Human De Soyza et al., 2013 
A5803 Community acquired pneumonia Human De Soyza et al., 2013 
39016 ICU (acute infection), Spain Human De Soyza et al., 2013 
AMT 0060-1 (AMT60-1) Paediatric CF, Seattle WA Human De Soyza et al., 2013 
15108/1 (5801) ICU (acute infection), Spain Human De Soyza et al., 2013 
13121/1 (13121) ICU (acute infection), France Human De Soyza et al., 2013 
LES400 CF, UK Human De Soyza et al., 2013 
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39177 Keratitis, Manchester UK Human De Soyza et al., 2013 
CHA CF Human De Soyza et al., 2013 
PAK Clinical non CF Human De Soyza et al., 2013 
1709.12 Leuven Belgium, Non clinical CF 
(2004) 
Human De Soyza et al., 2013 
LES 431 Non CF parent of CF patient, UK Human De Soyza et al., 2013 
AA43 CF (late), Germany Human De Soyza et al., 2013 
DK2 CF Denmark (earliest isolates 
1973-2007) 
Human De Soyza et al., 2013 
C3719 CF, Manchester UK Human De Soyza et al., 2013 
RP1 CF, Germany Human De Soyza et al., 2013 
Mi162 Non CF burn, Ann Arbour, MI , 
1997 
Human De Soyza et al., 2013 
AA2 CF (early), Germany Human De Soyza et al., 2013 
KK1 CF, Germany Human De Soyza et al., 2013 
679 Non CF urine sample, male, 
Wroclaw Poland, 2011 
Human De Soyza et al., 2013 
AA44 CF (late), Germany Human De Soyza et al., 2013 
PA01 (ATCC 15692) 
(Pa01esh) 
Genome sequenced isolate Human De Soyza et al., 2013 
NN2 CF, Germany Human De Soyza et al., 2013 
LES B58 (B58) CF, UK (1988) Human De Soyza et al., 2013 
 
 
 
2.2  Susceptibility Testing 
  
Minimum Inhibitory Concentration (MIC) Assays 
For all isolates, minimum inhibitory concentration (MIC) for polymyxin B and colistin 
from overnight broths of LB were performed using BSAC standardised methods 
(BSAC) (Andrews, 2001).  In brief, broth dilutions were performed in 96-well plates 
with antibiotic concentrations from 128 ug/ml to 0.25 ug/ml. Positive and negative 
controls were used throughout and all assays were performed in triplicate. When 
isolates displayed high levels of resistance, additional assays using higher 
concentrations up to 1024 ug/ml were performed. The plates were incubated at 
37oC and assessed after 24 and 48 hrs of growth.  Median values of the triplicate 
MIC results were used to calculate resistance levels. 
The susceptibility of each isolate was determined by the last concentration of 
polymyxin B at which each isolate was unable to grow.  For colistin, BSAC standard 
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breakpoints were used (4 ug/ml). This is consistent with the guidelines most 
commonly used by human clinical microbiology diagnostic laboratories.  However, 
breakpoints for polymyxin B are not clearly defined.  MIC values were interpreted 
according to CLSI guidelines as BSAC and EUCAST do not provide breakpoint 
guidelines for polymyxin B. CLSI recommended using breakpoints of S≤ 2 mg/L, I= 4 
mg/L, R≥ 8 mg/L.  It was considered that these breakpoints were justified for use in 
this study as no alternatives were provided by BSAC/EUCAST. (BSAC, 2015).  
 
MIC for Companion Animal Veterinary Antibiotic panel 
Subcultures were made of the human and companion animal samples by passage 
on blood agar or Columbia agar, cultured at 37oC overnight.  Following incubation, a 
few colonies were suspended in 5 mL sterile water solution to produce a uniform 
turbidity of 0.5 McFarland.  A 10 μL aliquot of this solution was then transferred to 
11 mL Mueller–Hinton broth, and this broth then transferred to the Sensititre 
COMPAN1F 96 well microtitre plate via the Trek Sensititre® AIM™ (TREK 
Diagnostics, Cleveland, OH) automated inoculation delivery system.  The plates 
were incubated at 37 oC for 24 hrs and the plates read using Sensititre OptiRead™ 
Automated Fluorometric Plate Reading SystemTrek Sensititre® (TREK Diagnostic 
Systems) to measure the MIC for inhibition of growth.  
 
2.3  Clondiag Tube Array Genotyping for P. aeruginosa 
Clondiag Tube Arrays (Alere Technologies) were used to type the isolates according 
to the protocol. In brief, a sweep of each isolate was emulsified in 1 ml of sterile 
diluted water (SDW) and centrifuged at 13000 rpm for 2 mins. The supernatant was 
removed and resuspended in 200 uL of SDW, boiled for 5 mins and centrifuged at 
13000 rpm for 2 mins.  A master mix of Labelling buffer B1 and Labelling enzyme B2 
was prepared. 5 ul of the supernatant was added to 5 ul of master mix. PCR was 
performed (5 mins at 96 for 1 cycle, 50 cycles of 20 secs at 62 oC, 40 secs at 72 oC 
and 60 secs at 96 oC.  Following hybridization and washing, reagent C3 (containing 
Horse Radish Peroxidase conjugate) was used to label the chip (the process is 
depicted in Figure 3).  Detection was performed using the Iconoscan, Iconoclust 
Software (Alere Technologies). Tube Array images were transformed into array 
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types as previously described (Wiehlmann et al., 2007). In order to study the 
veterinary isolates in the context of the wider population, an array type database of 
>900 recorded P. aeruginosa strains was used (Cramer et al., 2012). For displaying 
the wider P. aeruginosa population, the eBURST algorithm was applied (Feil et al, 
2004). The number of isolates = 981, number of STs = 256, number of loci per 
isolate =16 and number of resampling for bootstrapping = 1000 (for statistical 
confidences).  
 
 
 
 
 
Figure 2.1: Stages of the Clondiag Array Tube system adapted from Alere 
Technologies. 
(Alere, 2017a & Alere 2017b) 
 
 
Layout of the AT chip  
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The AT consists of 77 oligonucleotides immobilised and embedded in a microchip in 
the base of a tube (Wiehlmann et al., 2007). The layout is divided in to 3 sections, as 
shown in Figure 2.2.  These are; genomic islands, variable genes, and SNPs. The chip 
contains 29 markers for a range of genomic islands and islets, 15 markers for 
variable genes, a LES PS21 marker, and 16 markers relation to SNP loci. The markers 
for the genomic islands, variable genes, and the LES PS21 marker are represented 
by two spots on the chip, and the SNPs by four spots.  
 
 
 
Interpretation of the AT chip  
 
Analysis of the 13 SNP patterns at 7 conserved loci (ampC, citS, alkB2, fliCa, oprI, 
oprL, and oriC) and the presence or absences of 3 variable genes encoding the type 
III secretion virulence proteins ExoU and ExoS and the flagellin protein FliC provides 
a genetic profile, which is initially read as a 16 digit binary code, and then translated 
into a 4 digit hexidecimal code. The genomic islands and variable genes are 
represented by two oligonucleotides and the presence of the spots on the chip 
following hybridisation indicates whether the target is present. If the gene is 
present the isolate is assigned a “1” for that locus.  If the gene is not present it is 
assigned a “0”. Each SNP is represented by four oligonucleotides: two on the left 
which have sequences matching with PAO1 and two on the right with sequences 
that do not match with PAO1 (these are considered a “mutant strain”). If the 
hybridisation spots are stronger on the left (PAO1 sequence) the isolate is assigned 
a “0” for that locus. If the hybridisation spots are stronger on the right (“mutant” 
sequence) the isolate is assigned a “1” for that locus. Figure 5 demonstrates 
examples of binding for both wild type (PAO1) and non-PAO1 (mutant) variants of 
the hybridisation spots which were utilized to act as a guide when reading the AT 
image. 
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Hexadecimal code conversion  
The resulting hexadecimal binary code can then be converted to a 4 digit code as 
shown in figure 6 and a genetic fingerprint is produced and assigned to the strain. 
This code can then be compared to isolate information from several large, 
previously described databases (Ballarini et al., 2012; De Soyza et al., 2013; Hall et 
al., 2014; Wiehlmann et al., 2007).  A combined dataset was created including 
information from the isolates of the previous databases. The comparison allows for 
further information to be acquired about the strain in question, in particular if it has 
previously been assigned a clone type and environments from which isolates of the 
same strain type have been previously collected. 
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C-45  C-46  C-47  PAGI-3-1  PAGI-3-8  PAGI-2-1  
PAGI-2/3-1  PAGI-2/3-4  PAGI-2/3-5  PAGI-2/3-6  
pKL-1  pKL-3  TB-C47-1  TB-C47-2  PAPI-1-
Pili ch  
PAPI-1-
LuBiPr.  
pKLC-  
unknown  
pKLC-adhesion  pKLC-  
metabol  
Pyov. 
Rec.  
I  
Pyov. 
Rec. IIa  
Pyov. 
Rec.  
IIb  
Pyov. 
Rec.  
III  
Pyov. 
Rec.  
B  
LES  
PA0636  PA0722  PAGI-1  PA0980  
PA0728  PA2185  Fla-
island-1  
Fla-2-orfA  47D7-1  PAPI-2-
Actr  
PA2221  PA3835  Fla-2orfI  Fla-2orfj  47D7-2  PAPI-2-
xF1753  
ampC-7  fliCa  fliCb  exoS  exoU  
ampC-4  ampC-5  ampC-6  
oprI  ampC-1  ampC-3  
citS-1  citS-2  oprI  
fliCa  fliCa  alkB2  
oriC  oprL a  oprL  
 
Figure 2.2. Positions of SNPs, genomic islands, and variable genes on the AT chip.  
C45, C46, C47 – gene island in Clone C , PAGI – Pathogenicity Island, pKLC – pKLC102 plasmid in 
Clone C, pyov.rec 1,2a,2b,3 – pyoverdine type receptors I,II and III fpvA, pyov.rec B – pyoverdine 
type I receptor fpvB, LES PS21 marker, PA0636, PA0722, PA0728, PA2185, PA2221, PA3835 – PAO1 
sequences, TB –C47-1, TB- C47-2 - TB, pKLC102 related gene island integrated in tRNA(Lys), fla-
islands 1,2 orfA, orfI and orfJ – flagellin glycosylation islands. , fliCa, fliCb – Flagellin proteins, 
ExoU/ExoS – Type III secreted virulence factors, ampC – βlactamase, oprL – outer membrane 
lipoprotein, citS – citrate synthase, oprI – outer membrane lipoprotein, alkB2 – alkaline hydroxylase 
alkB2 
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Figure 2.3: Predetermined table for comparison of hybridisation patterns for the 
seven conserved loci used for AT chip interpretation. 
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Figure 2.4: Conversion of the hexadecimal binary code.  Adapted from (Wiehlmann 
et al., 2007) 
 
2.4 Genomic DNA extraction for Illumina sequencing  
A selection of 7 isolates were selected to undergo whole genome sequencing (some 
already carried out as part of preliminary unpublished work by Pottenger S,.& 
Fothergill,J. 2014). Genomic DNA (gDNA) was extracted from these isolates using a 
Promega Wizard Genomic DNA Purification Kit. The basic protocol was followed, 
with some minor adjustments to improve yield and purity. Asterisks indicate where 
the method used deviates from that provided by the manufacturer (experience of 
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lab has found these alterations gave better yields of DNA).  
A single colony was picked and grown overnight in 5 ml LB broth in a shaking 
incubator at 37°C and 180 rpm. To pellet the cells, 1 ml overnight culture was 
centrifuged for 2 min at 14 000 rpm and the supernatant discarded. Cells were lysed 
by adding 600 μl Nuclei Lysis Solution and mixing gently. The tubes were then 
incubated at 80°C for 5 min and then cooled on ice for a further 5 min*. Once cool 3 
μl RNase A Solution (Promega) was added and gently mixed. The tubes were then 
incubated at 37°C for 1 h and then cooled on ice for 5 min*. Protein was 
precipitated by adding 400 μl Protein Precipitation Solution* and vortexing 
immediately. The tubes were kept on ice for 5 min and then centrifuged at 14 000 
rpm for 5 min*. The supernatant was then transferred to a tube containing 600 μl 
room temperature isopropanol and mixed by inverting the tube several times. 
Following centrifugation at 14 000 rpm for 15 min* the supernatant was removed. 
Once dry, 600 μl room temperature 70% ethanol (V/V) was added to each tube and 
the samples were centrifuged at 14 000 rpm for 15 min*. The supernatant was then 
removed and the tubes left to air dry completely. The DNA pellet was then 
rehydrated by adding 100 μl DEPC-treated water and storing overnight at 4°C.  
 
Quantification of genomic DNA by Qubit fluorometer  
This process was carried out by colleague at University of Liverpool, Yasmin Hilliam.  
Quantification of gDNA in samples was performed using a Qubit 3.0 fluorometer 
and Qubit dsDNA broad range assay kit (Life Technologies). A working solution was 
made using concentrated assay reagent and dilution buffer in a 1:200 dilution. 190 
μl working solution was added to 10 μl of each of the two pre-diluted standards for 
a total reaction volume of 200 μl. 2 μl sample was used per reaction, and made up 
to a final volume of 200 μl with working solution. The tubes were vortexed for 2 – 3 
seconds and then incubated at room temperature for 2 min before being inserted 
into the Qubit fluorometer to measure fluorescence. Samples were required to 
contain >20 ng μl-1 gDNA in order to be sent for sequencing.  
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Quantification and purity testing of genomic DNA by NanoDrop 
spectrophotometer  
This process was performed by colleague at University of Liverpool, Yasmin Hilliam.  
Further quantification and purity testing of gDNA in samples was carried out using a 
NanoDrop 1000 spectrophotometer (Thermo Scientific). Extracted DNA had 
previously been eluted in DEPC-treated water and so the same was used as a blank 
for NanoDrop measurements. 2 μl DEPC-treated water was carefully pipetted on to 
the lower measurement pedestal of the spectrophotometer and the sampling arm 
then closed to form a liquid column to allow the machine to make a blank 
measurement. 2 μl sample was pipetted in the same manner on to the lower 
measurement pedestal of the machine and measurements made. Both the upper 
and lower measurement pedestals were wiped clean with a soft clean tissue 
between sample measurements (Nanodrop, 2017a).   
NanoDrop measurements provide a wide range of information on the absorbance 
of the sample but the measurements most highly relating to the purity of the 
sample are the ratios of sample absorbance at 260/280 nm and 260/230 nm. 
260/280 ratio of absorbance assesses purity of DNA present in the sample. A ratio 
of ~1.8 is generally accepted as “pure” for DNA samples. If the ratio is much lower 
than 1.8 it may indicate the presence of protein, phenol or other contaminants that 
absorb strongly at or near 280 nm. 260/230 ratio of absorbance is a secondary 
measure of DNA purity and 260/230 ratios for “pure” samples are often higher than 
the respective 260/280 ratios, often in the range of 1.8 – 2.2.  If the ratio is lower 
than expected, it may indicate the presence of contaminants which absorb at 
230nm (Nanodrop, 2017b).  
 
2.5 Whole Genome Sequencing  (Illumina) of Bacterial Isolates 
Genomic DNA from the seven polymyxin resistant isolates was extracted from 
overnight cultures using the DNeasy Blood and Tissue Kit (QIAGEN). Genomic DNA 
(500 ng) was mechanically fragmented for 40 sec using a Covaris M220 (Covaris, 
Woburn MA, USA) with default settings. Fragmented DNA was transferred to PCR 
tubes and library synthesis was performed with the Kapa Hyperprep kit (Kapa 
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biosystems, Wilmington MA, USA) according to manufacturer’s instructions. TruSeq 
HT adapters (Illumina, SanDiego, CA, USA) were used to barcode the samples and 
libraries were sequenced along with 41 other bacterial genomes in an Illumina 
MiSeq 300 bp paired-end run at the Plateforme d’Analyses Génomiques of the 
Institut de Biologie Intégrative et des Systèmes (Laval University, Quebec, Canada) 
(Freschi et al., 2015).  Resistant isolate genomes were assembled using the A5 
assembler version (Coil et al., 2015) and annotated using prokka version 1.5 
(Seemann, 2014). 
 
2.6  Genomics 
Genome assembly work was performed by Matthew Moore (University of 
Liverpool). in collaboration with the Pseudomonas Genomics Consortium (PGC) 
(Levesque RC, Kukavica-Ibrulj I, Jeukens J, Freschi L;  L'Institut de biologie intégrative 
et des systèmes (IBIS), Pavillon Charles-Eugène-Marchand 1030, avenue de la 
Médecine, Labo 4142 Université Laval, Québec (QC), G1V 0A6 Canada). 
 
The 7 polymyxin resistant isolate genomes were assembled using the A5 assembler 
version (Coil et al, 2015) and annotated using prokka version 1.5 (Seemann, 2014).  
 
All 7 polymyxin resistant genomes were aligned to reference genome PA01 and 
separately, PA14 using bwa mem version 0.7.5a (McKenna et al, 2010). Resulting 
.sam alignment files were sorted, converted to .bam format and duplicates marked 
and removed using picardtools version 1.85. The Genome Analysis Toolkit (GATK) 
version 3.3 was used to create indel targets, realign them and call variants using the 
Unified Genotyper (UG) module. All variants were filtered using vcffilter version 
GitHub (GitHub 2015) ‘DP >9’ and ‘QUAL >10’ to produce the final .vcf files.  
 
Reference genomes PA01, PA14, PA7 and LESB58 and 338 deemed to represent the 
wider population (Kos et al., 2015) were downloaded from the Pseudomonas 
Database (Winsor et al., 2011). The core genome was defined and extracted by 
Panseq (Laing et al., 2010) as 500bp fragments matching in all 342 genomes with 
>=85% similarity. MEGA6 (Tamura et al, 2013) was used for all phylogenetic 
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analyses. Phylogeny was estimated using the maximum likelihood method (ML) and 
tamura-nei substitution model from concatenated polymorphic sites within the 
defined core genome. Inner node support was based on 100 bootstrap replicates. 
The tree was drawn using figtree (Figtree, 2015). 
 
Ortholog sequences for 31 polymyxin resistance associated genes were downloaded 
from the Pseudomonas Database (Winsor et al., 2011).  A custom blast database 
was curated consisting of the 7 polymyxin resistant isolate genomes using the 
BLAST+(55) makeblastdb software. Each polymyxin resistance associated gene was 
aligned against the custom database using BLAST+ blastall. A python script was used 
to extract matching regions and convert to amino acid sequences from the 7 
polymyxin resistant isolate genomes.  
 
 
2.7  Comprehensive Antibiotic Resistance Database (CARD) sequence data analysis 
 
The CARD integrates disparate molecular and sequence data, provides a unique 
organizing principle in the form of the Antibiotic Resistance Ontology (ARO), and 
can quickly identify putative antibiotic resistance genes in new unannotated 
genome sequences (CARD 2015).  In addition to extensive browsing tools, 
integrated within the CARD and available as tools on the website are BLAST 
databases for all genes stored in the CARD. BLAST searches can include all genes or 
subsets of CARD reflecting antibiotic resistance genes, antibiotic targets, and 
antibiotic biosynthesis genes.  The Resistance Gene Identifier (RGI) is a novel 
analytical tool that provides a preliminary annotation of the submitted DNA 
sequence(s) based upon the data available in the CARD. RGI accepts GenBank 
accession or GI numbers, pasted sequences, or uploaded nucleotide sequence files 
in FASTA format. Data with two or more FASTA sequences, such as whole-genome-
sequencing (WGS) assembly contigs, can be accepted (maximum size, 20 Mb). The 
RGI analyzes the submitted sequences and provides a detailed output of predicted 
antibiotic resistance genes and targeted drug classes. This includes resistance to 
antibiotics via mutations in their targets or via dedicated antibiotic resistance gene 
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products (enzymes, protective proteins, and efflux systems). RGI results are then 
summarized using a “resistance wheel,” with overall antibiotic resistance in the 
center, antibiotic resistance classes in the middle, and individual antibiotic 
resistance genes on the outer ring (McArthur et al., 2015; McArthur et al., 2013).  
Seven of the sequenced isolates were uploaded in FASTA format and analysed using 
this particular tool. 
 
2.8  eBURST algorithm 
 
The eBURST algorithm (eBurst, 2015) was devised as a way of displaying the 
relationships between closely-related isolates of a bacterial species or population.  
Using a model of bacterial evolution in which a founding genotype increases in 
frequency in the population, and while doing so, begins to diversify to produce a 
cluster of closely-related genotypes that are all descended from the founding 
genotype. This cluster of related genotypes is referred to as a “clonal complex”.   
The algorithm predicts descent of genotypes from the ancestor and displays the 
output as a radial diagram.  eBURST was originally devised and developed by Ed Feil 
from the University of Bath (Feil et al, 2004).  An enhanced version (eBurstv3) has 
been developed with funding from the Wellcome Trust, and is hosted by 
department of Infectious Disease Epidemiology Imperial College London.   The 
eBURST algorithm has mainly been applied to MLST data, although in this study it 
has been used to display the relationships between genotypes identified through AT 
genotyping. For use with the AT genotypes, the profiles were converted into a tab 
delineated text file and uploaded to the eBURST site. For analysis, the programme 
was set to estimate the relatedness based on 16 loci, with a minimum of one 
identical loci for group definition, a single locus variant (SLV) count of 0 for 
subgroup definition, and number of re-samplings for bootstrap support set to 1000.  
The data is divided into groups of sequence types (STs) that have a level of similarity 
in their SNP profiles. Within a single group all STs must be an SLV of at least one 
other ST in the group. The primary founder of any group is defined as the ST that 
differs from the largest number of other STs at only a single locus. In the case of two 
STs having the same number of SLVs, the one with the greater number of double 
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locus variants (DLVs) is selected as the founding member. More than one group can 
be displayed, appearing as a cluster, in a single eBURST diagram along with any 
unlinked STs. The eBURST diagram shows the patterns of descent within a group in 
a radial fashion with lines connecting the founder to each of its SLVs, and lines 
connecting these STs to other STs varying from them at only one locus. The size of 
the node representing an ST indicates the relative abundance of that ST within the 
population.   
 
2.9  Statistical Analysis: 
 
SigmaPlot (version12.3) was used to make comparisions between the human and 
veterinary polymyxin susceptibilities, using Fisher’s exact test. Non parametric test 
were used on the basis that the results were not normally distributed. 
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Materials and Methods for Results Chapter 4 - PCR characterisation of antibiotic 
resistant determinants in P. aeruginosa from companion animals: 
  
2.10  Bacterial Isolates 
 
Clinical P. aeruginosa (n=106) isolates from companion animal diagnostic samples 
sent to Veterinary Diagnostic Laboratory at the Small Animal Teaching Hospital, 
Leahurst (University of Liverpool, UK) between 2010-2015 were selected for this 
study (Table 2.2).  Selection of isolates for this study was made on the basis of 
species (ie. any isolate that was from a companion animal species) and bacterial 
species identification (all P. aeruginosa). Any duplicates were excluded.  No clinical 
data or prior knowledge of use of antibiotics in these cases was known.  Overall, 
106 isolates from companion animals (canine n=93, equine n=11, feline n=2) were 
selected. The collection of isolates were stored at -80°C (Microbank, Pro-Lab 
Diagnostics, Cheshire, UK).  When required isolates were then transferred to 
Mueller-Hinton nutrient agar (MHA, Oxoid, Basingstoke, UK) and incubated 
overnight at 37oC in aerobic conditions. P. aeruginosa  ATCC27853  was used as a 
control strain. 
 
Table 2.2 Clinical veterinary bacterial isolates used in this study from companion 
animals 
Isolate Ref number    Description                                                                                               Species 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Chest drain fluid Canine 
Right ear swab Canine 
Skin swab Canine 
Abdominal fluid Canine 
Ear swab Canine 
Vulval swab Canine 
Urine Canine 
Ear swab Canine 
Ventral abdomen tissue Canine 
Chin furuncle and foot swab Canine 
Left stifle fluid Canine 
Ear swab Canine 
Ear swab Canine 
Right ear swab Canine 
Wound swab Right hind limb Canine 
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16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
Left ear swab Canine 
Nasal swab Equine 
Left ear swab Canine 
Abdominal incision swab Equine 
Ear swab Canine 
Urine Equine 
Wound swab Canine 
Urine Canine 
Wound swab Canine 
Swab right mandible (Non healing wound) Canine 
Neck swab Canine 
Urine Canine 
Right ear swab Canine 
Oesophagostomy tube stoma swab Feline 
Right elbow wound swab Canine 
Bile Canine 
Vaginal swab Canine 
Right ear swab Canine 
Lip fold Canine 
Right ear swab Canine 
Buccal swab Canine 
Skin lesion swab Canine 
Left neck swab Canine 
Testicle/scrotum swab Canine 
Tissue Canine 
Vaginal swab Canine 
Wound swab Canine 
Right ear swab Canine 
Tracheal Canine 
Left ear swab Canine 
Right ear swab Canine 
Tissue Canine 
Right ear swab Canine 
Right ear swab Canine 
Bronchial aspirate Canine 
Skin Canine 
Urine Canine 
Urinary catheter Canine 
Right ear swab Canine 
PEG tube stoma wound Canine 
Left ear swab Canine 
Bronchial aspirate Canine 
Tissue Canine 
Skin swab Canine 
Wound swab Canine 
Tracheal Canine 
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62 
63 
64 
65 
66 
67 
68 
69 
70 
71 
72 
73 
74 
75 
76 
77 
78 
79 
80 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
96 
97 
98 
99 
100 
101 
102 
103 
104 
105 
106 
  
Wound swab Canine 
Wound swab Canine 
Right anal sac swab Canine 
Catheter Equine 
Tracheal wash Equine 
Guttural pouch washes Equine 
Tissue Canine 
Right ear swab Canine 
Wound serous discharge and fat tissue Canine 
Urine Canine 
Tissue Canine 
Wound swab Canine 
Right and Left BAL Feline 
Left ear swab Canine 
Urine catheter Canine 
Maxillary sinus Equine 
Colic incision swab Equine 
Urine Canine 
Urine Canine 
Tissue Canine 
Vulval fluid swab Canine 
Urine Canine 
Skin Canine 
Left ear swab Canine 
Right ear swab Canine 
Ear swab Canine 
Right ear swab Canine 
Ear swab Canine 
Left ear swab Canine 
Right ear swab Canine 
Urine Equine 
Urine Canine 
Midline swab Equine 
Ear swab Canine 
Ear swab Canine 
Vulval swab Canine 
TrWash ETTmu Canine 
Ear swab Canine 
Vaginal swab Canine 
Urine Canine 
Wound swab Canine 
Urine Canine 
Wound swab Canine 
Right Ear Swab Canine 
Urine Equine 
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Table 2.3 Clinical veterinary bacterial isolates used in this study from companion 
animals and identification of the sources of samples used. 
 
Source of isolate Total No No from 
Equine 
No from 
Canine  
No from 
Feline 
Ear 32  32  
Skin (includes lip fold and 
neck swabs) 
8  8  
Wound/Nonhealing 
wound 
14    
Urine 14 2 12  
Urine catheter 2  2  
Catheter 1 1   
Testicle/Scrotum swab 1  1  
Vulval/Vaginal swab 6  6  
Surgical wound/incision 
(including midline swab 
and colic incision) 
4 1 3  
Abdominal fluid 1  1  
Foot swab 1  1  
Stifle fluid 1  1  
Tracheal/Tracheal wash 4 1 3  
Guttural pouch 1 1   
Maxillary sinus 1  1  
Bronchial aspirate 2  2  
Tissue swab (including 
abdominal tissue) 
7  7  
Anal sac swab 1  1  
Buccal swab 1  1  
Bile 1  1  
Oesophogostomy tube 
stoma swab 
1  1  
Chest drain fluid 1  1  
Bronchoalveolar lavage 1   1 
 
 
 
2.11  Susceptibility Testing 
 
Determination of Minimal Inhibitory Concentration (MIC) to a selection of 
veterinary used antibacterials    
 
Minimal Inhibitory Concentration (MIC) testing was performed using commercially 
available Trek Sensititre COMPAN1F microtitre 96 well plates (Trek Diagnostics 
Systems, West Sussex, UK), in accordance with manufacturer’s guidelines and as per 
the method detailed earlier in Chapter 2 ‘MIC for Companion Animal Veterinary 
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Antibiotic panel’s – refer to page 31).   P. aeruginosa ATCC27853 was used as the 
quality control strain for MIC evaluations.  
The MIC ranges were tested to a series of twenty two veterinary-used 
antimicrobials (concentration ranges tested in brackets in mg/mL); ampicillin (0.25-
16), amoxicillin/clavulanic acid (4/2-32/16), trimethoprim/sulphamethoxazole 
(0.5/9.5-2/38), penicillin (0.06-8), cefovecin (0.25-8), cefpodoxime (2-16), 
erythromycin (0.5-4), oxacillin+2%NaCl (0.25-4), cefoxitin (2-16), clindamycin (0.5-
4), doxycycline (2-8), cefazolin (4-16), chloramphenicol (4-16), rifampicin (1-2), 
amikacin (4-32), ceftiofur (2-16), enrofloxacin (0.25-2), gentamicin (1-8), imipenem 
(1-8), marbofloxacin (0.25-2), ticarcillin (8-64), ticarcillin/clavulanic acid (8/2-64/2).  
Three positive control wells were included on the plate.  Results were interpreted 
using standard EUCAST or CLSI breakpoint guidelines as appropriate. 
 
 
Phenotypic detection of extended spectrum beta-lactamses (ESBL) 
 
Detection of ESBL production was performed by double disc synergy test (DDST) (S.-
P. Lin, Liu, Lin, & Shi, 2012).  Pairs of discs (MastDiscs, MAST Diagnostics Group Ltd, 
Bootle, Merseyside, UK) containing the extended spectrum cephalosporins 
cefotaxime, ceftazidime and cefpodoxime alone and in combination with clavulanic 
acid (cefotaxime/clavulanic acid 30 mg/10 μg, ceftazidime/clavulanic acid 30 mg/10 
μg and cefpodoxime/ clavulanic acid 30 mg/10 μg) were placed on the plates using 
a multi-dispenser.  Results were read after 24 hrs incubation at 37 °C.  The test 
isolate was regarded as an ESBL producer if the zone of inhibition around the 
combination disc was at least 5mm larger (≥5mm larger) than that of the 
cephalosporin alone (MAST group 2017). 
Cloxacillin or boronic acid (250 μg/mL; both from Sigma-Aldrich Company Ltd. 
Dorset, UK) was added to MHA to inhibit chromosomal cephalosporinase activity.  
Following overnight culture, test isolates were suspended to 0.5 turbidity using 
McFarland standards, and used to inoculate a Mueller-Hinton agar plate containing 
the 250μg/mL cloxacillin or boronic acid (Lin et al., 2012) (Aghazadeh et al., 2014).  
After plate drying, the discs were placed as described earlier.   
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Disc diffusion susceptibility testing against a human antibacterial panel 
 
Antimicrobial susceptibility testing was performed by disc diffusion method to a 
panel of clinically relevant commonly used human antibacterials containing 
aztreonam (30 μg), meropenem (10 μg), cefepime (30μg), piperacillin (30 μg), 
piperacillin (30 μg)/tazobactam (36 μg), and cefoxitin (30 μg) (all from Oxoid, Oxoid 
Ltd, Thermo Fisher Scientific group, UK).  Preparation of a standard bacterial 
suspension equal to 0.5 McFarland was inoculated on MHA and the antibiotic discs 
were placed on the plate using a multi-dispenser. Results were read after 24 hrs 
incubation at 37 °C.  The diameter of zone of growth inhibition were measured 
interpretation performed by using the European Committee on Antimicrobial 
Susceptibility Testing breakpoints (EUCAST 2015).  Disc diffusion susceptibility 
testing is a published, acceptable method for determining susceptibility and was 
chosen in this instance as it enables large scale screening that wouldn’t be possible 
in the time frame of this project if MICs were used for all antibiotics. 
 
 
2.12  DNA Extraction 
 
For DNA extraction a standard boil preparation method was followed. Subcultures 
were made of the isolates by passage on MHA and incubation for 24 hrs at 37 °C.  A 
few bacterial colonies (two 5 μl sterile loops) were added to 1ml of sterile water in 
1.5ml Eppendorf tube and mixed.  The solution was then heated for 10 mins at 95 
°C on a thermoplate, followed by centrifuging at 10,000 rpm for 2 mins.  The 
supernatant was removed to a fresh sterile Eppendorf tube for DNA use and labeled 
appropriately for each isolate.  This was stored at 4 °C for direct usage. 
 
DNA Extraction –  Wizard® Genomic DNA Purification Kit Method 
Bacterial DNA was extracted from a selection of the P. aeruginosa isolates using a 
commercially available Genomic DNA Purification kit (Wizard® Genomic DNA 
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Purification Kit, Promega Corporation, Madison, WI 53711-5399 USA) according to 
the manufacturers guidelines. 
1 ml of an overnight culture was added to a 1.5 ml microcentrifuge tube and 
centrifuged at 13,000–16,000 × g for 2 minutes to pellet the cells. The supernatant 
was removed.  3μl of RNase Solution was added to the cell lysate and the tube 
inverted 2–5 times to mix.  The sample was incubated at 37°C for 15–60 minutes 
and then cooled to room temperature. A 200μl aliquot of Protein Precipitation 
Solution was added to the RNase-treated cell lysate. This was then vortexed 
vigorously at high speed for 20 seconds to mix the Protein Precipitation Solution 
with the cell lysate.  The sample was then incubated the on ice for 5 minutes. Then 
centrifuged at 13,000–16,000 × g for 3 minutes.   The supernatant (containing the 
DNA) was transfered to a clean 1.5ml microcentrifuge tube containing 600 μl of 
room temperature isopropanol.  This was gently mixed by inversion until the 
thread-like strands of DNA form a visible mass.  Then centrifuged at 13,000–16,000 
× g for 2 minutes.  The supernatant was poured off and drained the tube.  600 μl of 
room temperature 70% ethanol was added and the tube gently inverted several 
times to wash the DNA pellet.  After centrifuging at 13,000–16,000 × g for 2 
minutes, aspirate the ethanol.  The tube was drained on clean absorbent paper and 
the pellet allowed to air dry for 10–15 minutes.  Then adding 100 μl of DNA 
Rehydration Solution to the tube and rehydrate the DNA by incubating the solution 
overnight at room temperature or at 4 °C then stored the DNA at 2–8 °C. 
 
2.13  Polymerase Chain Reaction (PCR)  
 
DNA extraction was performed as previously described by boil preparation method.  
PCR amplification (for both simplex and multiplex) was performed in a final volume 
of 25 μl, using the primers as presented in Table 2.5. 
The composition of PCR mixture was: 5 μl of a Master Mix, FIREPol® (5 x FIREPol® 
Master Mix Ready to Load, Solis BioDyne, Estonia, a premixed ready-to-use solution 
containing all reagents required for PCR - except template, primers and water).   
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In addition for each genes tested the forward and reverse primers (final primer 
concentrations were 10pcm/μl PCR reaction), water and template DNA were added 
in the quantities as listed in Table 2.3 for multiplex and Table 2.4 for simplex. 
 
The PCR products were electrophoresed in 1% agarose gels containing PeqGREEN® 
dye (VWR International Ltd, Leicestershire, England). The DNA fragments were 
imaged with UV transilluminator and UViProMW software documentation system.  
The DNA loading dye DNA/BsuRI (HaeIII) Marker 9, 50 mg (0.5 
μg/μl)(ThermoScientific Molecular Biology), was placed on each gel run.  
 
Table 2.4 Multiplex PCRs conditions 
 
Genes Tested PCR Mixture  PCR Conditions (using 
Applied BioSystems, 
Thermocycler 2720) 
References 
TEM, SHV, OXA 5 μl of FIREPol® Mastermix, 
1μl of each forward and 
reverse primers, 12 μl  
water and 2 μl of each 
template DNA. 
 
 
 
The amplification program 
for all of the 
aforementioned genes 
consisted of initial 
denaturation at 94 °C for 10 
mins, annealing at 94 °C for 
40 secs, 60 °C for 40 secs, 
extension at 72 °C for 1 min 
(for 30 cycles) and a final 
extension at 72 °C for 7 mins 
in a thermocycler. 
 
(Dallenne et al.,  
2010) 
GES, VEB, PER 5 μl of FIREPol® Mastermix, 
0.75 μl of each forward 
and reverse primers, 13.5 
μl  water and 2 μl of each 
template DNA. 
 
(Dallenne et al., 
2010) 
VIM, IMP, KPC 5 μl of FIREPol® Mastermix, 
1.25 μl of each forward 
and reverse primers, 10.5 
μl  water and 2 μl of each 
template DNA. 
 
(Dallenne et al., 
2010) 
qnrA, qnrB, qnrS 5 μl of FIREPol® Mastermix, 
1 μl of each forward and 
reverse primers, 12 μl 
water and 2 μl of each 
template DNA. 
initial denaturation at 94 °C 
for 10 mins, annealing at 94 
°C for 1 min, 53 °C for 1 min, 
extension at 72 °C for 1 min 
(for 35 cycles) and a final 
extension at 72 °C for 10 
mins in a thermocycler 
(Robicsek et al., 
2006) 
 
 
 
The multiplexPCRs were not continued throughout due to misleading results (refer 
to detail in Results Chapter 4) therefore it was decided to do all PCRs as simplex 
method (details in Table 2.5). 
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Table 2.5 Simplex PCR conditions 
 
Genes Tested PCR Mixture  PCR Conditions (using 
Applied BioSystems, 
Thermocycler 2720) 
References 
blaTEM, blaSHV, 
blaOXA 
5 μl of FIREPol® Mastermix, 
1μl of each forward and 
reverse primers, 16 μl water 
and 2 μl of template DNA. 
 
 
 
The amplification program for 
all of the aforementioned 
genes consisted of initial 
denaturation at 94 °C for 10 
mins, annealing at 94 °C for 40 
secs, 60 °C for 40 secs, 
extension at 72 °C for 1 min 
(for 30 cycles) and a final 
extension at 72 °C for 7 mins in 
a thermocycler. 
 
(Dallenne et al., 
2010) 
blaGES, blaVEB, 
blaPER 
5 μl of FIREPol® Mastermix, 
0.75 μl of each forward and 
reverse primers, 16.5 μl 
water and 2 μl of template 
DNA. 
 
(Dallenne et al., 
2010) 
blaVIM, blaIMP, 
blaKPC 
5 μl of FIREPol® Mastermix, 
1.75 μl of each forward and 
reverse primers, 15.5 μl 
water and 2 μl of template 
DNA. 
 
(Dallenne et al., 
2010) 
group OXAs; OXA-
1, OXA-2, OXA-10 
5 μl of FIREPol® Mastermix, 
0.5 μl of each forward and 
reverse primers, 18 μl  water 
and 1μl of template DNA. 
initial denaturation at 95 °C for 
5 mins, annealing at 95 °C for 1 
min, 55 °C for 40 secs, 
extension at 72 °C for 1 min 
(for 25 cycles) and a final 
extension at 72 °C for 10 mins 
in a thermocycler 
(Poirel, et al, 2010) 
qnrA, qnrB, qnrS 5 μl of FIREPol® Mastermix, 
0.5 μl of each forward and 
reverse primers, 18 μl water 
and 1 μl of template DNA. 
initial denaturation at 94 °C for 
10 mins, annealing at 94 °C for 
1 min, 55 °C for 40 secs, 
extension at 72 °C for 1 min 
(for 25 cycles) and a final 
extension at 72 °C for 10 mins 
in a thermocycler 
(Robicsek et al., 
2006) 
 
AmpC 5 μl of FIREPol® Mastermix, 
0.5 μl of each forward and 
reverse primers, 18 μl water 
and 1 μl of template DNA. 
initial denaturation at 94 °C for 
3 mins, annealing at 94 °C for 1 
min, 60 °C for 40 secs, 
extension at 72 °C for 1 min 
(for 25 cycles) and a final 
extension at 72 °C for 5 mins in 
a thermocycler 
(Rodríguez-
Martínez et al, 
2009) 
CTX-MU, BEL-1, 
CS(integrons) 
5 μl of FIREPol® Mastermix, 
0.5 μl of each forward and 
reverse primers, 17 μl  water 
and 2 μl of template DNA. 
initial denaturation at 94 °C for 
3 mins, annealing at 94 °C for 
1min, 56.9 °C for 40 secs, 
extension at 72 °C for 1 min 
(for 25 cycles) and a final 
extension at 72 °C for 5 mins in 
a thermocycler 
(Wedley et al., 
2011) 
(Bogaerts, et al, 
2007) 
(Zhao et al., 2003) 
AAC(lb) cr variant 5 μl of FIREPol® Mastermix, 1 
μl of each forward and 
reverse primers, 16 μl  water 
and 2 μl of template DNA. 
 
initial denaturation at 94 °C for 
3 mins, annealing at 94 °C for 
45 secs, 55 °C for 45 secs, 
extension at 72 °C for 45 secs 
(for 34 cycles) and a final 
extension at 72 °C for 5 mins in 
a thermocycler 
(Hong et al., 2009; 
Park et al, 2006) 
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2.14  Primers 
 
Table 2.6 DNA sequencing primers used in this study. 
Primers purchased from Eurofins Genomics (Eurofins, Ebersberg, Germany) 
 
 
 
 
 
 
2.15  Quantification and purity testing of genomic DNA by NanoDrop 
spectrophotometer  
Further quantification and purity testing of gDNA in samples was carried out using a 
NanoDrop 1000 spectrophotometer (Thermo Scientific). Extracted DNA had 
previously been eluted in DEPC-treated water and so the same was used as a blank 
for NanoDrop measurements. 1 μl DEPC-treated water was carefully pipetted on to 
Primer name 
 
Sequence 
 
Product size 
(bp) 
Reference 
TEM Fw 
TEM Rev 
CATTTCCGTGTCGCCCTTATTC 
CGTTCATCCATAGTTGCCTGAC 
800 (Dallenne et al., 2010) 
SHV Fw 
SHV Rev 
AGCCGCTTGAGCAAATTAAAC 
ATCCCGCAGATAAATCACCAC 
713 (Dallenne et al., 2010) 
OXA Fw 
OXA Rev 
GGCACCAGATTCAACTTTCAAG 
GACCCCAAGTTTCCTGTAAGTG 
564 (Dallenne et al., 2010) 
GES Fw 
GES Rev 
VEB Fw 
VEB Rev 
PER Fw 
PER Rev 
VIM Fw 
VIM Rev 
IMP Fw 
IMP Rev 
KPC Fw 
KPC Rev   
qnrA Fw 
qnrA Rev 
qnrB Fw 
qnrB Rev 
qnrS Fw 
qnrS Rev 
OXA-1 Fw 
OXA-1 Rev 
OXA-2 Fw 
OXA-2 Rev 
OXA-10 Fw 
OXA-10 Rev 
CTX-MU Fw 
CTX-MU Rev 
BEL-1 Fw 
BEL-1 Rev 
CS-1 Fw 
CS-1 Rev 
AAC-61b Fw 
AAC-61b Rev 
AmpC Fw 
AmpC Rev 
AGTCGGCTAGACCGGAAAG 
TTTGTCCGTGCTCAGGAT 
CATTTCCCGATGCAAAGCGT 
CGAAGTTTCTTTGGACTCTG 
GCTCCGATAATGAAAGCGT 
TTCGGCTTGACTCGGCTGA 
GATGGTGTTTGGTCGCATA 
CGAATGCGCAGCACCAG 
TTGACACTCCATTTACDG 
GATYGAGAATTAAGCCACYCT 
CATTCAAGGGCTTTCTTGCTGC 
ACGACGGCATAGTCATTTGC  
ATTTCTCACGCCAGGATTTG 
GATCGGCAAAGGTTAGGTCA  
GATCGTGAAAGCCAGAAAGG 
ACGATGCCTGGTAGTTGTCC  
ACGACATTCGTCAACTGCAA 
TAAATTGGCACCCTGTAGGC 
AGCCGTTAAAATTAAGCCS 
CTTGATTGAAGGGTTGGGCG 
GCCAAAGGCACGATAGTTGT 
GTCCGAGTTGACTGCCGG 
TCTTTCGAGTTACGGCATTAGC 
CCAATGATGCCCTCACTTTCC 
TGGGTRAARTARGTSACCAGAAYCAGCGG  
TGGGTRAARTARGTSACCAGAAYCAGCGG  
CGACAATGCCGCAGCTAACC 
CAGAAGCAATTAATAACGCCC 
GGCATCCAAGCACAAGC 
AAGCAGACTTGACTGAT 
TTGCGATGCTCTATGAGTGGCTA 
CTCGAATGCCTGGCGTGTTT 
ATGCAGCCAACGACAAAGG 
CGCCCTCGCGAGCGCGCTTC 
399 
 
648 
 
520 
 
390 
 
139 
 
538 
 
516 
 
469 
 
417 
 
908 
 
700 
 
760 
 
593 
 
 
 
 
 
482                                                                   
 
1243 
 
(Dallenne et al., 2010) 
 
(Dallenne et al., 2010) 
 
(Dallenne et al., 2010) 
 
(Dallenne et al., 2010) 
 
(Dallenne et al., 2010) 
 
(Dallenne et al., 2010) 
 
(Robicsek et al., 2006) 
(Robicsek et al., 2006) 
(Robicsek et al., 2006) 
(Poirel et al., 2010) 
(Poirel et al 2010) 
(Poirel et al., 2010) 
(Wedley et al., 2011) 
 
(Bogaerts et al., 2007) 
 
(Zhao et al., 2003) 
 
(Hong et al., 2009) 
 
(Rodríguez-Martínez et 
al., 2009) 
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the lower measurement pedestal of the spectrophotometer and the sampling arm 
then closed to form a liquid column to allow the machine to make a blank 
measurement. 1 μl sample was pipetted in the same manner on to the lower 
measurement pedestal of the machine and measurements made. Both the upper 
and lower measurement pedestals were wiped clean with a soft clean tissue 
between sample measurements.  
PCR products of adequate quantity were sent for sequencing to Source BioScience 
(Source BioScience). The concentration of DNA required was dependent upon the 
length of the sample sent. A concentration of 1 ng/ μl per 100 base pairs is required 
for successful sequencing from putified PCR samples.  Primers forwards and reverse 
were also sent. These were required to be sent at 3.2 pmol/μl.   For sequencing 5 μl 
per reaction of both primer and DNA at the above specified concentrations was 
required thus 15 μl of each was prepared. 
 
2.16  DNA Sequencing 
Genomic DNA from positive simplex PCR P. aeruginosa isolates was extracted using 
a commercially available PCR clean up Gel extraction kit (NucleoSpin® Gel and PCR 
Clean-up, Macherey-Nagel GmbH & Co, Duren, Germany) according to the 
manufacturers guidelines. 
The PCR amplicons were purified and sequenced on both strands.  The DNA 
sequences were analyzed with Staden software and compared with published DNA 
sequences in the GenBank database https://blast.ncbi.nlm.nih.gov/Blast.cgi 
 
2.17  Statistical Analysis 
The 95% CIs were performed on proportions using the Wilson method 
(http://epitools.ausvet.com.au) 
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Chapter 3: Results 
 
3. Reservoirs of resistance: polymyxin resistance in veterinary-associated isolates 
of Pseudomonas aeruginosa: 
 
3.1 Introduction  
 
Polymyxins are produced naturally by Bacillus polymyxa. They demonstrate 
bactericidal activity against a wide range of species of Gram-negative bacilli 
including Escherichia coli, Salmonella spp and P. aeruginosa. Polymyxins that are 
utilised in clinical practice include polymyxin B and polymyxin E (colistin). These are 
cationic peptides and the main difference between the two molecules is that 
polymyxin B contains phenylalanine in position 6 (from the N-terminal), while 
colistin contains D-leucine (Tran et al., 2016; Velkov et al., 2014).  The outer 
membrane normally serves as a protective barrier for Gram-negative bacteria 
against antimicrobial peptides and disinfectants.  The mechanism of action by which 
polymyxins exert their effect is through electrostatic interaction with divalent 
cations of the outer bacterial membrane. The polymyxin antibacterial peptides can 
selectively bind to the lipopolysaccharide (LPS) of the outer cell membrane, the 
membrane permeability is disturbed and this destabilization results in lysis of the 
bacteria and ultimately leads to cell death (Chen et al., 2011; Yu., et al, 2015).   
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Figure 3.1  Antibacterial mechanisms of polymyxin: (a) classic mechanism of membrane 
lysis; (b) alternative mechanism of vesicle-vesicle contact.  Polymyxin is shown as red. LPS- 
lipopolysaccharide Referenced from (Chen et al., 2011; Yu et al, 2015)  
 
 
Mechanisms of resistance in P. aeruginosa to polymyxins include adaptive 
resistance (where various cell surface alterations are reported) (Fernández et al., 
2010; Moore et al, 1984) and genetic mutations.  
 
Adaptive resistance describes a reversible refractoriness to the bactericidal effect of 
an antibacterial agent.  Adaptive resistance is a phenomenon by which certain 
environmental cues, including sub-inhibitory concentrations of antibiotics, can 
transiently induce resistance to otherwise lethal doses of antimicrobial agents 
(often refered to as tolerance).  The cause is not deemed a genetic mutational 
change but rather a protective phenotypic alteration in bacterial characteristics 
(Darmon & Leach, 2014).  This can include the reversible down-regulation of the 
active transport of aminoglycosides into Gram-negative bacteria (Barclay & Begg, 
2001; Poole, 2005a).  In P. aeruginosa, adaptive resistance to polymyxins and 
cationic antimicrobial peptides occurs in response to limiting extracellular 
concentrations of divalent Mg2+ and Ca2+ cations. This adaptation is controlled by 
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the two-component regulators PhoP-PhoQ and PmrA-PmrB which up-regulate the 
expression of the arnBCADTEF lipopolysaccharide (LPS) modification operon 
(Fernández et al., 2010; Olaitan et al., 2014). The products of these arn genes 
participate in the addition of 4-aminoarabinose to lipid A of LPS, thereby reducing 
the net negative charge of LPS and limiting the interaction and self-promoted 
uptake of polycationic antibiotics, such as polymyxins, host defense peptides, and 
aminoglycosides, with the outer membrane (Fernández et al., 2010). However, this 
adaptation to low divalent cations is unlikely to be clinically meaningful. Sub-
inhibitory concentrations of peptides can induce the expression of the pmrAB and 
arnBCADTEF operons in P. aeruginosa. However, neither PhoP-PhoQ nor PmrA-
PmrB seems to be essential for this upregulation. Thus, an unidentified regulatory 
system has been proposed to respond to peptides and promote the activation of 
the arnBCADTEF and pmrAB operons independently of PhoP-PhoQ and PmrA-PmrB, 
consequently increasing resistance to antimicrobial peptides (Fernández et al., 
2012; Gooderham et al., 2009; Macfarlane et al, 1999; McPhee et al, 2003).  That is 
the peptides themselves are able to induce adaptive resistance via LPS modification 
(Fernández et al., 2010). 
 
Genetic mutation is more stable and is inheritable.  It is characterized by alterations 
in the outer membrane.  A study by Fernandez et al (Fernández et al., 2013) 
reported a relatively small polymyxin B resistome involving 17 
susceptibility/intrinsic resistance determinants.  Their findings demonstrated that 
the changes in susceptibility to polymyxin B and to colistin suggested evidence of 
cross resistance.  They showed that many of the same genes influence the 
susceptibility of P. aeruginosa to different antibiotic classes and suggest that certain 
genes may coordinate multidrug resistance possibly by affecting regulatory 
pathways.  In their study they determined the MICs of these strains to other 
cationic antimicrobial peptides, including colistin.  All of the tested transposon 
mutants had altered susceptibility to colistin.  The fold change in susceptibility of 
the mutant was determined compared to that of wild-type PA14 by broth 
microdilution for the polymyxins.  In particular, it was of note that a 2 fold change in 
 71 
MIC for polymyxin B also produced an identical 2 fold change in the MIC for colistin 
(Fernández et al., 2013). This would suggest that the resistance genes of 
P.aeruginosa appear to have the same effect on colistin as they do on polymyxin B 
and may infer cross-resistance in the two polymyxins. This raises concern regarding 
the use of polymyxins within the veterinary community whereby their use may help 
drive development of polymyxin B/colistin resistant P. aeruginosa strains.  These 
could act as a potential source of resistant P.aeruginosa. 
Several indications for polymyxin usage in veterinary medicine exist (as referenced 
earlier in more detail in Chapter 1.1.5).  Infections caused by Enterobacteriaceae in 
rabbits, pigs, poultry, cattle, sheep and goats are a main indication for their use 
(Bassetti et al 2015).  In Europe, colistin and polymyxin B are used for treating 
infections caused by Enterobacteriaceae in rabbits, broilers, veal, beef cattle, dairy 
cattle and primarily pigs.  In other areas of the world, polymyxins are still utilised as 
growth promoters, however in Europe this usage has been banned since 2006 
(Castanon, 2007; Millet et al., 2011).  Polymyxin B is an antibiotic utilised in 
veterinary medicine as a common first line topical therapy for treatment of otitis 
externa in the form of proprietary ear drops product and may be used for systemic 
treatment of endotoxaemia associated with severe colic and other gastrointestinal 
diseases (Bassetti et al 2015).  A 2013 European Medicines Agency report on colistin 
usage in animals within the EU stated that across 19 EU/EEA European countries for 
which sales data are available for 2010, polymyxins were the 5th most sold group of 
antimicrobials (4.5%), after tetracyclines (39%), penicillins (23%), sulphonamides 
(11%), and macrolides (9%) (Bassetti et al., 2015).  However, this was based on food 
producing animals (including horses) only and would not include companion 
animals such as cats and dogs.  The use of polymyxins specifically in companion 
animals is not reported.  However, several studies looking at the usage of 
antimicrobial prescribing in small animal practice exist (Bassetti & Righi, 2015).  
More recently there has been the development of a number of real time data 
surveillance schemes that monitor illness and disease in pet animals using 
veterinary practice and laboratory data SAVSNET (SAVSNET, 2017).  Such 
surveillance systems may prove useful for future analysis and development of 
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studies of antibiotic resistance data from companion animal across the UK (Jones et 
al., 2014; Radford et al., 2011; Singleton et al., 2017). 
Mechanisms of resistance in P. aeruginosa to polymyxins include adaptive 
resistance and genetic mutations and generally characterized by alterations in the 
outer membrane (Moore et al., 1984).  A study by Fernandez et al (Fernández et al., 
2013) reported a relatively small polymyxin B resistome involving 17 
susceptibility/intrinsic resistance determinants including evidence of cross 
resistance between colistin and polymyxin B (Fernandez, 2013). This raises concern 
regarding use of polymyxins within the veterinary community whereby their use 
may help drive development of polymyxin B/colistin resistant P. aeruginosa strains.  
Potentially selecting in veterinary medicine polymyxin-resistant isolates that may 
subsequently be transferred to humans.  These could then act as a source of 
resistant P. aeruginosa populations (Moore et al., 2012). 
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Table 3.1. Polymyxin Resistome Genes and Gene Function 
  
Gene Gene Function 
pyrC  Cell metabolism-associated 
pyrB Cell metabolism-associated 
phoQ Sensor kinase, mediates 
virulence 
pdxB  Cell metabolism-associated 
sucC Cell metabolism-associated 
parR  Acquired/adaptive resistance 
through LPS modification 
galU Biosynthetic 
processes/pathogenesis 
pyrD Biosynthetic/metabolic 
processes 
Mpl Recycling of cell wall 
components 
rmlD Biosynthetic processes 
ampR  Transcriptional regulator-
associated with resistance to 
antibiotics 
lptC LPS binding 
tpiA Cell metabolism-associated 
pmrA  Activation of LPS-modifying 
operon by mutations in TCSs 
wapR  LPS biosynthesis-related 
functions 
Ssg LPS biosynthetic processes 
aroB Biosynthetic/metabolic 
processes 
http://www.pseudomonas.com 
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Polymyxin Resistance Mechanisms 
 
PhoP-PhoQ Two-Component System: 
The OM usually serves as a permeability barrier to protect Gram-negative bacteria 
from various antibacterial peptides and chemicals. The electrostatic interaction 
between positively charged Dab residues on polymyxin and negatively charged 
phosphate groups on lipid A of LPS are critical in its bactericidal activity. The 
bacterial cell is able to reduce the initial electrostatic attraction by reducing net 
negative charge of OM via lipid A modification, thereby increasing resistance to 
polymyxins. The most common polymyxin-resistance mechanism in bacteria is 
attributed to the ‘shielding’of phosphates on lipid A with positively charged groups.  
This is mediated by PhoP-PhoQ regulatory system encoded by phoP locus (Yu., et al, 
2015).  Activated by PhoP-PhoQ, the PmrA-PmrB encoded by pmrCAB operon is the 
major regulator to mediate the LPS modification in Gram-negative bacteria. PmrA-
dependent modification can occur on each of the three distinct LPS domains, 
namely, lipid A, core polysaccharide, and O-antigen chain (McPhee et al., 2006; 
Gellatly et al, 2012; McPhee et al., 2003). 
 
 
Figure 3.2  Model describing the signals controlling expression of PhoP-PhoQ-
regulated determinants and the interaction between the PhoP-PhoQ and PmrA-
PmrB two-component systems, as well as some of the genes and phenotypes 
governed by the PhoP-PhoQ system. Referenced from (Groisman, 2001). 
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MexAB-OprM efflux pump: 
The MexA-MexB-OprM efflux system (Li et al., 1995) contributes to both intrinsic 
and acquired resistance in P. aeruginosa.  Reported studies with mutants that 
overproduce or lack MexAB-OprM demonstrated that this efflux system extrudes 
quinolones, macrolides, tetracycline, chloramphenicol, novobiocin, and most β-
lactams but not imipenem (Li et al., 1995; Masuda & Ohya, 1992; Srikumar et al, 
1997).  The MexAB-OprM efflux pump in P. aeruginosa has been proposed to confer 
tolerance towards polymyxin E, due to the increase of mexAB-oprM expression in P. 
aeruginosa upon polymyxin E exposure (Henrichfreise et al., 2007; Hirakata et al., 
2009; Li et al., 2000).  
 
OM Protein: 
Polymyxin resistance is reported to be associated with the expression of OM 
proteins in bacteria. It has been suggested that the OM protein OprH, a membrane 
stabilization protein, can promote resistance to polymyxin B in P. aeruginosa 
(Macfarlane et al., 1999; Olaitan et al., 2014; Yu et al., 2015). 
 
Plasmid mediated colistin resistance: 
Liu et al 2015 (Liu et al., 2016) first reported the emergence of plasmid mediated 
resistance gene, mcr-1 in E.coli and Klebsiella pneumonia isolates from pigs, meat 
and human patients in China. In their study, the mcr-1 gene was present in 20.6% of 
E. coli isolates from pigs, 14.9% of E. coli isolates from retail meat (pig and poultry) 
and 1.4% of patients sampled (Liu et al., 2016).  Occurrence of the mcr-1 gene has 
been reported in E. coli, Salmonella and Klebsiella from Laos, Thailand, Tunisia, 
Nigeria, South America and several European countries from people, pigs, poultry 
and foodstuffs and in the UK (Anjum et al., 2016; Castanheira et al., 2016; 
Falgenhauer et al., 2016; Kluytmans-van den bergh et al., 2016; Malhotra-Kumar et 
al., 2016). 
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3.2 Aims  
 
The significance of the role of companion animals as reservoirs of antimicrobial 
resistance is an understudied area and merits further investigation. There is a risk of 
transfer of resistant bacteria and/or resistance genes from animals to humans.  
The overall aim of this study is to evaluate susceptibility of P. aeruginosa veterinary 
isolates to polymyxin antibacterials and to determine whether the veterinary niche 
represents a potential reservoir of resistant isolates. 
 
Specific aims are to: 
- Measure the susceptibility of a set of clinical P. aeruginosa isolates to 
polymyxin antibiotics colistin (polymyxin E) and polymyxin B by broth micro 
dilution. 
- Compare these susceptibilities to a panel of human P. aeruginosa isolates. 
- Determine the susceptibility of the P. aeruginosa isolates in the study to a 
selection of antibacterials used in human clinical medicine by disc diffusion.  
- Determine susceptibility of the P. aeruginosa isolates in the study to a 
selection of commonly used veterinary antibacterials using an automated 
microdilution system. 
- Perform genotyping of the veterinary P. aeruginosa isolates using the 
Clondiag Array Tube. 
- Perform whole genome sequencing on a selection of resistant isolates to 
determine genetic mutations in a defined subset of genes associated with 
resistance to polymyxin antibacterials. 
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3.3 Results  
 
Resistance to polymyxin antibiotics 
 
Resistance of all P. aeruginosa isolates to polymyxin B and colistin were tested using 
broth dilution MICs.  For the veterinary isolates, 92 % displayed resistance to 
polymyxin B and the remaining isolates were classed as displaying intermediate 
resistance (Table 3.2), whilst 68% displayed resistance to colistin.  For the human 
isolates 33% displayed resistance to polymyxin B and just 3% (one isolate) to 
colistin.  Using the Fisher’s exact test the levels of resistance were signicantly higher 
(ie. p<0.05) as compared to that of the human isolates (p = 0.033) for polymyxin B 
and also significantly higher for colistin (p = 0.002). 
 
 
Table 3.2 Minimum inhibitory concentration tests to show antimicrobial 
resistance of P. aeruginosa in companion animal (n=24) and human (n=37) 
isolates to polymyxin antimicrobials (calculated using median of triplicate MICs). 
 
Isolate Antimicrobial Resistance 
Breakpoint 
(ug/mL) 
Resistant 
Strains 
(n) 
Resistant 
Strains 
(%) 
Animal Polymyxin B ≥8 22 92 
Animal Colistin >4 8 33 
Human Polymyxin B ≥8 25 68 
Human Colistin >4 1 3 
 
Fisher’s exact test (significant = p<0.05):  
p value for polymyxin B MIC human v animal  p=0.033 
p value for colistin MIC human v animal  p=0.002 
 
The highest resistance was observed in isolate 970, from a canine wound, which 
had an MIC of >100 mg/L (Figure 3.3). The level of resistance to colistin amongst the 
veterinary isolates was 33% compared to only 3% in the human-associated panel 
(Table 3.2). The isolates with the highest resistance to colistin were 856 and 1098 
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(Figure 3.3). Isolate 856 was of equine origin, from an abdominal incision and 1098 
from a canine vaginal swab (refer to Chapter 2, Table 2.1).  
 
 
Figure 3.3. Levels of resistance of P. aeruginosa to polymyxins in isolates from companion 
animals and humans (calculated using median of triplicate MICs). A). Polymyxin B 
resistance in veterinary isolates B). Polymyxin B resistance in human isolates C) Colistin 
resistance in veterinary isolates D). Colistin resistance in human isolates. 
 
 
 
There was some evidence for cross-resistance between the two polymyxins. All the 
eight veterinary-associated isolates that were resistant to colistin were also 
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resistant to polymyxin B.  The single human associated P. aeruginosa isolate, that 
was resistant to colistin was also resistant to polymyxin B (Figure 3.3). 
Resistance of veterinary-associated P. aeruginosa to other antibiotics 
Disk diffusion susceptibility assays were performed using 5 commonly used 
antibiotics in humans; ciprofloxacin, ceftazidime, tobramycin, meropenem and 
tazobactam/piperacillin. No resistance was detected to ceftazidime, meropenem or 
tobramycin. Two isolates were resistant to ciprofloxacin and a further three 
displayed intermediate resistance. The two resistant isolates (1055 and 823) were 
both of canine origin. Isolate 823 was completely resistant to ciprofloxacin with no 
zone of inhibition (Figure 3.4). The isolates with intermediate resistance were 1095 
(canine buccal swab), 467_L and 467_R (from the left and right ear of the same 
dog). One isolate was resistant to TZP, isolate 823, from a canine ear. Isolate 823 
had the lowest susceptibility of all the isolates tested.  It was resistant to only 
ciprofloxacin and tazobactam/piperacillin antibacterials (and intermediate to 
meropenem). 
 
 
 
Figure 3.4  Ciprofloxacin resistance in veterinary P. aeruginosa isolates (n=24).  The 
breakpoints are indicated by the red lines. 
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Using the Sensititre COMPAN1F mircotitre susceptibility assay, a panel of antibiotics 
commonly used for veterinary clinical diagnostics was tested. Table 3.3 shows the 
antibiotics with interpretation guidelines for P. aeruginosa.  
 
Table 3.3 Antimicrobial resistance of P. aeruginosa isolated from companion 
animals (n=24)  
 
Antimicrobial Breakpoint 
mg/L 
Resistant 
strains (n) 
Intermediate 
strains (n) 
Sensitive 
strains (n) 
Resistant 
strains (%) 
Amikacin S=8, I=16), 
R>16 
0 0 24 0 
Ceftiofur S=2, I=4, R>4 22 2 0 92 
Enrofloxacin S=0.5, I=2, 
R>2 
8 13 3 33 
Gentamicin S=4, I=8. R>8 
 
1 0 23 4 
Imipenem S=4, I=8. R>8 
 
0 2 22 0 
Marbofloxacin S=1, I=2. R>2 
 
5 2 17 21 
Ticarcillin S=64, R>64 
 
5 0 19 21 
Ticarc/clavulanic acid S=64, R>64 1 0 23 4 
 
 
No resistance to amikacin was detected in the companion animal isolates and only 
intermediate resistance was detected to imipenem. Four percent of isolates were 
resistant to gentamicin and ticarcillin/clavulanic acid. Higher levels of resistance 
were detected to ticarcillin (21%), marbofloxacin (21%) and enrofloxacin (33%). The 
majority of isolates were resistant to ceftiofur (92%). The three most resistant 
companion animal isolate to this panel of antibiotics were 823 (canine ear swab), 
984 (canine ear swab) and 1055 (canine lip fold swab).  Each of these isolates was 
resistant to four of the antibiotics panel tested including enrofloxacin, 
marbofloxacin and ticarcillin.  These three isolates could be considered as multi 
drug resistant (MDR) being non susceptible to 3 antimicrobial categories; ie. anti-
pseudomonal penicillin/beta lactamase inhibitor, fluroquinolones and a 3rd 
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generation cephalosporin.  The companion animal isolates 467R and 467L (samples 
from the same dog but Right and Left ear) were the least resistant.   
 
The human isolates were also tested using the Sensititre COMPAN1F mircotitre 
susceptibility assay. A similar trend in resistance was observed with the highest 
resistance to ceftiofur and the lowest to amikacin. The human isolates showed 
generally higher levels of resistance to the antibiotics tested (Table 3.4).  The most 
resistant human isolate to this panel was AUST03.   
 
 
Table 3.4.  Antimicrobial resistance of a human panel of P. aeruginosa strains (n=37) 
Antimicrobial BreakPoints 
mg/L 
Resistant 
strains (n) 
Intermediate 
strains (n) 
Sensitive 
strains (n) 
Resistant 
strains (%) 
Amikacin S=8, I=16), 
R>16 
2 3 32 5.4 
Ceftiofur  S=2, I=4, R>4 35 2 0 95 
Enrofloxacin S=0.5, I=2, 
R>2 
13 21 3 35 
Gentamicin S=4, I=8. R>8 
 
10 0 27 27 
Impinenem S=4, I=8. R>8 
 
8 7 22 22 
Marbofloxacin S=1, I=2. R>2 
 
13 0 24 35 
Ticarcacillin S=64, R>64 
 
8 0 29 22 
Ticarc/clavulanic acid S=64, R>64 
 
7 0 30 19 
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Circulating strain types of P. aeruginosa 
The Clondiag Tube Array has been used to determine the population structure of P. 
aeruginosa and a database of 955 isolates can be used to infer the wider population 
(Wiehlmann et al., 2007). This typing technique was used to classify the companion 
animal isolates. From the 24 isolates, 20 different array types were identified (Table 
3.5).  
 
Table 3.5. Clondiag Array Tube Hexidecimal codes of veterinary P. aeruginosa 
isolates. SNP=single nucleotide polymorphism. 
 
ANIMAL 
ISOLATE 
NUMBER 
SNP 
CODE 
DETAILS OF 
ISOLATES SHARING 
THE SAME CLONE 
TYPE AS THE 
ANIMAL ISOLATES 
1114 2C12 Water, Germany 
467.L 0002 Same group as PA01 
CF Germany. 
Pneumonia, Switzerland. 
1115 AF92 COPD, USA. 
467.R 0002 CF Germany. 
Pneumonia, Switzerland. 
1098 B429 Keratitis, Great Britain. 
River, Germany. 
1095 AA0A Novel 
978 6C12 
 
CF, Italy. 
COPD, USA 
984 241A Acute infection, source 
unknown. 
Catheter, Germany. 
823 241A Acute infection, source 
unknown. 
Catheter, Germany. 
982 2FAA CF throat swab, Water, 
Italy and Germany 
1070 2D92 Novel 
811 AA01 Novel 
1107 2422 Novel 
992 AF92 COPD, USA. 
856 B420 Sputum, nose and water, 
Germany. 
969 840A Keratitis, Bristol. 
903 B429 Keratitis, Great Britain 
and River Germany. 
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994 0C12 CF sputum Germany. 
897 848A Novel 
970 0B9A Novel 
886-1 2B92 Novel 
886-2 2B92 Novel 
1090 2O22 Novel 
1055 0812 Found in CF patients, 
bacteraemia and ICU, 
France, Switzerland and 
Austria. 
 
 
Eight of these were novel array types not previously identified in the database. One 
array type had previously been associated only with the environment from water). 
However, the remaining array types had been previously associated with human 
infections such as keratitis, cystic fibrosis and pneumonia lung infections and 
catheter associated infections (Table 3.5). Using the database of array types to 
generate a P. aeruginosa population structure, the isolates were mostly distributed 
amongst the main P. aeruginosa clades. Five isolates were located as outliers, 
isolates 811, 1107, 856 and the two isolates from the same dog, 467L and 467R 
(Figure 3.5). The latter two isolates share an array type with the widely used 
laboratory strain of P. aeruginosa, PAO1. 
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Figure 3.5. Distribution of the array tubes codes of the veterinary P. aeruginosa 
isolates amongst a larger panel of P. aeruginosa isolates (Cramer et al., 2012) 
using Eburst analysis. Veterinary isolates highlighted in red. 
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Genome sequencing and analysis of the polymyxin resistome 
Seven isolates that displayed resistance to colistin and polymyxin B were selected 
for whole genome sequencing. A phylogenetic tree of the veterinary isolates and 
342 P. aeruginosa available genomes (Figure 3.6) shows that four of the isolates are 
located in clade I and another two in clade II of the main P. aeruginosa population. 
Although none of the isolates were found to be PA7-like, isolate 856 was diverse 
from the main population and was located on a new arm of the phylogenetic tree 
(Figure 3.6). 
 
 
 
 
 
 
Figure 3.6. Maximum likelihood tree using the Tamura-Nei substitution model of P. aeruginosa 
core genome SNPs. The core genome is defined as polymorphic sites within 500bp fragments 
matching => 85% similarity in 342 genomes. The tree is based on 1336 phylogenetically informative 
polymorphic sites after gaps and N's were removed. Three clear groups are distinguishable: that 
containing PA14, PAO1 and PA7 (indicated by yellow coloured circles) respectively. Branches to PA7 
and 856 (veterinary sequenced isolated indicated by blue coloured circles) have been truncated for 
clarity, so an impression of the real distances in the same tree has also been provided (the smaller 
diagram depicted below). 
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This genome had 125303 SNPs and 1884 indels compared to PAO1 and 130312 
SNPs and 1985 indels in comparison to PA14 (Table 3.6). This was double the 
number of SNPs and indels than any other isolate sequenced. 
 
Table 3.6. Counts of overall variable sites, SNPs and Indels between each 
polymyxin resistant isolate genome compared with PA01 and PA14 respectively, 
by short read mapping and variant calling. Ts = transition and Tv = Transversion. 
 
31 genes associated with resistance to polymyxins were analysed (Table 3.7 and 
Table 3.8).  
Multiple stop codons were identified in isolate 856, these causing potential loss of 
function mutations. A stop codon in pyrC was identified in isolate 1098. Additional 
amino acid modifications resulting in a change in hydrophobicity were identified in 
all 7 genomes (Table 3.7). 
 
 
Strain SNP count Indel count Total count Ts Tv Ts/Tv 
vs PAO1 reference genome 
903 56361 887 57248 43128 13233 3.26 
856 125303 1884 127187 92796 32507 2.85 
1098 57288 927 58215 43734 13554 3.23 
982 29399 498 29897 21979 7420 2.96 
1090 28373 538 28911 21404 6969 3.07 
994 28454 507 28961 21415 7039 3.04 
886_1 29138 532 29670 22016 7122 3.09 
vs PA14 reference genome 
903 35750 613 36363 27611 8139 3.39 
856 130312 1985 132297 96630 33682 2.87 
1098 42853 768 43621 32050 10803 2.97 
982 59452 953 60405 45147 14305 3.16 
1090 61403 1050 62453 46431 14972 3.1 
994 60900 1004 61904 46129 14771 3.12 
886_1 59378 950 60328 45211 14167 3.19 
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Table 3.7. Amino acid changes (presence of stop codons and changes in 
hydrophobicity) identified in the 7 genome sequenced veterinary P. aeruginosa 
isolates, for a selection of 31 genes analysed through whole genome sequencing 
compared with PA01 and PA14 respectively, by short read mapping and variant 
calling. 
Function Amino 
Acid/ 
Protein 
856 886 903 994 982 1090 1098 
Cell metabolism 
associated 
 
pyrC G423STOP      G423STOP 
pdxB   V109K 
 
 D324A 
 
 V109K 
 
aroB A200E A200E A200E A200E 
 
A200E A200E 
 
A200E 
Acquired/adaptive 
resistance through 
LPS modification 
 
parR L153R  L153R 
 
L153R 
 
L153R 
 
 L153R 
 
parS A115E       
Recycling of cell 
wall components 
mpl A404P 
E451STOP 
      
Transcriptional 
regulator associated 
with resistance to 
antibiotics 
ampR E114A 
M228R 
R291STOP 
E114A 
E172V 
 
E114A 
M228R 
   E114A 
M228R 
Activation of LPS-
modifying operon by 
mutations in TCSs 
pmrA L71R L71R  L71R  L71R L71R 
LPS biosynthesis-
related functions 
wapR W114R 
295STOP 
      
Modification of lipid 
A or Kdo with 
aminoarabinose 
arnC P23A       
arnD A284D       
arnF P137L       
 
This showed the presence of resistance determinants including beta-lactamase 
(PDC-1-7, amr), efflux (smeB, mex), fluoroquinolone resistance and elfamycin. 
Isolate 856 had the least additional resistance genes however this was the most 
divergent isolate through sequencing.  In addition, the genome sequences were 
analysed using the CARD database (refer to Figure 3.7).  
 
Table 3.8.  All amino acid changes to the selected 31 genes, identified in the 7 
genome sequenced veterinary P. aeruginosa isolates for a selection of 31 genes 
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analysed through whole genome sequencing compared with PA01 and PA14 
respectively, by short read mapping and variant calling.  
Gene 856 886 903 994 982 1090 1098 
pyrC D16G 
T184S 
Q247R 
N297S 
S355A 
R368S 
V402I 
G423STOP 
D16G 
Q383E 
D16G D16G D16G D16G 
G130S 
R363H 
D16G 
G423STOP 
pyrB P272S       
phoQ D90E 
E267Q 
V369L 
      
pdxB Q369L A307V 
T337N 
Q365R 
V109K 
H183Y 
P192T 
A105V 
L310M 
A361T 
E191G 
D324A 
Q365R 
R179H 
R247H 
V109K 
H183Y 
P192T 
 
parR T135A 
L153R 
 L153R 
S170N 
P128S 
L153R 
S170N 
L153R 
S170N 
 L153R 
S170N 
Mpl S221T 
I226S 
Q347R 
A404P 
E451STOP 
V358I V297M 
A415V 
V297M    
rmlD V98I       
ampR E114A 
G283E 
M228R 
R291STOP 
E114A 
E172V 
A208T 
E114A 
G283E 
M228R 
   E114A 
I251V 
G283E 
M228R 
tpiA S47G 
T78I 
      
pmrA L71R L71R  L71R  L71R L71R 
wapR A83T 
T85A 
W114R 
295STOP 
T85A R58H 
R78K 
T85A 
T85A R78K 
T85A 
 R58H 
R78K 
T85A 
Ssg S35G      A109V 
aroB L54F 
Q58E 
V85A 
E89G 
A200E 
V85A 
A200E 
V85A 
A200E 
V85A 
A200E 
S235L 
I297T 
V85A 
A200E 
V85A 
A200E 
I297T 
V85A 
A200E 
amgS Q100R  I260V   I260V I260V 
galU     N338S   
pyrD        
sucC        
lptC        
arnA T42I 
L50F 
H199R 
V250I 
T297A 
C312S 
S313G 
C312S 
S313G 
S509N 
I551V 
H59Y 
F80Y 
C312S 
S313G 
C312S 
S313G 
I551V 
C312S 
S313G 
C312S 
S313G 
F80Y 
C312S 
S313G 
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V564I 
arnB G120S 
T143A 
V153I 
I231V 
K286E 
V302A 
S321T 
H332R 
R363G 
E376D 
A316V 
V302A 
K286E 
V302A 
E376D 
V302A 
A316V 
V302A 
A316V 
V302A V302A 
K286E 
E376D 
 
arnC P23A 
E35G 
A265S 
T316A 
      
arnD E25D 
F58L 
V123T 
G208S 
A284D 
 F58L     
arnE A32T 
D33S 
T26A 
L56V 
A84V 
F87L 
S114N 
     R28H 
arnF A129T 
P137L 
   V14M T106I  
arnT C7W 
L93F 
L163F 
A267S 
P290A 
L337Q 
D440G 
T443A 
H447Y 
R502Q 
I509V 
R502Q 
I509V 
C7W 
H151Y 
L337Q 
I509V 
T16S 
E386D 
R502Q A267S 
R448H 
R502Q 
I509V 
V266I 
A282S 
C7W 
A214V 
T443A 
I509V 
colS Q60K 
V425I 
      
cprR V27A 
I59V 
E183D 
      
cprS V22I 
A78E 
D89G 
V159I 
V165I 
T170A 
E386D 
     T16S 
parS E90K 
A115E 
V304I 
H398R 
H398R H398R 
R243H 
H398R H398R H398R H398R 
pmrB        
colR        
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Figure 3.7. Heat map of resistance genes present in 7 veterinary P. aeruginosa 
isolates identified through whole genome sequencing. The shading of colour refers 
to the percentage similarity between the resistance genes in the 7 isolates (the 
darker colour representing highest % value (perfect match); mid-blue representing 
a variant of the known AMR gene sequence and white for no sequence present. 
Similar values are displayed as similar areas of colour.) 
 
 
3.4 Discussion  
 
In the veterinary setting P. aeruginosa can cause disease in a number of species.  As 
previously discussed in earlier Chapter 1 these include ears, skin, respiratory tract, 
urinary tract, reproductive, ocular and wound infections.  Similar to its nature in 
humans, P. aeruginosa is also less common as a primary cause of disease in the 
healthy animal.  In canines, it is a frequently isolated pathogen in chronic otitis 
externa, otitis media and chronic deep pyodermas (Morris, 2004; Nuttall & Cole, 
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2007).  One of the commonly used first line therapies for canine otitis externa is the 
effective commercial product Surolan® which contains polymyxin B as one of its 
active ingredients.  It is licenced for use in cats and dogs for several ear conditions 
and skin infections.  
 
A high proportion of the isolates within this companion animal sample set are of 
canine origin and from skin (including wounds) or ear, sample sites.  A recent report 
looking at antimicrobial susceptibility profiles of bacterial isolates in the canine ear 
in Australia identified P. aeruginosa as one of the 5 most commonly isolated 
bacterial pathogen (Bugden, 2013).  Of 3541 canine ear swabs, 35.5% isolated P. 
aeruginosa. However, although they raised concerns of resistance levels in the 
other Gram negative bacterial isolates (Escherichia coli and Proteus sp.) to 
polymyxin B, the resistance in P. aeruginosa isolates was comparatively low to 
polymyxin B (7%) and gentamicin (5%), although enrofloxacin was reasonably high 
(36%) (Bugden, 2013).  This is in contrast to the findings presented in our study 
whereby polymyxin resistance levels of veterinary isolates was high.  However, it is 
of note that the samples are from a referral centre and as such the cases seen here 
may be particularly extreme and difficult to treat having been sent from first 
opinion general practice veterinary surgeons.  
 
A number of other diseases involving P. aeruginosa in animals are known, including 
that of contagious equine metritis (Allen et al., 2011) and in chronic equine wounds 
where the ability of P. aeruginosa to form and survive within protective biofilms has 
been reported (Freeman, 2009; Westgate 2011).   Three of the samples within this 
study were from horses; a urine sample, a nasal swab and an abdominal incision 
wound and isolate 856 (equine abdominal incision swab) was shown to be the most 
diverse from the main P. aeruginosa population.  These findings add further 
evidence that the veterinary niche is underrepresented in many population-wide 
studies (Guardabassi et al., 2004). 
Polymyxin B is used as a common treatment in veterinary medicine and it is feasible 
that this longterm use in veterinary medicine has contributed to the increased 
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resistance.  Therapeutics often use polymyxin B sulphate in the form of a topical 
preparation (eg. Surolan®).  A number of other formulations that include polymyxin 
B for topical ocular solutions/ointments and ear preparations are available in other 
countries (eg. Australia, Netherlands) but these are not marketed in the UK.  
Polymyxin B in the form of polymyxin B sulphate administered intravenously has 
previously been reported as a use in equine colics as a treatment of endotoxaemia. 
Several studies document its efficacy (Barton et al., 2004; Werners et al., 2005). This 
would be an off license use.  Polymyxin B is on the list of substances essential for 
the treatment of equidae for systemic treatment for endotoxaemia (antitoxigenic 
effect, not antibacterial as such) associated with severe colic and other 
gastrointestinal diseases (EU Agency, 2013; Barton et al., 2004; Richez & Burch, 
2016).  In the EU/EEA, colistin has been used in veterinary medicine since the 1950s 
(Koyama et al., 1950), primarily for pigs including group treatments and prevention 
of diarrhoea caused by E. coli and Salmonella spp., as first choice treatments for 
neonatal diarrhoea in piglets (Timmerman et al., 2006) and veal calves (Pardon et 
al., 2012) caused by E. coli as well as for the therapy of mild colibacillosis in poultry.  
Colistin is not a therapeutic in use for companion animals in the UK although it has 
previously been available as a licensed product for administration in various food 
production animals for the indication of diarrhoea.  However, in 2015 the 
organisation RUMA (Responsible Use of Medicines in Agriculture Alliance) 
announced that they would voluntarily restrict the use of colistin in UK livestock 
(RUMA, 2015). This was following the reports of a new gene (MRC-1) that makes 
common bacteria resistant to colistin, reports have been in E. coli (Castanheira et 
al., 2016; Liu et al., 2016; Zhi et al., 2016a).  There are now recent reports of 
Salmonella and E. coli colistin resistance reported in the UK (Munja et al.,2016).  It is 
possible that the use of the polymyxins among veterinary species has driven 
resistance within this niche of Pseudomonas isolates.  Hence we have seen higher 
levels of resistance in companion animal isolates as compared to that of the 
comparative human panel.   
Within the EU Member States, colistin and polymyxin B are authorised nationally. 
The main indication for colistin in veterinary medicine is for preventing infection of 
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the gastrointestinal tract caused by non-invasive E. coli in pigs, poultry, cattle, 
sheep, goats and rabbits. Colistin is also used in laying hens and cattle, sheep and 
goats producing milk for human consumption. Colistin is also active against 
endotoxins produced by some E. coli strains in the gastrointestinal tract. Typically, 
colistin products are administered orally, in feed, in drinking water, as a drench, or 
through milk replacer diets. Combinations of colistin with other antimicrobials are 
available for group treatments of food-producing animals in some EU countries 
(EMA, 2016b). Products for parenteral and intra-mammary administration are also 
available, and infections due to Gram-negative bacteria in ruminants including 
endotoxaemia are claimed indications.  
As in human medicine, colistin and polymyxin B are registered for topical 
administration to individual veterinary patients, except for food-producing animals 
in the case of polymyxin B, in the absence of Meat Residue Limits. In companion 
animals, prescription eye and eardrops are available with colistin alone, or in 
combination with other antimicrobials. Colistin tablets are available for calves for 
the prevention and treatment of neonatal colibacillosis. In some EU Member States, 
veterinary medicinal products (VMPs) containing colistin are not on the market, i.e. 
not commercialised (EMA/ESVAC, 2015).  
Colistin products (polymyxin E) have never been marketed for use in animals in the 
United States (US Food and Drug Administration, 2016). Sources from the FDA have 
indicated that there is only one polymyxin B product (ophthalmic ointment, 
combination of polymyxin B and oxytetracycline) approved for use in food-
producing species. In recent years, this product has been marketed in 2009 and 
2012-2015, although it has been marketed in small quantities. Polymyxin B is also 
available in the US as a component of approved ophthalmic products (for use in 
dogs and cats) and otic products (for use in dogs). There is documented legal off-
label use in other non-food-producing species, such as horses. Sources from the 
Public Health Agency of Canada have indicated that there are no approved colistin 
products (polymyxin E) for use in animals in Canada (Public Health Agency of 
Canada, 2016).  
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In 2013, the total sales of polymyxins in the 26 EU/EEA countries reporting data to 
the ESVAC project (EMA/ESVAC, 2015), including tablets (but excluding topical 
forms), polymyxins were the 5th most sold group of antimicrobials (6.1%), after 
tetracyclines (36.7%), penicillins (24.5%), sulphonamides (9.6%), and macrolides 
(7.4%). Total sales in weight summed up 495 tonnes. Of those 99.7% were for oral 
forms as follows: 43.3% were oral solution (powder and liquid for use in drinking 
water), 42.5% were premix (premixes for medicated feeding stuff) and 14.0% were 
oral powder (powder to be administered with the feed or milk). Small amounts 
were sold as: injectables (0.2%), tablets (0.1%) and intramammaries, intrauterines 
and oral paste (less than 0.0% for each of the three forms). Of the group of 
polymyxins, colistin represented more than 99.9% of the sales. In addition 
combinations of colistin with other antimicrobials are authorised in some Member 
States. The sales of those combination products represented less than 10% of the 
overall sales of colistin (EMA/ESVAC, 2015).  Colistin is used in aquaculture for the 
prevention of Gram-negative infections (Xu et al., 2012), consumption data are not 
available separately for this food production sector.  In the Danish monitoring 
programme (DANMAP), details on consumption do not refer to the use of colistin in 
fish (DANMAP, 2012; EMA 2016). 
 
Resistance to polymyxins has been attributed to modifications to the outer 
membrane include modifications to lipid A and LPS as well as two-component 
regulators.  
The outer membrane normally serves as a protective barrier for Gram-negative 
bacteria against the cationic antimicrobial peptides. The main difference between 
the two molecules (polymyxin B and polymyxin E) being that polymyxin B contains 
phenylalanine in position 6 (from the N-terminal), while colistin contains D-leucine 
(Falagas & Kasiakou, 2005; Yu et al., 2015).  Fernandez et al (Fernández et al., 2013) 
reported a relatively small polymyxin B resistome involving 17 
susceptibility/intrinsic resistance determinants.  This study demonstrated 
considerable cross-resistance in susceptibility to polymyxin B and to colistin. This 
would suggest that the resistance genes of P.aeruginosa appear to have the same 
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effect on colistin as they do on polymyxin B and suggests some cross-resistance in 
the two polymyxins. Seven of the veterinary isolates were genome sequenced and 
mutations, including stop codons, were detected in genes previously implicated in 
polymyxin resistance. Many of the sequences studied showed modifications in 
genes leading to an altered amino acid, many of which had altered 
hydrophobic/hydrophilic properties. Here, it is possible that a combination of 
mutations leads to a change in phenotype through membrane remodelling.   
 
A study by Manivannan et al (Manivannan et al, 2016) looking at a draft genome of 
a MDR P. aeruginosa  clinical isolate (from a female patient’s urine sample having 
had ureteric reimplant) documented the presence of genes responsible for 
virulence factors, quorum sensing and biofilm formation. The isolate was 
extensively drug resistant and found to be resistant to penicillins, second and third 
generation cephalosporins, aminoglycosides, carbapenems, tetracyclines, 
quinolones, and trimethoprim-sulfamethoxazole and sensitive to only colistin, as 
tested with the automated antibiotic susceptibility testing system Vitek®-2 
(Manivannan et al., 2016).  In their study, analysis indicated that the draft genome 
has genes encoding for resistance to aminoglycosides, fosfomycin, beta-lactams, 
sulfonamides, and trimethoprim (Manivannan et al., 2016).  
 
A study by Lee et al (Lee et al., 2014), investigated genetic variations involved in the 
acquisition and loss of colistin resistance in three clinical isogenic P. aeruginosa 
isolates taken from a single patient and assessed their impacts on colistin 
resistance. 
Through the use of whole genome sequencing to identify single nucleotide 
polymorphisms and insertions or deletions in two colistin-resistant isolates, which, 
were then compared with a susceptible isolate. Their results showed 37 non-
synonymous mutations in 33 coding sequences detected in the colistin-resistant 
isolates. One gene was significantly down-regulated in both colistin-resistant 
isolates (a gene encoding erythronate-4-phosphate dehydrogenase). Eight genes 
were up-regulated in the colistin-resistant isolates.  Of these three encoded 
hypothetical proteins and five were predicted to be involved in core biological 
 96 
functions, encoding a cell wall-associated hydrolase, a response regulator EraR, a 
sensor/response regulator hybrid, a glycosyltransferase and an arabinose efflux 
permease (Lee et al., 2014). None of theses genes were identified in our polymyxin 
study. They may be novel determinants that may be associated with the acquisition 
of colistin resistance (Li., et al, 2014). 
 
Using both the tube array typing method and genome sequencing on a limited 
subset of isolates, the P. aeruginosa veterinary isolates were found to be 
distributed thoughout the P. aeruginosa population. Using tube array, 9 of the 
isolates had no previous description and were classified as novel. 15 isolates shared 
array types with isolates previously found to cause human infections such as 
pneumonia, cystic fibrosis and chronic obstructive pulmonary disease lung 
infection, keratitis and bacteraemia and therefore highlight the ability of these 
bacteria to cause human infections. Using whole genome sequencing, the 
veterinary isolates were generally clustered within the main P. aeruginosa 
population however one isolate, 856, did not cluster with any other previously 
sequenced isolate. Through mapping to both PAO1 and PA14, the isolates had 
double the number of SNPs and indels than any of the other isolates sequenced. 
The isolate was of equine origin and this highlights the importance of studying 
alternative and underrepresented niches in order to fully characterise the P. 
aeruginosa pan genome. 
In this study it is likely that polymyxin resistance involved chromosomal mutations 
and there was no evidence of mcr-1 plasmid mediated colistin resistance. However, 
a recent study discussed the emergence of plasmid-mediated colistin resistance 
mechanism MCR-1 resistance in humans and animals (Liu et al., 2016).  This study 
was based in China and during a routine surveillance project on antimicrobial 
resistance in commensal E.coli from food animals in China, a major increase of 
colistin resistance was observed. When an E. coli strain, SHP45, possessing colistin 
resistance that could be transferred to another strain, was isolated from a pig, 
further analysis of possible plasmid-mediated polymyxin resistance was carried out. 
This particular study demonstrated the emergence of the first plasmid-mediated 
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polymyxin resistance mechanism, MCR-1, in Enterobacteriaceae.  The plasmid-
borne mcr-1 gene encodes a phosphoethanolamine transferase that mediates 
addition of phosphoethanolamine to the lipid A moiety of the lipopolysaccharide 
and thus transferring resistance to polymyxins (Liu et al., 2016).  This is a gene that 
to date has predominantly been identified in E. coli and also Klebsiella spp and 
Salmonella spp.  Since the first report by Liu et al 2016, further identifications 
worldwide have emerged with reports in countries including in Algeria, Denmark, 
France, Germany, Laos, the Netherlands, Malaysia, Nigeria, Switzerland and 
Thailand (Castanheira et al., 2016; Doumith et al., 2016; Falgenhauer et al., 2016; 
Kluytmans-van den bergh et al., 2016; Liu et al., 2016; Malhotra-Kumar et al., 2016; 
Rolain et al., 2016; Liu et al., 2016; Zhi et al., 2016).  The gene was also identified 
from imported food products in Denmark – meat products (Hasman & Hammerum, 
2015) and Switzerland, vegetables (Zurfluh, 2016).  Plasmid-encoded carbapenem 
and colistin resistance may be co-associated in E. coli (Falgenhauer et al., 2016).  
Positive Salmonella enterica isolates of different serotypes were identified from 
food samples in Portugal in 2011, and France in 2012 and 2016 (Figueiredo et al., 
2016; Lin et al., 2012; Zhi et al., 2016a). An epidemiological survey conducted in 
France on a collection of ESBL-producing E. coli isolates recovered from the faeces 
of diarrhoeic veal calves on farms from 2005 to 2014 showed a very high rate of 
MCR-1-positive isolates (20.5%) (Haenni et al., 2015).  Following these new reports 
it was felt prudent to carry out further genomic assessment (courtesy of Matthew 
Moore, University of Liverpool) of the seven P. aeruginosa isolates that had already 
undergone WGS in this study.  This additional work was performed by Matthew 
Moore and Dr Jo Fothergill (University of Liverpool) after the main body of this 
thesis work was completed (as this was only a one year funded Fellowship).  The 
seven isolates were screened for the presence of the mcr-1 determinant but none 
were identified in this instance.  As yet there does not appear to be reports of 
plasmid encoded polymyxin resistance mechanism mcr-1 in P. aeruginosa isolates 
(Baron et al., 2016). 
In conclusion, all of these findings raise concerns regarding the use of polymyxins 
within the veterinary community whereby their use may help drive development of 
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polymyxin B/colistin resistant P. aeruginosa strains.  These could then potential act 
as a source of resistant genetic material for the human associated P. aeruginosa 
population. The findings suggest that future surveillance of polymyxin resistance in 
animal associated P. aeruginosa strains should be recommended and highlights the 
importance of improved correspondence between veterinary and medical 
professions with regards to use of polymyxins. The veterinary setting, particular in 
companion animals is an, often ignored, niche that provides close proximity 
between humans and companion animals and therefore cross infection of resistant 
organisms would be possible.  The preservation of colistin as a “last resort” 
successful anti-pseudomonal drug is of great concern (Kempf et al, 2016). 
 
3.5 Conclusions  
 
In this study, the increased resistance to polymyxin antibiotics, polymyxin B and 
colistin in a panel of veterinary isolates from companion animals is described. To 
the author’s knowledge, this is the first description of increased resistance to 
colistin in this environmental niche. Resistance to other commonly used human 
antibiotics was low.  
Companion animals are an understudied source of antimicrobial resistant P. 
aeruginosa isolates however, resistance to polymyxin amongst these isolates is 
high. These findings merit sustained surveillance of the veterinary niche as a 
potential reservoir for resistant, clinically-relevant bacteria. 
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4. PCR characterisation of antibiotic resistant determinants in P. aeruginosa from 
companion animals  
 
4.1 Introduction  
 
AMR mechanisms in P. aeruginosa 
P. aeruginosa can develop resistance to antibacterials either through the acquisition 
of resistance genes on mobile genetic elements (i.e.integrative and conjugative 
elements (ICEs))  or through mutational processes that alter the expression and/or 
function of chromosomally encoded mechanisms. The main mechanisms associated 
with antibiotic resistance are shown in Figure 4.1 
 
 
 
 
 
 
 
 
Figure 4.1 Mechanisms of resistance in P. aeruginosa. Image from (Gullberg et al., 
2011) 
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Transmissible resistance refers to the ability to spread resistance genes via 
horizontal gene transfer. ICEs (including plasmids ) are found in particular in 
Enterobacteriaceae where they may play a role as important carriers of 
antimicrobial resistance genes. Like plasmids, ICEs can exist in P. aeruginosa as 
circular extrachromosomal elements and can impact on resistance to the beta-
lactams and aminoglycoside antibiotics. This is in contrast to resistance mechanisms 
to fluoroquinolone among P. aeruginosa isolates which has mainly been associated 
with chromosomal genes mutations such as gyrA, gyrB, parC and parE and/or 
overexpression of multidrug efflux pumps (Fàbrega et al, 2009).  Although the 
plasmid-mediated qnr and the fluoroquinolone-modifying enzyme aac 6Ib-cr can 
contribute to fluoroquinolone resistance among strains of Enterobacteriaceae 
(Jacoby, 2005; Robicsek et al., 2006; Strahilevitz et al, 2009b), these two plasmid-
encoded mechanisms have not been found in clinical isolates of P. aeruginosa. 
Resistance to the beta-lactams involves the production of inactivating beta-
lactamases and several families of these have been identified among clinical isolates 
of P. aeruginosa (Lister et al., 2009). The most common imported beta-lactamases 
found among P. aeruginosa isolates are penicillinases. The therapeutic impact of 
these penicillinases is relatively limited since they do not impact the clinical efficacy 
of extended-spectrum cephalosporins, monobactams, or carbapenems.  
P. aeruginosa shows high intrinsic resistances to antibiotics and this can, in part, be 
attributed to its’ low outer membrane permeability.  The low permeability can 
further contribute to other resistance mechanisms such as inducible 
cephalosporinase or antibiotic efflux pumps therefore leading to highly resistant 
bacteria. P. aeruginosa, in addition to being intrinsically resistant to several 
antimicrobial agents, can acquire resistance to conventional anti-pseudomonal 
antibiotics including anti-pseudomonal penicillins, ceftazidime, carbapenems, 
aminoglycosides and ciprofloxacin. 
 
Table 4.1 summarises the resistance mechanisms of P. aeruginosa. 
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Table 4.1. Examples of resistance mechanisms in Pseudomonas aeruginosa.  
(Referenced from Gellatly et al., 2012). 
  
 
Mechanism  Example(s)  
Efflux pumps  MexAB–OprM, MexCD–OprJ, MexEF–OprN, MexXY–OprM (cephalosporins,  
carbapenems, aminoglycosides, quinolones, ureidopenicillins)  
Outer membrane 
impermeability  
OprF, OprD, OprB (carbapenems, aminoglycosides, quinolones)  
β-lactamases  AmpC (penicillins)  
Targeted mutation  DNA gyrase, DNA topoisomerase (quinolones)  
MexZ (quinolones, cefepimes, aminoglycosides)   
Horizontal transfer  Metallo-β-lactamases, ESBLs (penicillins, cephalosporins, carbapenems)  
Membrane changes  Lipid A modification (aminoglycosides, polymyxins)  
AmpC upregulation (penicillins)   
ESBL, extended spectrum β-lactamase 
 
Inherent and aquirred resistance can severely limit the therapeutic options for 
treatment of serious infections (Lister et al., 2009).   
 
Resistance types 
Changes can be made to a bacteria's genetic inheritance in two ways; through 
mutations that alter the pre-existing DNA of the cell—these alterations, base 
changes and DNA deletions, insertions and inversions (Avison, 2005), change genes 
already possessed but do not add new genes, to the cell genome.  Alternatively, 
resistance can also be obtained through the acquisition of new genetic material 
(Bennett 2008). 
 
1. Acquisition of additional genetic material 
 
In bacteria, new genetic material can be acquired through mobile genetic elements 
(ICEs) and can include plasmids, phages, transposons and integrons. The acquisition 
of new genetic material is a naturally occurring process in bacteria and is facilitated 
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by the lack of a nucleus membrane protecting the genome.  A study by Johnston et 
al (Johnston., et al 2014) stated a total of 82 species having been shown to be 
naturally transformable showing that acquisition through transformation is 
common amongst many different species of bacteria.  Gene transfer through 
plasmids is one of the major routes for spreading antibiotic resistance in bacteria. 
Many of the ICEs carrying antibiotic-resistant genes can be transferred between 
different species of bacteria and therefore widespread resistance to a specific 
antibiotic can develop rapidly.  One example is a plasmid carrying a gene that 
encodes the enzyme beta-lactamase. Beta-lactamases alters the structure of the 
beta-lactam antibiotics (such as penicillin), rendering them inactive (Araujo et al., 
2016; Drawz & Bonomo, 2010). Outbreaks of life-threatening multi-drug resistant 
superbugs such as New Delhi metallo-β-lactamase-1 (NDM-1) bacteria are often 
due to the transfer of antibiotic resistance genes in ICEs (Abraham et al, 2014; Ji et 
al, 2007; Liu et al., 2016; Poirel et al., 2010; Schmidt & Beutin, 1995). 
 
Integrons are genetic elements first described at the end of the 1980s (Stokes & 
Hall, 1989). Although most integrons were initially described in human clinical 
isolates, they have now been identified in many non-clinical environments, such as 
water and soil (Domingues et al, 2012; Nardelli et al., 2012). Integrons consist of 
two conserved segments of DNA separated by a segment of variable length and a 
sequence often carrying resistance determinants.  Class 1, 2 and 3 integrons are 
recognized (Domingues et al., 2012).  Most resistance integrons belong to class 1, 
which is the most frequent among isolates of human origin and has been found in P. 
aeruginosa isolates from dogs (Lin et al., 2012; Rubin et al., 2008). 
The class 1 integrons are important in the dissemination of resistance in Gram-
negative bacteria. Class 1 integrons being important in the worldwide problem of 
antibiotic resistance, as they can capture and express diverse resistance genes and 
may often be embedded in plasmids and transposons, facilitating their lateral 
transfer into a wide range of pathogens (Gillings et al., 2008). 
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As described above, the acquisition of new genetic material requires gene transfer 
from some outside source. Bacteria have three methods by which DNA may be 
transferred from one cell to another; transformation, transduction and conjugation 
(Bennett, 2009). 
 
 
Resistance acquisition mechanisms: 
 
i) Conjugation – 
 
Conjugation is the process by which one bacterium transfers genetic material to 
another through direct contact. During conjugation, one bacterium serves as the 
donor of the genetic material, and the other serves as the recipient.  Conjugative 
plasmids, commonly present in bacterial cells (Sherley et al, 2003; Shintani et al, 
2015) can be transferred to other cells by conjugation. This process often requires 
sex pili to establish a mating-pair by promoting cell aggregation (Cabezón et al, 
2015).  Conjugation usually imposes a fitness cost on plasmid hosts as it requires 
resources, alters cell physiology and determines viral susceptibility because sex pili 
can serve as receptors for viruses (Cabezón et al., 2015).  
 
This requires the participation of either a conjugative plasmid or a conjugative 
transposon, each of which encodes a DNA transfer system that has evolved 
specifically to mediate horizontal transfer of itself. Conjugation is responsible for 
much of the horizontal gene transfer, particularly of resistance genes, seen among 
prokaryotic cells, both Gram-negative and Gram-positive (Van Hoek et al., 2011). 
 
 
ii) Transduction – 
 
This involves gene transfer by bacterial ‘viruses’, called bacteriophages (‘phages’).  
Phages tend to have very narrow host ranges.  Transduction is the transfer of DNA 
from one cell to another, mediated by a bacteriophage and occurs as a 
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consequence of rare errors in phage reproduction, when a small percentage of the 
phage particles produced contain DNA sequences from the host cell, in place of or 
in addition to the normal phage genome.  Transduction is responsible for some of 
the transfer of bacterial drug resistance genes (Munita et al, 2016).  Fragments of 
bacterial genomes or small bacterial plasmids can be moved from one bacterial cell 
to another in this way. Survival of the DNA in the new cell requires either 
recombination, prophage integration or the transferred DNA must be able to 
replicate independently in its new host i.e. act as a plasmid (Van Hoek et al., 2011).  
 
 
iii) Transformation –  
 
Transformation requires no connection between the donor and recipient cells, 
other than the DNA itself.  The bacterial cell uptakes the DNA from its environment 
and incorporates it into its own genome (Van Hoek et al., 2011).  
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Figure 4.2 The processes of bacterial, transformation(a), transduction(b) and 
conjugation(c). (Furuya & Lowy, 2006) 
a. Transformation occurs when DNA is released on lysis of an organism and is taken up by another 
organism. The antibiotic-resistance gene can be integrated into the chromosome or plasmid of the 
recipient cell.  
b. In transduction, antibiotic-resistance genes are transferred from one bacterium to another by 
means of bacteriophages and can be integrated into the chromosome of the recipient cell.  
c. Conjugation occurs by direct contact between two bacteria: plasmids form a mating bridge across 
the bacteria and DNA is exchanged, which can result in acquisition of antibiotic-resistance genes by 
the recipient cell. Transposons are sequences of DNA that carry their own recombination enzymes 
that allow for transposition from one location to another; transposons can carry antibiotic-resistance 
genes. (Furuya & Lowy, 2006) 
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2 Intrinsic Resistance:   
 
Intrinsic resistance is the ability of a bacterial species to resist activity of a particular 
antibacterial agent through its inherent structural or functional features, which 
allow tolerance of a particular drug or class of antibacterials (Munita et al., 2016). 
This characteristic may be due to a lack of affinity of the drug for the bacterial 
target.  An example of such would be P. aeruginosa and the 
sulphonamides/trimethoprim, tetracyclines and chloramphenicol whereby there is 
a lack of uptake.  Intrinsic resistance may also be due to inaccessibility of the drug 
into the bacterial cell.  This is the case for vancomycin and Gram-negative bacteria, 
whereby the lack of uptake results from inability of vancomycin to penetrate the 
outer membrane.  Intrinsic resistance may be due to the extrusion of the drug by 
chromosomally encoded active exporters or innate production of enzymes that 
inactivate the drug.  For example the production of beta lactamase enzymes by that 
destroy beta lactam antibiotic such as ampicillin and destroy it before it can reach 
the PBP (penicillin binding protein) target (Kong et al, 2010; Zeng & Lin, 2013) or 
AmpC type beta lactamases which confer resistance to beta lactams. P. aeruginosa 
also has constitutive expression of AmpC beta-lactamase (cephalasporinases) and 
efflux pumps, combined with a low permeability of the outer membrane (Cabot et 
al., 2011; Jacoby, 2009).  The natural resistance of the species relates to the beta-
lactams: penicillin G; aminopenicillins, including those combined with beta-
lactamase inhibitors; first and second generation cephalosporins.  Strains of a 
particular bacterial species will exhibit the same mechanisms of innate resistance 
and this is unaffected by prior antibiotic exposure (Beceiro et al., 2013; Schroeder et 
al, 2017). 
 
P. aeruginosa as discussed is intrinsically resistant to several antibiotics because of 
the low permeability of its outer-membrane, the constitutive expression of various 
efflux pumps, and the production of antibiotic-inactivating enzymes (e.g. 
constitutive expression of AmpC beta-lactamase - cephalosporinases).  
Furthermore, it also has a remarkable ability to develop or acquire further 
mechanisms of resistance to multiple groups of antimicrobial agents, including 
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beta-lactams, aminoglycosides and fluoroquinolones (Mesaros et al., 2007a; 
Mesaros et al., 2007b).  P. aeruginosa exhibits many of the known mechanisms of 
antimicrobial resistance; derepression of chromosomal AmpC cephalosporinase; 
acquisition of integron-mediated beta-lactamases from different molecular classes 
(carbenicillinases and extended-spectrum beta-lactamases belonging to class A, 
class D oxacillinases and class B carbapenem-hydrolysing enzymes); diminished 
outer membrane permeability (loss of OprD proteins); overexpression of active 
efflux systems with wide substrate profiles; synthesis of aminoglycoside-modifying 
enzymes (phosphoryltransferases, acetyltransferases and adenylyltransferases); and 
structural alterations of topoisomerases II and IV determining quinolone resistance.  
Concerningly, these mechanisms are often present simultaneously, thereby 
conferring multi-resistant phenotypes (Strateva & Yordanov, 2009). 
 
Membrane Permeability 
P. aeruginosa, has a relatively impermeable outer membrane (OM) and expression 
of numerous MDR efflux pumps that effectively reduce the intracellular 
concentration of the given drug (Li et al., 1995).  The OM is a semi-permeable 
barrier to the uptake of antibiotics or nutrient molecules.  Small hydrophilic 
molecules (such as beta-lactam antibiotics) (refer to Figure 4.3. Blair et al, 2015) 
have uptake restricted to a small portion of the OM (namely the water filled 
channels of porin proteins) and as a result the entry of these molecules into the cell 
is limited (Hancock, 1998).  This low overall OM permeability is especially true of P. 
aeruginosa, which is considered to be lower than some other Gram negatives.  It is 
estimated that the permeability of P. aeruginosa and Acinetobacter baumannii 
outer membranes are only 1-8% of that E. coli and that non specific slow porins 
OprF and OmpA-AB, respectively, restrict access of molecules larger than approx. 
200Da, which is the size of a typical monosaccharide (Zgurskaya et al, 2015).  The 
major porin OprF is responsible for the large exclusion limit of the P. aeruginosa 
OM.  The porin OprD only mediates passage of zwitterionic carbapenem beta 
lactams (eg. imipenem, meropenem) see Figure 4.5), as this porin contains a 
binding site specifically for these dipeptides.  Uptake across the OM of polycationic 
antibiotics (eg. gentamicin, tobramycin and colistin) are mediated by a system 
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termed self-promoted uptake.  This system involves the interactions of the 
polycation with divalent cation binding site that are on the LPS cell surface and that 
normally stabilise the OM.  Since the polycationic antibiotic molecules are much 
larger than the native divalent cations, they cause a disruption to the OM that 
makes it become more permeable. – see Figures 4.4 and 4.5 (Lister et al., 2009). 
 
 
 
 
Figure 4.3  Overview of intrinsic resistance mechanisms (Blair et al, 2015).   
Depicting β-lactam antibiotics targeting a penicillin-binding protein (PBP). Antibiotic A can enter the 
cell via a membrane-spanning porin protein, reach its target and inhibit peptidoglycan synthesis. 
Antibiotic B can also enter the cell via a porin, but unlike Antibiotic A, it is efficiently removed by 
efflux. Antibiotic C cannot cross the outer membrane and so is unable to access the target PBP (Blair 
et al, 2015). 
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Figure 4.4  Mutational resistance to fluoroquinolones and carbapenems involving 
chromosomally encoded mechanisms expressed by P. aeruginosa (Lister et al., 
2009).  
Image (A) Depicts interactions of fluoroquinolones and carbapenems with susceptible P. aeruginosa 
expressing basal levels of AmpC, OprD, and non-mutated fluoroquinolone target genes (gyrA, gyrB, 
parC, and parE). Fluoroquinolone molecules pass through the outer membrane, peptidoglycan, 
periplasmic space, and cytoplasmic membrane and interact with DNA gyrase and topoisomerase IV 
(Topo IV) targets in the cytoplasm when these enzymes are complexed with DNA. The carbapenem 
molecules pass through the outer membrane-specific porin OprD and interact with their target PBPs 
(Penecillin-binding proteins), located on the outside of the cytoplasmic membrane.  
Image (B) Depicts chromosomally encoded mechanisms of resistance to fluoroquinolones and 
carbapenems. Fluoroquinolone resistance is mediated by (i) overexpression of RND efflux pumps 
extruding the drug molecules from the periplasmic and cytoplasmic spaces and/or (ii) mutational 
changes within the target genes. Locations of the QRDRs within target genes are highlighted in 
yellow. Carbapenem resistance is mediated primarily by (i) decreased production or loss of 
functional OprD in the outer membrane and/or (ii) overproduction of RND efflux pumps (with the 
exception of imipenem). Minor changes in susceptibility can be observed due to overexpression of 
AmpC, adding to the resistance potential (Lister et al., 2009) 
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Efflux Pumps 
Efflux pumps are transport proteins involved in the extrusion of toxic substrates 
from within cells into the external environment (Figure 4.5). These are known to be 
important for intrinsic resistance of P. aeruginosa to antibiotics such as some 
fluroquinolones, beta-lactams (except imipenem), tetracyclines and 
chloramphenicol antibiotics.  The active efflux systems of P. aeruginosa involve a 
number of efflux systems including MexAB-OprM, MexCD-OprJ, MexEF-OprN and 
MexXY-OprM (Webber & Piddock, 2003). 
 
 
 
 
 
 
 
Figure 4.5.  Three-component efflux pump (Livermore, 2002).  
The pump itself (MexB, MexD, or MexF, according to the system) lies in the cytoplasmic membrane 
and is attached via a linker lipoprotein (MexA, MexC, or MexE) to the exit portal (OprM, OprJ, or 
OprN). Efflux system components appear in large roman type; other membrane components appear 
in small italic type (Livermore, 2002). 
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3. Mutation of existing DNA: 
 
This refers to the change by mutation of an existing gene product or control 
mechanism.  Changes in the bacterial genome through mutation may consequently 
lead to a change in the nature of proteins expressed by the organism and this can 
result in changes in antibacterial resistance. There are many mechanisms of 
resistance through the accumulation of mutations. These are often through gene 
‘loss of function’ mutations resulting from small nucleotide polymorphisms (SNPs) 
or insertions/deletions of DNA. In P. aeruginosa, these mutations are very common 
and contribute to the high resistance in many P. aeruginosa isolates. The 
accumulation of mutations is also very common during chronic infections and 
repeated exposure to antibiotics can help to select for mutated isolates with higher 
resistance. These mutations can results in altered target sites and altered activity of 
existing mechanisms such as efflux pumps. The target site may be altered by 
mutation such that it evades the action of or no longer binds the antimicrobial 
agent (e.g. ciprofloxacin).  Mutations that result in alterations of an antibiotic's 
target can also confer resistance, for example where a mutation in DNA gyrase 
reduces the binding affinity of the enzyme for fluoroquinolones leading to 
resistance (Breidenstein et al, 2011; Gellatly et al., 2012; Schweizer, 2003).  
Mutations in bacterial DNA may change the target enzyme in a metabolic pathway 
to therefore bypass the primary target (e.g. trimethoprim) (Munita et al., 2016; Van 
Hoek et al., 2011). Bacteria may develop higher activity of efflux pumps that expel 
the antimicrobial agent before it reaches an effective concentration (e.g 
tetracyclines). Examples of these include, natural inducers, such as aminoglycosides 
and other antibiotics targeting ribosomes, a mutation in mexZ, which normally 
suppresses expression of mexXY , leads to the overexpression of the MexXY efflux 
pump (Matsuo et al, 2004). 
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4. Further Mechanisms of Resistance 
Tolerance and resistance of bacteria growing in biofilms: 
Bacteria can grow as multicellular communities called biofilms, distinct from 
planktonic growth. Biofilm-associated bacteria typically cause subacute (subacute 
being not yet chronic >3mths, but has passed the acute phase <1mth. It may also 
indicate that the condition is not as severe as the acute stage) and chronic 
infections. They are clinically significant due to their persistence despite sustained 
antimicrobial treatments and adequate host defenses. Biofilm bacteria are highly 
resistant to a wide range of antimicrobial compounds and disinfectants, and the 
mechanism underlying this resistance is multifactorial.  Biofilms can be difficult to 
eradicate when they cause biofilm-related diseases, e.g., implant infections, cystic 
fibrosis, urinary tract infections, and periodontal diseases. A number of phenotypic 
features of the biofilm can be involved in biofilm-specific tolerance and resistance. 
Little is known about the molecular mechanisms involved (Olsen, 2015). 
Antibiotic resistance typically refers to an increase in the minimum inhibitory 
concentration (MIC) value of an antibiotic due to a permanent change in the 
bacteria, e.g. mutation or resistance acquired through horizontal gene transfer. 
However, antibiotic tolerance is the ability of cells to survive the effect of an 
antibiotic due to a reversible phenotypic state.  In biofilms, antimicrobial tolerance 
is related to the mode of growth of the biofilm. This is in contrast to bacteria 
growing in planktonic culture.  A number of mechanisms have been reported to 
operate together to produce a high total biofilm tolerance or resistance (Cao et al., 
2015; Sousa & Pereira, 2014; Strateva & Mitov, 2011).  Biofilms are not regarded as 
uniform cultures of physiologically identical cells and different mechanisms can 
protect subpopulations of cells in the biofilm (O’Toole et al., 2000).  Antibiotic 
tolerance mechanisms in biofilms include failure of antibiotics to penetrate biofilms, 
slow growth rate, altered metabolism, persister cells, oxygen gradients, and 
extracellular biofilm matrix (Olsen, 2015). 
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Biofilms play an increasing role within the medical and veterinary community. Due 
to the increased resistance of a biofilm, they can complicate chronic non-healing 
wounds, implant/prosthesis infection and mastitis (Pye et al., 2013; Scaccabarozzi 
et al., 2015; Westgate et al., 2011). With maturity, biofilms may become more 
resistant to the effects of antimicrobials, which make the infection harder to treat 
(Olsen, 2015; Sousa & Pereira, 2014).  Many antibiotic therapies currently used to 
treat bacterial infections are aimed at planktonic bacterial cells as opposed to cells 
encased in a biofilm; this makes their treatment increasingly problematic. Without 
adequate diagnostic and treatment protocols to treat veterinary biofilms, their 
impact will remain a significant challenge. 
 
 
Resistance to Beta-lactam Antibiotics 
 
Beta-lactamases and Classification 
 
β-lactam antibiotics are one of the most effective and commonly used antibacterials 
with their useage approximating 60% of the global antibiotic use (Kong et al., 2010). 
The Infectious Diseases Society of America (IDSA) reported that three of the top six 
listed dangerous pathogens are β -lactam resistant bacteria (IDSA, 2017). Resistance 
to β -lactam antibiotics may be through production of β -lactamase enzymes that 
hydrolyse the β -lactam ring of the antibiotic or, changes of the penicillin binding 
proteins that maintain the peptidoglycan structure in bacterial cell wall.  Also via 
alteration of porin channels and by initiation of efflux exporter proteins (Öztürk et 
al, 2015). 
 
The most widely used classification of the β-lactamases is the Ambler classification. 
This divides β-lactamases into four classes (A, B, C and D) based upon their 
homology of amino acid sequences (Table 4.2).  Ambler class A is the active-site 
serine β-lactamases; Ambler class B, is the metallo-β-lactamases that require a 
bivalent metal ion (usually Zn 2+) for activity. Ambler class C refers to the serine β-
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lactamases that were found to have dissimilar sequence to those already identified 
as the class A enzymes. Within the designated class C, includes the ‘AmpC’ β-
lactamases. Ambler class D is a further classification of serine β-lactamases, referred 
to as the OXA β-lactamases (Bush & Jacoby, 2010; Hall & Barlow, 2005; Weldhagen 
et al., 2003). 
 
The metallo-β-lactamases, are a group of enzymes that hydrolyse β-lactams through 
an enzymatic process that is distinctly different from that of the serine β-
lactamases, and they are structurally unrelated to the serine β-lactamases.  All 
metallo-β-lactamases have been defined as class B β-lactamases. These are sub-
dived into three subgroups, B1, B2 and B3.6 (Hall & Barlow, 2005). 
 
IMP and VIM are metallo—β-lactamases that rapidly hydrolyze penicillins, 
cephalosporins, and carbapenems (not aztreonam) (Hall & Barlow, 2005). 
Resistance to penicillins and cephalosporins usually accompanies production, but 
carbapenem resistance may also require the loss of OprD. Various IMP enzymes 
have been reported in Japan, Canada, Italy, France, Greece, and South 
Korea,Taiwan (Deshpande et al., 2013; Docquier et al., 2003; Hayakawa et al., 2014; 
Jeannot et al., 2012; Tada et al., 2016).  VIM enzymes resemble IMP types with 
regard to their hydrolytic properties, they but share only 30%–40% amino acid 
identity (Livermore, 2002). 
The genes for VIM and IMP enzymes, like those for OXA-ESBLs, are often carried as 
cassettes within integrons, which are natural recombination systems that assemble 
series of acquired genes behind a single promoter.  This organization facilitates 
gene recombination. The β-lactamase genes are often adjacent to aminoglycoside 
6′-N acetyltransferase [aac(6′)-1b] determinants (Araujo et al., 2016; Galimand et al, 
1993).  A P. aeruginosa strain with this combination of cassettes is susceptible only 
to polymyxins, ciprofloxacin, and, perhaps, aztreonam. If MexAB-OprM is up-
regulated by mutation, or if the isolate has topoisomerase and ampD mutations, 
then only susceptibility to polymyxins remains (Livermore, 2002). 
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Table 4.2  Ambler Classification of beta-lactamases (Bush & Jacoby, 2010; B. G. Hall 
& Barlow, 2005). 
 
Class Active site Enzyme type 
A Serine Narrow spectrum 
A Serine Extended 
spectrum 
A Serine Carbapenemases 
B Zinc Metallo beta 
lactamases 
(carbapenemases) 
C Serine Cephalasporinases 
D Serine OXA type 
enzymes (ESBLs, 
carbapenemases) 
 
There currently exists a second classification scheme for the beta-lactamases which 
classifies the beta lactamases on their hydrolytic properties. The functional 
classification scheme is based on the 1995 proposal by Bush et al (Bush et al., 1995). 
It takes into account substrate and inhibitor profiles to group the enzymes in ways 
that can be correlated with their phenotype in clinical isolates. Major groupings 
generally correlate with the more broadly based molecular classification. The 
updated system includes group 1 (class C) cephalosporinases; group 2 (classes A and 
D) broad-spectrum, inhibitor-resistant, and extended-spectrum beta-lactamases 
and serine carbapenemases; and group 3 metallo-beta-lactamases. Several new 
subgroups of each of the major groups are described, based on specific attributes of 
individual enzymes. A list of attributes is also suggested for the description of a new 
beta-lactamase, including the requisite microbiological properties, substrate and 
inhibitor profiles, and molecular sequence data that provide an adequate 
characterization for a new beta-lactam-hydrolyzing enzyme (Bush & Jacoby, 2010). 
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Table 4.3 shows the selection of genes used in this study and their relevant 
classifications. 
Table 4.3. A selection of genes used in this study known to be associated with 
ESBLs and involved in transmissible resistance (Strateva & Yordanov, 2009) 
 
Gene Description/Function Reference 
blaTEM Ambler Class A beta lactamases  and extended spectrum beta 
lactamases 
(Bush & 
Jacoby, 2010; 
Weldhagen et 
al., 2003) 
blaSHV Ambler Class A beta lactamases  and extended spectrum beta 
lactamases 
(Bush & 
Jacoby, 2010; 
Weldhagen et 
al., 2003) 
blaOXA Ambler Class A beta lactamases  and extended spectrum beta 
lactamases 
(Bush & 
Jacoby, 2010) 
blaGES Ambler Class A extended spectrum beta lactamases (Bush & 
Jacoby, 2010; 
Weldhagen et 
al., 2003) 
blaVEB Ambler Class A extended spectrum beta lactamases (Bush & 
Jacoby, 2010; 
Weldhagen et 
al., 2003) 
blaPER Ambler Class A extended spectrum beta lactamases (Weldhagen et 
al., 2003) 
blaKPC Mechanism of carbapenemase resistance, plasmid transferable 
in Enterobacteracea 
(Chen et al, 
2012; Poirel et 
al , 2010; Xu et 
al., 2015) 
blaVIM Ambler class B (metallo beta lactamase) beta lactamases, 
plasmid transferable 
(Bush & 
Jacoby, 2010; 
Rossolini et al, 
2007) 
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blaIMP Ambler class B (metallo beta lactamase) beta lactamases, 
plasmid transferable 
Rossolini et al., 
2007 and  
Bush & Jacoby 
2010 
blaOXA-1 Extended spectrum oxacillinases from Ambler Class D (Bush & 
Jacoby, 2010) 
blaOXA-2 Extended spectrum oxacillinases from Ambler Class D (Bush & 
Jacoby, 2010) 
blaOXA-10 Extended spectrum oxacillinases from Ambler Class D (Bush & 
Jacoby, 2010) 
BEL-1 Clavulanic acid inhibited Ambler Class A specific extended beta 
lactamase, chromosome encoded, embedded in class1 integrons. 
Activity inhibited by clav acid, tazobactam, cefoxitin, 
moxobactam, imipenem. Hydrolyses most extended spectrum 
cephalosprins and aztreonam. 
(Bush & 
Jacoby, 2010; 
Weldhagen et 
al., 2003) 
CTX-M Ambler Class A , Extended spectrum beta-lactamase  (Bush & 
Jacoby, 2010; 
Weldhagen et 
al., 2003) 
Amp-C Overexpression of naturally occurring Amp C is associated wit a 
reduced susceptibility or resistance to extended spectrum 
cephalosporins such as ceftazidime. 
AmpC beta-lactamases (AmpC) are enzymes which convey 
resistance to penicillins, second and third generation 
cephalosporins and cephamycins. They also result in resistance 
to combinations of these antibiotics and substances which are 
actually intended to inhibit the effect of beta-lactamases. They 
do not convey resistance to fourth generation cephalosporins. 
The genes for these enzymes occur naturally in some bacteria 
species as so-called chromosomal AmpC (e.g. in E. coli, but not in 
Salmonella). The enzymes are only actually formed and only 
become effective under certain conditions. The important thing 
is the increasing number of AmpC genes localised outside the 
chromosome on so-called plasmids, which is why they are often 
referred to as ”plasmidic AmpC” (pAmpC). They ensure the 
constant formation of the enzyme and lie on transmissible gene 
(Rodríguez-
Martínez et 
al., 2009) 
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sections. These can be exchanged between bacteria of the same 
type or of different types (horizontal gene transfer). 
CS integrons Integrons are naturally occurring genetic elements found as part 
of the Tn21 transposon family or located on various broad host-
range plasmids. Principle importance in clinical isolates as they 
mediate resistance.  
(Bass et al., 
1999; 
Lévesque et al, 
1995) 
(Lister et al., 2009) 
 
 
Many acquired beta-lactamases have been noted in P. aeruginosa (Cuzon et al., 
2011; Godfrey & Bryan, 1984; Poole, 2005b; Sacha et al., 2008; Williams, 1991).  
Clinical P. aeruginosa isolates producing class A extended-spectrum beta-
lactamases (ESBLs) such as TEM, SHV, PER, GES, VEB, BEL and CTX-M are 
occasionally described (Weldhagen et al., 2003).  The Ambler class B enzymes 
(metallo-beta-lactamases, such as IMP – Imipenemase and VIM - Verona 
imipenemase) are also spread among clinical P. aeruginosa isolates, especially in 
Asia and Europe (Rossolini et al., 2007).  Metallo-β-lactamases (MBL) are a set of 
enzymes that catalyze the hydrolysis of a broad range of β-lactam drugs including 
carbapenems. The enzyme mechanisms differ based on whether one or two zincs 
are bound in the active site, which in turn, is dependent on the subclass of β-
lactamase. The dissemination of genes encoding these enzymes is widely reported 
in P. aeruginosa making them an important cause of resistance (Palzkill, 2014).  The 
first plasmid-mediated MBL was reported in P. aeruginosa in Japan in 1991 (Butt et 
al, 2005). Since then many reports from a number of countries have documented 
the prevalence of MBLs (Akya et al.,2015; Marra et al., 2006; Pitout et al., 2005; 
Pitout et al., 2008; Varaiya et al, 2008). 
P. aeruginosa strains producing extended-spectrum oxacillinases from the Ambler 
class D (i.e. OXA-10, OXA-2 and OXA-1 derivatives) have sporadically been described 
but knowledge of their spread in the clinical setting remains poor (Bert et al 2002; 
Farshadzadeh et al, 2014; Strateva & Yordanov, 2009). 
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Extended spectrum beta lactamases (ESBLs) 
Extended spectrum beta-lactamase (ESBLs)-producing P. aeruginosa have spread 
rapidly worldwide and pose a serious threat as a healthcare-associated infections 
(Goossens & Grabein, 2005; Marcel et al., 2008; Microbiology et al., 2004). Since the 
discovery of ESBLs in 1983, their prevalence has been reported in many regions of 
the world and now comprises over three hundred variants (Rossolini et al., 2007). 
Inactivating enzymes are prominent facilitators of resistance.  Extended-spectrum 
beta-lactamases (ESBLs) refer to enzymes that have activity against a broad 
spectrum of beta-lactam antibiotics, thus making them ineffective. Bacteria which 
produce these enzymes become resistant to important active substances such as 
aminopenicillins (e.g. ampicillin), cephalosporins (including those of the third and 
fourth generation) and monobactams (Chen et al., 2015; Shaikh et al., 2015). The 
genes for these enzymes are found on transmissible gene sections that can be 
exchanged between bacteria of the same type or of different types (horizontal gene 
transfer). ESBLs are plasmid-mediated bacterial enzymes typically found in enteric 
Gram-negative bacteria.  Plasmids encode several beta lactamases (eg TEM-1, OXA-
1, OXA-2).  This resistance can be detected in various bacteria species, in particular 
enterobacteria (eg. Salmonella, Klebsiella and E.coli).  Pathogens that produce ESBLs 
are difficult to treat and are increasingly responsible for serious healthcare-
associated infections (HAIs) (Peleg & Hooper, 2011; Santajit & Indrawattana, 2016). 
 
The prevalence of different ESBLs genotypes in Enterobacteriaceae varies in 
different countries and regions (Bradford, 2001). The PER, VEB, GES TEM, SHV and 
CTX genotypes are prevalent in Asian countries and regions. They have been 
extensively reported in members of the family Enterobacteriaceae since the early 
1980s In P. aeruginosa ESBL producers were described only more recently (Chen et 
al., 2015; Crespo et al., 2004; Empel et al., 2007; Glupczynski et al., 2010; Kouda et 
al., 2009; Laudy et al., 2017; Libisch et al., 2008; Patzer et al., 2009; Woodford et al., 
2008)  These enzymes are either of the TEM and SHV types, which are also well 
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known in the Enterobacteriaceae; with the PER type, mostly originating from 
Turkish isolates; the VEB type from Southeast Asia; and recently, the GES and IBC 
types, which have been reported in France, Greece and South Africa (Chen et al., 
2015; Tawfik et al, 2012; Woodford et al., 2008) 
 
In P. aeruginosa specifically, many acquired β-lactamases have been noted (Bert et 
al., 2002; Z. Chen et al., 2015; Crespo et al., 2004; Empel et al., 2007; Glupczynski et 
al., 2010; Kouda et al., 2009; Laudy et al., 2017; Libisch et al., 2008; Patzer et al., 
2009).  Some of these are widely prevalent among isolates from southern Europe, 
Turkey, and Southeast Asia, although they are not known to be widely prevalent in 
the United Kingdom. β-lactamases that give wider resistance are emerging in P. 
aeruginosa (Paterson & Bonomo, 2005; Shaikh et al., 2015), and include PER-1 β-
lactamase and the extended-spectrum OXA types.  PER-1, a class A β-lactamase, 
confers high-level resistance to ceftazidime, with susceptibility restored by the 
addition of clavulanate, but it has little in vitro effect on piperacillin; carbapenems 
are stable to PER-1 producers. PER-1 is frequently noted in P. aeruginosa from 
Turkey and has also occasionally been reported in Europe (Empel et al., 2007; 
Kolayli et al., 2005; Libisch et al., 2008; Llanes et al., 2006; Vahaboglu et al., 1997).  
The OXA-ESBLs, are also, mainly are reported in P. aeruginosa from Turkey.  A few 
P. aeruginosa isolates from Turkey produce PER ESBLs, often together with potent 
aminoglycoside-modifying enzymes (discussed in later section of this Chapter). 
 
Since the first description of ESBL producing Enterobacteriaceae isolated from 
hospitalized humans, many nosocomial outbreaks have been reported and 
furthermore an increase in the detection of ESBL producing strains in the 
community.  Reports have also noted the dissemination of ESBL producing E. coli in 
healthy food producing animals in several countries in Europe, and Asia, and USA in 
food products including meat (Geser et al, 2012) fish and raw milk.  There are 
reports of ESBL producing P. aeruginosa in animal related isolates.  There has been 
the emergence of livestock associated ESBL-producing P. aeruginosa in cows, 
poultry and pigs (Odumosu et al, 2016). 
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Plasmid mediated AmpC 
AmpC β-lactamases are clinically important cephalosporinases encoded on the 
chromosomes of many of the Enterobacteriaceae and a few other organisms, where 
they mediate resistance to cephalothin, cefazolin, cefoxitin, most penicillins, and β-
lactamase inhibitor-β-lactam combinations. In many bacteria, AmpC enzymes are 
inducible and can be expressed at high levels by mutation. Overexpression confers 
resistance to broad-spectrum cephalosporins including cefotaxime, ceftazidime, and 
ceftriaxone.   
P. aeruginosa can be susceptible to carboxypenicillins, ceftazidime and aztreonam; 
however, it can develop resistance to third generation cephalosporins. The most 
frequent mechanism by which this occurs is through the constitutive hyper-
production of AmpC beta-lactamase (stable derepression) (Bagge et al, 2000).  P. 
aeruginosa produces an inducible chromosome-encoded AmpC beta-lactamase 
(cephalosporinase).  Usually the enzyme is produced in low quantities (‘low-level’ 
expression) and determines resistance to aminopenicillins and most of the early 
cephalosporins (Langaee et al, 2000). However, chromosomal cephalosporinase 
production in P. aeruginosa may increase from 100 to 1000 times in the presence of 
inducing beta-lactams (especially imipenem) (Bagge et al, 2000). This resistance is 
usually mediated by derepression of chromosomal beta-lactamase, caused by the 
bla1 mutation.  However, derepression of the chromosomal ampC beta lactamase 
reduces susceptibility to penecillins and cephalosporins, the levels of resistance will 
depend upon the degree of derepression. 
 
Transmissible plasmids have acquired genes for AmpC enzymes, which 
consequently can then appear in bacteria lacking or poorly expressing a 
chromosomal blaAmpC gene.  Resistance due to plasmid-mediated AmpC enzymes 
is less common than extended-spectrum β-lactamase production in most parts of 
the world but may be both harder to detect and broader in spectrum (Jacoby, 
2009). Carbapenems can usually be used to treat infections due to AmpC-producing 
bacteria, but carbapenem resistance can arise in some organisms by mutations that 
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reduce influx (outer membrane porin loss) or enhance efflux (efflux pump 
activation) (Jacoby, 2009). 
 
Figure 4.6.  Mechanisms involved in regulation of ampC expression (Lister et al., 
2009).  
These figures represent the current knowledge obtained from studies with members of the Enterobacteriaceae and appear to 
parallel events in P. aeruginosa. (A) Wild-type basal expression of ampC. During normal cell wall recycling, 1,6-
anhydromuropeptides are removed from the cell wall and transported into the cytoplasm via the AmpG permease. The 1,6-
anhydromuropeptides are cleaved by AmpD to generate free tripeptides, which are later converted into UDP-MurNAc-
pentapeptides. UDP-MurNAc-pentapeptide interacts with AmpR bound to the ampR-ampC intergenic region, creating a 
conformation that represses transcription of ampC. Low basal levels of AmpC are produced, and the enzyme is localized to the 
periplasmic space. (B) β-Lactam induction of ampC expression. Inducing β-lactams, such as cefoxitin and imipenem, cross the 
outer membrane through porins, enter the periplasmic space, and interact with target PBPs. An increase in pools of 1,6-
anhydromuropeptides is observed, and AmpD is unable to efficiently process the higher levels of cell wall fragments. The 
anhydro-MurNAc-peptides (inducing peptides) replace UDP-MurNAc-pentapeptides (suppressing peptides) bound to AmpR, 
causing a conformational change in the protein. AmpR is converted into a transcriptional activator, ampC is expressed at 
higher levels, and levels of AmpC increase in the periplasmic space. When the amount of β-lactam decreases below “inducing 
levels,” the cytoplasmic pool of anhydro-MurNAc-peptides also decreases, and AmpD is able to efficiently cleave these 
peptides, restoring wild-type ampC expression, as shown in panel A. (C) AmpD-associated derepression of ampC expression. 
Mutations leading to the inactivation of AmpD or decreased expression of ampD impair the processing of cell wall recycled 
products and lead to increased levels of anhydro-MurNAc-peptides (inducing peptides) in the cytoplasm. As a result, the 
binding of inducing peptides to AmpR is favored, AmpR is “locked” in a conformation for transcriptional activation of ampC 
expression, and high-level constitutive expression of ampC is observed (Lister et al., 2009). 
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Polymyxins 
 
The polymyxins, colistin (polymyxin E) and polymyxin B, are cationic polypeptide 
antibiotics that disrupt the outer bacterial cell membrane by binding to the anionic 
outer membrane and thereby causing bacterial cell death. This has been reviewed 
extensively in Chapter 3. 
 
 
Resistance to Fluroquinolones 
 
Fluoroquinolones exhibit concentration-dependent bactericidal activity by inhibiting 
the activity of DNA gyrase and topoisomerase enzymes essential for bacterial DNA 
replication.  After oral and parenteral administration, fluoroquinolones are widely 
distributed in most extracellular and intracellular fluids and are concentrated in the 
prostate, lungs, and bile.  Most fluoroquinolones are metabolized in the liver and 
excreted in urine, reaching high levels in urine.  The fluoroquinolones are a group of 
antibiotics with considerable application for use in veterinary dermatology. They 
are most useful in the management of recurrent pyoderma and in chronic, deep 
pyoderma with extensive scar tissue. In addition, fluouroquinolones frequently are 
the drugs of choice for canine ear infections caused by P. aeruginosa. For many 
years the only veterinary-licensed fluoroquinolone available was enrofloxacin. The 
selection of a fluoroquinolone has now become wider with the availability of 
orbifloxacin, difloxacin,marbofloxacin and pradofloxacin. Resistance to 
fluroquinolones in P. aeruginosa, namely enrofloxacin is widely reported in 
worldwide studies in dogs/cats predominantly in cases of canine otitis, from Canada 
(Rubin et al., 2008), Denmark (Pedersen et al., 2007), USA (McKay et al., 2007),  
Japan (Harada et al, 2012) and Brazil. 
In veterinary species, fluroquinolones are frequently used in farm animal species 
and avian and ‘exotic’ species along with small animals (cats and dogs) for various 
respiratory conditions, mastitis, and skin or urinary tract infections.  However, the 
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BVA (British Veterinary Association) advocates that the use of fluoroquinolones 
(along with third and fourth generation cephalosporins and macrolides) should 
always be carefully considered. It is strongly discouraged for use in groups or flocks 
of animals except in very specific situations, and special attention should be given 
to the risk of antimicrobial resistance. Use of these antimicrobials should be 
reserved for the treatment of clinical conditions that have responded poorly, or are 
expected to respond poorly, to other classes of antimicrobials. Off label use is 
strongly discouraged (BVA, 2017). 
Quinolone resistance can be both chromosome or plasmid mediated.  Two major 
mechanisms are described in P.aeruginosa strains: active efflux pump and structural 
changes in target enzymes due to point mutations in chromosomal DNA gyrase 
(gyrA, gyrB) and topoiso- merase IV (parC and parE). Mutations in the gyrA and gyrB 
genes occur in a quinolone resistance determinant region (QRDR) near the active 
enzyme site (Hooper, 2000).  Resistance may also be plasmid-mediated (qnrA, qnrB, 
qnrS and aac(6)Ib and the cr variant) whilst  efflux systems have also been reported 
as alternate mechanisms of resistance. The acquisition of certain plasmids can lead 
to the production of enzymes that can also modify the aminoglycosides by variously 
acetylating, adenylating or phosphorylating the antibiotic molecule (Galimand et al., 
1993; Park et al., 2006; Strateva & Yordanov, 2009).  Plasmid mediated quinolone 
resistance genes have been found in a variety of Enterobacteriaceae, especially E. 
coli and species of Enterobacter, Klebsiella, and Salmonella.  They have occasionally 
been reported in P. aeruginosa, other Pseudomonas spp. (Cattoir et al., 2007; Hong 
et al., 2009; Ogbolu et al, 2011; Strahilevitz et al., 2009a).  Although most 
prevalence studies have surveyed hospital isolates, animals have not been 
neglected. Plasmid mediated quinolone resistance genes have been found in 
samples of Enterobacter from domestic or wild birds, chicken, cattle, horses, cats, 
dogs, reptiles and zoo animals (Ma et al., 2009; Mcmahon et al, 2015; Schink et al., 
2013; Schink et al, 2012; Verner-jeffreys et al., 2009; Yang et al., 2015). 
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Table 4.4. A selection of genes used in this study known to be associated with 
fluroquinolones and involved in transmissible resistance  
 
Gene Description/Function Ref  
 
aac(6')-Ib-cr 
 
 
aminoglycoside acetyltransferase enzyme capable of also 
modifying ciprofloxacin plasmid transferable 
(Galimand et 
al., 1993) 
qnrA Fluroquinolone resistance, protects DNA gyrase and 
topoisomerase IV from quinolone inhibition plasmid transferable 
(G. Jacoby et 
al., 2008; 
Strahilevitz et 
al., 2009a) 
qnrB Fluroquinolone resistance, protects DNA gyrase and 
topoisomerase IV from quinolone inhibition, plasmid transferable 
(G. Jacoby et 
al., 2008; 
Strahilevitz et 
al., 2009a) 
qnrS Fluroquinolone resistance, protect DNA gyrase and 
topoisomerase IV from quinolone inhibition, plasmid transferable 
(G. Jacoby et 
al., 2008; 
Strahilevitz et 
al., 2009a) 
(Lister et al., 2009) 
 
Resistance to Aminoglycosides 
 
Aminoglycosides are important antibacterial agents for the treatment of various 
infections in humans and animals, although they are seldom the sole treatment 
option. In veterinary medicine in the European Union (EU), aminoglycosides 
account for 3.5% of the total sales of antimicrobials (EMA, 2017).  
 
In P. aeruginosa specifically, many aminoglycoside-modifying enzymes have been 
noted.  Some of these are widely prevalent among isolates from southern Europe, 
Turkey, and Southeast Asia, although they are not known to be widely prevalent in 
the United Kingdom (Fàbrega et al., 2009; Hong et al., 2009).  As discussed 
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previously, P. aeruginosa isolates from Turkey have been shown to produce both 
PER enzymes and ESBLs, often together with potent aminoglycoside-modifying 
enzymes (Nordmann & Naas, 1994). Acquired resistance occurs through several 
mechanisms, but enzymatic inactivation of aminoglycosides is the most common 
one.  Resistance mechanisms differ between the aminoglycoside molecules and 
between bacterial species. Cross-resistance to several aminoglycosides by a single 
mechanism/plasmid CIEs does occur, but generally there is no complete cross-
resistance to all aminoglycosides by one mechanism. Mechanisms conferring 
resistance to streptomycin and spectinomycin usually differ from those of the other 
aminoglycosides (Ramirez et al., 2010). Aminoglycosides resistance has been found 
in many different bacterial species, including those with zoonotic potential 
(Garneau-tsodikova & Labby, 2016).  
Resistance genes are often located on mobile elements facilitating their spread 
between different bacterial species and between animals and humans.  The same 
resistance genes have been found in isolates from humans and animals (Ho et al., 
2010).  In human medicine, gentamicin, tobramycin and amikacin are of 
greater importance than the other aminoglycosides. Resistance to gentamicin, 
tobramycin and amikacin is generally still considered scarce in veterinary organisms 
and use of these aminoglycosides in animals is more often through local 
administration (topical eye or ear medications) or by injection. Aminoglycosides are 
important in human medicine for the treatment of MDR tuberculosis, Gram-
negative infections and enterococcal/streptococcal endocarditis and have been 
categorized by WHO as critically important for human medicine (WHO CIA, 2017). 
Aminoglycosides are, however, rarely the sole treatment option in either veterinary 
or human medicine. Veterinary-authorised aminoglycosides useage should be 
considered on the basis of (i) their importance in human medicine and (ii) the high 
potential for transmission of resistance determinants between animals and humans 
and the potential for co-selection of resistance. 
Acquired resistance to aminoglycosides can be due to the production of 
aminoglycoside-modifying enzymes encoded by horizontally acquired resistance 
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determinants, or by mutations that reduce aminoglycoside accumulation in the 
bacterial cell. The most prevalent aminoglycoside-modifying enzymes found in P. 
aeruginosa are the acetyl-transferases (AAC).  Reduced aminoglycoside uptake 
could be due to mutations causing lipopolysaccharide changes or up-regulation of 
efflux systems based on the MexX–MexY linked-pump module. Unlike resistance 
mediated by modifying enzymes, the spectrum of which can be variable depending 
on the nature of the enzyme, resistance mediated by efflux systems tends to be 
more broad spectrum (Galimand et al., 1993; Hocquet et al., 2006; Morita et al., 
2012). 
 
Table 4.5 A selection of genes used in this study known to be associated with 
aminoglycoside resistance and involved in transmissible resistance  
 
Gene Description/Function Ref  
 
aac(6′)-Ib-cr 
 
Aminoglycoside resistance, plasmid transferable (Park et al., 
2006) 
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4.2 Aims  
 
Resistance to beta-lactams, aminoglycosides and fluoroquinolones have been 
widely reported through various mechanisms in human clinical isolates and in some 
isolates of animal origin, predominantly the Enterobacteriaceae.  However, 
prevalence in isolates from companion animals particularly in P. aeruginosa is 
relatively understudied. Here, the aim was to study the resistance characteristics of 
a set of 106 P. aeruginosa isolates from companion animals, collected between 
2010- 2015, at the Veterinary Diagnostic laboratory (VDL) at Leahurst Veterinary 
Teaching Hospital (University of Liverpool, UK). 
 
More specifically, the aim of the work presented in this chapter was to: 
 
- Characterize the resistance of the isolates to beta-lactam antibiotics using disk 
diffusion, MICs and double-disc synergy testing (DDST). Isolates were also screened 
by PCR for a subset of genetic markers associated with beta-lactam resistance. 
 
-Screen the isolates to study phenotypic resistance to aminoglycosides and the 
presence of genes associated with the presence of aminoglycoside resistance 
(aac(6′)-Ib-cr). 
 
- Screening for genes (qnr A, qnr B, qnrS and aac(6′)-Ib-cr) associated with the 
presence fluroquinolone resistance. 
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4.3 Results  
 
The panel of isolates used were sourced from companion animals comprising 11 
equine, 2 feline, and 93 canine samples (refer to Chaper 2 Methods, Table 2.2). 
Samples originated from mostly ear infections, urine, wounds/non-healing wounds 
including skin, vaginal/vulval, scrotal/testicle swabs and also limited respiratory 
samples (tracheal washes, maxillary sinus, bronchoalveolar lavage) (refer to Chaper 
2 Methods, Table 2.3).  The inclusion criteria for isolates in this study were 
performed on the basis of species (ie. any isolate that was from a companion animal 
species) and bacterial species identification (all P. aeruginosa). Only a single isolate 
from each sample was included in the analysis. It was accepted that in being a 
Diagnostic Laboratory closely associated with the Small Animal Teaching Hospital, 
Leahurst and so receiving a high number of samples from the referral centers 
(equine and small animal Veterinary Teaching Hospitals) that the isolates from 
these are more likely to be associated with disease more difficult to treat (hence 
the patients being referred to a specialist center from a first opinion veterinary 
practitioner). 
 
Resistance to Beta-Lactam Antibiotics 
There was expected high occurrence of resistance to third generation cephalosporin 
ceftiofur (98.1% resistant ). The prevelance of fourth generation cephalosporin, 
cefepime (Figure 4.9) was found to be 9.4%.  Resistance to piperacillin, 
piperacillin/tazobactam, ticarcillin and ticarcillin/clavulanate were 17%, 17.9%, 9.4% 
and 5.7% respectively.  The resistance to beta-lactam antibiotics is detailed in Table 
4.6 and Table 4.7.  Of the carbapenems; meropenam resistance (Figure 4.8) was 
particularly low (3.7%) and also low for imipenam (8.5%) (Table 4.7), although 
slightly higher in aztreonam (Figure 4.7) at 11%. 
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Table 4.6 Susceptibility testing of Pseudomonas aeruginosa isolates from 
companion animal (n=106) isolates against beta-lactam antibiotics using disk 
diffusion methodology (EUCAST 2015) 
Antimicrobial Antibiotic Class Resistance 
Breakpoin
t 
S≥/<R 
(mm) 
Resistan
t Strains 
(n) 
Intermediat
e Strains  
(n) 
Sensitiv
e Strains 
(n) 
Resistant 
Strains 
(%) 
Aztreonam Monobactam 50/16 12 94 0 11.3 [6.6, 
18.8] 
Meropenem Carbapenem 24/18 4 11 91 3.7 [1.5, 
9.3] 
Cefepime 4th Generation 
Cephalosporin 
19/19 10 - 96 9.4 
[5.2,16.5] 
Piperacillin Ureidopenecilli
n (4th 
Generation B-
lactam) 
18/18 18 - 88 17.0 [1.1, 
25.3] 
Piperacillin/tazobacta
m 
Ureidopenecilli
n with B-
lactamase 
inhibitor 
18/18 19 - 87 17.9 
[11.8,26.3
] 
 
 
 
 
 
Table 4.7 Minimum inhibitory concentration tests to show antimicrobial 
resistance of P. aeruginosa in companion animal (n=106) isolates to a panel of 
beta-lactam antibiotics using the TREK COMPAN1F diagnostic plates assay. 
 
Antimicrobial       
 
Antibiotic class Breakpoint 
mg/L 
                               MIC mg/mL   
0.25     0.5     1      2      4       8     16    32     64     >64 
MIC
50 
         
MI
C90 
         
Resistant strains (%) 
  
Ceftiofur Caphalosporin 
(veterinary) 
S≤2, I=4, R≥8  1                                   1     104 8 8 98.1  [93, 99] 
Imipenem 
Ticarcacillin 
 
Ticarc/clavul 
acid 
 
Carbapenem 
Carboxypenecill
in 
Carboxypenecill
in and B-
lactamase 
inhibitor 
S≤4, I=8, R>8  
S≤64, R>64 
 
S≤64/2, R>64/2 
                      42    42   13      6      3 
                                               5      28    57     6       10 
 
 
                                               3      28     63    6        6  
2 
32 
 
32 
4 
32 
 
32 
8.5  [5, 15] 
9.4  [5, 17] 
 
5.6  [3, 12] 
Confidence intervals are 95% {Lower, Upper) Wilson method 
 
Other antibacterials (amoxicillin/clavulanic acid, ampicillin, cefazolin, cefovecin, cefoxitine, cefpodoxime, chloramphenicol, 
clindamycin, doxycycline, erythromycin, oxacillin, +2%NaCl, penicillin, rifampicin, trimethoprim sulfamethoxazole) included 
in the Trek COMPAN1F plate were also tested but are not reported due to intrinsic P.aeruginosa resistance.
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Figure 4.7 Susceptibility testing results of the P.aeruginosa isolates from companion animals (n=106) against Aztreonam 30mcg 
(DDST) (red line indicates ‘cut off’ value.  Quality control used ATCC278539. 
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Figure 4.8  Susceptibility testing results of the P.aeruginosa isolates from companion animals (n=106) against Meropenem 10mcg 
(DDST) (red line indicates ‘cut off’ value.  Quality control used ATCC278539. 
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Figure 4.9  Susceptibility testing results  of the P.aeruginosa isolates from companion animals (n=106) against Cefepime 30mcg 
(DDST) (red line indicates ‘cut off’ value. Quality control used ATCC278539. 
 
 
 
 
 
 
0
5
10
15
20
25
30
35
40
1 3 5 7 9
1
1
1
3
1
5
1
7
1
9
2
1
2
3
2
5
2
7
2
9
3
1
3
3
3
5
3
7
3
9
4
1
4
3
4
5
4
7
4
9
5
1
5
3
5
5
5
7
5
9
6
1
6
3
6
5
6
7
6
9
7
1
7
3
7
5
7
7
7
9
8
1
8
3
8
5
8
7
8
9
9
1
9
3
9
5
9
7
9
9
1
0
1
1
0
3
1
0
5
A
T
C
C
2
7
8
5
3
9
(Q
C
)
Z
o
n
e
 o
f 
In
h
ib
it
io
n
 (
m
m
)
Isolate No. 
 134 
 
Figure 4.10  Susceptibility testing results  of the P.aeruginosa isolates from companion animals (n=106) against Piperacillin 30mcg 
(DDST) (red line indicates ‘cut off’ value.  Quality control used ATCC278539. 
 
 
 
 
 
 
 
0
5
10
15
20
25
30
35
1 3 5 7 9
1
1
1
3
1
5
1
7
1
9
2
1
2
3
2
5
2
7
2
9
3
1
3
3
3
5
3
7
3
9
4
1
4
3
4
5
4
7
4
9
5
1
5
3
5
5
5
7
5
9
6
1
6
3
6
5
6
7
6
9
7
1
7
3
7
5
7
7
7
9
8
1
8
3
8
5
8
7
8
9
9
1
9
3
9
5
9
7
9
9
1
0
1
1
0
3
1
0
5
A
T
C
C
2
7
8
5
3
9
(Q
C
)
Z
o
n
e
 o
f 
In
h
ib
it
io
n
 (
m
m
)
Isolate No. 
 135 
 
 
 
 
 
 
Figure 4.11  Susceptibility testing resultsof the P.aeruginosa isolates from companion animals (n=106) against 
Piperacillin/Tazobactam 36mcg (DDST) (red line indicates ‘cut off’ value.  Quality control used ATCC278539 (labelled as isolate 107). 
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Figure 4.12   Susceptibility testing results  of the P.aeruginosa isolates from companion animals (n=106) against Ceftazidime 30mcg 
(DDST) (red line indicates ‘cut off’ value.  Quality control used ATCC278539 (labelled as isolate 107)
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ESBL phenotyping results 
 
Results are detailed for both methods in Table 4.8.  The two methods did not 
produce consistent results.  Of the 106 isolates tested 3 were positive ESBL 
producers by cloxacilliin method and 7 were positive by boronic acid method. 
(begins page p138) 
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Table 4.8. ESBL testing results performed via two methods of the 106 P. 
aeruginosa veterinary isolates 
 
Isolate ESBL 
Results 
(Cloxacillin 
method) 
ESBL 
results 
(Boronic 
acid 
method) 
Isolate ESBL 
Results 
(Cloxacillin 
method) 
ESBL 
results 
(Boronic 
acid 
method) 
Isolate ESBL 
Results 
(Cloxacillin 
method) 
ESBL 
results 
(Boronic 
acid 
method) 
1 - - 37 - - 73 - - 
2 - - 38 - - 74 + - 
3 - - 39 - - 75 - - 
4 - - 40 - - 76 - - 
5 - - 41 - - 77 - - 
6 - - 42 - - 78 - - 
7 - - 43 - + 79 - - 
8 - - 44 - + 80 - - 
9 - - 45 - + 81 - - 
10 - - 46 - + 82 - - 
11 - - 47 - - 83 - - 
12 - - 48 - - 84 - - 
13 - - 49 - - 85 - - 
14 - - 50 - - 86 - + 
15 - - 51 - - 87 - - 
16 - - 52 - - 88 - - 
17 - - 53 - - 89 - - 
18 - - 54 . - 90 - - 
19 - - 55 + - 91 - - 
20 - - 56 - - 92 - - 
21 - - 57 - - 93 - - 
22 - - 58 - - 94 - - 
23 - - 59 - - 95 - + 
24 - - 60 - - 96 - - 
25 - - 61 - - 97 - - 
26 - - 62 - - 98 - - 
27 - - 63 - - 99 - - 
28 - - 64 - - 100 + - 
29 - - 65 - - 101 - - 
30 - - 66 - - 102 - - 
31 - - 67 - - 103 - - 
32 - - 68 - - 104 - - 
33 - - 69 - - 105 - - 
34 - - 70 - - 106 - - 
35 - + 71 - -    
36 - - 72 - -    
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Tables 4.9 -4.12 show details of PCR screening results for the ESBL-associated 
resistance genes within the veterinary P. aeruginosa isoaltes for the genes blaTEM, 
blaSHV,  blaOXA; blaGES, blaVEB, blaPER; blaVIM, blaIMP, blaKPC and blaOXA-1, blaOXA-2, blaOXA-
10 respectively.  Of the 106 isolates, 11 isolates (highlighted with grey shading in 
Table 4.9) showed positive PCR product for ESBL-associated resistance gene blaTEM. 
While eight isolates identified positive for blaSHV (Table 4.9) and three isolates 
positive for blaOXA (Table 4.9).  The three isolates that were identified as positive 
resistance determinants for blaOXA (isolates 71, 72 and 73) – refer to Figure 4.12, 
were also positive for the other ESBL-associated resistance genes blaTEM and blaSHV. 
(begins page 140)
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Table 4.9. Results of the PCR screening of ESBL-associated resistance genes within 
the veterinary P. aeruginosa isolates (n=106) - shows results for the genes blaTEM, 
blaSHV, blaOXA genes. 
 
Isolate blaTEM blaSHV blaOXA Isolate blaTEM blaSHV blaOXA 
1 - - - 54 + + - 
2 - - - 55 - - - 
3 - - - 56 - - - 
4 - - - 57 - - - 
5 - - - 58 + + - 
6 - - - 59 - - - 
7 - - - 60 - - - 
8 - - - 61 - - - 
9 - - - 62 - - - 
10 - - - 63 - - - 
11 - - - 64 - - - 
12 - - - 65 - - - 
13 + - - 66 - - - 
14 - - - 67 - - - 
15 - - - 68 - - - 
16 - - - 69 - - - 
17 - - - 70 + + + 
18 - - - 71 + + + 
19 - - - 72 + + + 
20 - - - 73 - - - 
21 - - - 74 - - - 
22 - - - 75 - - - 
23 - - - 76 - - - 
24 - - - 77 - - - 
25 - - - 78 - - - 
26 - - - 79 - - - 
27 - - - 80 - - - 
28 - - - 81 - - - 
29 - - - 82 - - - 
30 - - - 83 - - - 
31 - - - 84 - - - 
32 - - - 85 + - - 
33 - - - 86 - - - 
34 - - - 87 - - - 
35 - - - 88 - - - 
36 - - - 89 - - - 
37 - - - 90 - - - 
38 - - - 91 - - - 
39 - - - 92 - - - 
40 - - - 93 - - - 
41 - - - 94 - - - 
42 + + - 95 - - - 
43 + + - 96 - - - 
44 + + - 97 - - - 
45 + - - 98 - - - 
46 - - - 99 - - - 
47 - - - 100 - - - 
48 - - - 101 - - - 
49 - - - 102 - - - 
50 - - - 103 - - - 
51 - - - 104 - - - 
52 - - - 105 - - - 
53 - - - 106 - - - 
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The Figure 4.13 shows the PCR gel results for the blaOXA genes as reported. 
 
 
Figure 4.13  Simplex PCR assay using primers to detect blaOXA gene performed on isolates 
from isolates from the VDL, Leahurst. Isolates 70, 71, 72 appear to show strong 
amplification of blaOXA-1. The DNA loading dye DNA/BsuRI (HaeIII) Marker 9, 50 mg (0.5 
μg/μl)(ThermoScientific Molecular Biology), was placed on each gel run.  
 
 
 
Table 4.10 details the results of the PCR screening of ESBL-associated resistance 
genes within the veterinary P. aeruginosa isolates for the genes blaGES, blaVEB, blaPER.  
Of the 106 isolates, five isolates (highlighted with grey shading in Table 4.10) 
showed positive PCR product for ESBL-associated resistance gene blaGES. While four 
isolates identified positive for blaPER (Table 4.10) there were no positives identified 
for blaVEB.  It is noted that although there was amplification of the multiple ESBL-
associated resistance genes as detailed here, some were feint and only weakly 
positive but are still noted above in the table. 
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Table 4.10. Results of the PCR screening of ESBL-associated resistance genes 
within veterinary P. aeruginosa isolates (n=106) – shows the detection of blaGES, 
blaVEB, blaPER genes.   
Isolate blaGES blaVEB blaPER Isolate blaGES blaVEB blaPER 
1 - - - 54 + - - 
2 - - - 55 - - - 
3 - - - 56 - - - 
4 - - - 57 - - - 
5 + - - 58 - - - 
6 - - - 59 - - - 
7 - - - 60 - - - 
8 - - + 61 - - - 
9 - - - 62 - - - 
10 - - - 63 - - - 
11 - - - 64 - - - 
12 - - - 65 - - - 
13 - - - 66 - - - 
14 - - + 67 - - - 
15 - - - 68 - - - 
16 - - - 69 - - - 
17 - - - 70 - - - 
18 - - - 71 - - - 
19 - - - 72 - - - 
20 - - - 73 - - - 
21 - - - 74 - - - 
22 - - - 75 - - - 
23 - - - 76 - - - 
24 - - - 77 - - - 
25 - - - 78 - - - 
26 - - - 79 - - - 
27 - - - 80 - - - 
28 - - - 81 - - - 
29 - - - 82 - - - 
30 - - - 83 - - - 
31 - - - 84 - - - 
32 - - + 85 - - - 
33 - - - 86 - - - 
34 - - - 87 - - - 
35 - - - 88 - - - 
36 - - - 89 - - - 
37 - - - 90 - - - 
38 - - - 91 - - - 
39 - - - 92 - - - 
40 - - - 93 - - - 
41 - - - 94 - - - 
42 - - + 95 - - - 
43 - - - 96 - - - 
44 - - - 97 - - - 
45 - - - 98 - - - 
46 - - - 99 - - - 
47 + 
+ 
- - 100 - - - 
48 - - 101 - - - 
49 - - - 102 - - - 
50 - - - 103 - - - 
51 - - - 104 - - - 
52 - - - 105 - - - 
53 + - - 106 - - - 
*Although there was amplification of the multiple ESBL-associated resistance genes, some were feint and only weakly 
positive but are still noted above in table. 
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In the table 4.11 results of the PCR screening of ESBL-associated resistance genes of 
the veterinary P. aeruginosa isolates for the blaVIM , blaIMP, blaKPC  genes are shown.  
Of the 106 isolates, 26 isolates (highlighted with grey shading in Table 4.11) showed 
positive PCR product for ESBL-associated resistance gene blaGES, while six isolates 
identified positive for blaKPC (Table 4.11).  There were no positives identified for 
blaIMP.  It is noted that although there was amplification of the multiple ESBL-
associated resistance genes as detailed here, some were feint and only weakly 
positive but are still noted above in the table.  There was also the presence of 
multiple unspcific bands produced on the gels making the resultant images difficult 
to interpret.  An example gel is depicted in Figure 4.13 and this issue is discussed 
later in this Chapter.  (Table 4.11 begins p144) 
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Table 4.11. Results of the PCR screening of ESBL-associated resistance genes of the 
veterinary panel of P. aeruginosa  isolates (n=106) - shows the genes blaVIM, blaIMP, 
blaKPC.  
Isolate blaVIM  blaIMP,  blaKPC Isolate blaVIM  blaIMP, blaKPC 
1 - - - 54 - - - 
2 - - - 55 - - - 
3 - - - 56 - - - 
4 - - - 57 - - - 
5 - - - 58 + - - 
6 + - - 59 - - - 
7 - - - 60 + - - 
8 - - - 61 - - - 
9 - - - 62 - - - 
10 - - - 63 + 
+ 
- - 
11 - - - 64 - - 
12 - - - 65 - - - 
13 - - - 66 - - - 
14 + 
+ 
+ 
- - 67 - - - 
15 - - 68 + - + 
16 - - 69 - - - 
17 - - - 70 + - + 
18 - - - 71 - - - 
19 + 
+ 
- - 72 - - - 
20 - - 73 + - - 
21 - - - 74 - - - 
22 - - - 75 - - - 
23 + - - 76 - - - 
24 - - - 77 - - - 
25 - - - 78 - - - 
26 - - - 79 - - - 
27 - - - 80 + - - 
28 - - - 81 - - - 
29 - - - 82 - - - 
30 - - - 83 - - - 
31 - - - 84 - - - 
32 - - - 85 - - - 
33 + 
+ 
- +  86 + 
+ 
- - 
34 - - 87 - - 
35 - - - 88 - - - 
36 - - - 89 + - - 
37 + 
+ 
- - 90 - - + 
+ 38 - - 91 - - 
39 - - - 92 + - - 
40 - - - 93 - - - 
41 - - - 94 + 
+ 
- - 
42 - - - 95 - + 
43 - - - 96 - - - 
44 - - - 97 - - - 
45 + - - 98 - - - 
46 - - - 99 - - - 
47 - - - 100 - - - 
48 - - - 101 - - - 
49 - - - 102 - - - 
50 - - - 103 - - - 
51 - - - 104 - - - 
52 - - - 105 - - - 
53 - - - 106 - - - 
*Although there was amplification of the multiple ESBL-associated resistance genes, some were feint and only weakly positive 
but are still noted above in table. There was also multiple banding produced on the gels making the resultant images difficult 
to interpret. 
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Table 4.12 shows details the results of the PCR screening of ESBL-associated 
resistance genes of the veterinary P. aeruginosa isolates for the genes blaOXA-1, 
blaOXA-2, blaOXA-10.  Of the 106 isolates, three isolates (highlighted with grey shading 
in Table 4.12) showed positive PCR product for ESBL-associated resistance gene 
blaOXA-2. There were no positives identified however for blaOXA-1 and blaOXA-10.   It is 
noted that although there was amplification of the multiple ESBL-associated 
resistance genes as detailed here, some were feint and only weakly positive but are 
still noted above in the table. (Table 4.12 begins page 146) 
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Table 4.12. Results of the PCR screening of ESBL-associated resistance genes 
within the larger veterinary panel of P. aeruginosa isolates (n-106) - shows the 
genes blaOXA-1, blaOXA-2, blaOXA-10.   
Isolate blaOXA-1 blaOXA-2 blaOXA-10 Isolate blaOXA-1 blaOXA-2 blaOXA-10 
1 - - - 54 - - - 
2 - - - 55 - - - 
3 - - - 56 - - - 
4 - - - 57 - - - 
5 - - - 58 - - - 
6 - - - 59 - - - 
7 - + 
+ 
- 60 - - - 
8 - - 61 - - - 
9 - - - 62 - - - 
10 - - - 63 - - - 
11 - - - 64 - - - 
12 - - - 65 - - - 
13 - - - 66 - - - 
14 - - - 67 - - - 
15 - - - 68 - - - 
16 - - - 69 - - - 
17 - - - 70 - - - 
18 - - - 71 - - - 
19 - - - 72 - - - 
20 - - - 73 - - - 
21 - - - 74 - - - 
22 - - - 75 - - - 
23 - - - 76 - - - 
24 - - - 77 - - - 
25 - - - 78 - - - 
26 - - - 79 - - - 
27 - - - 80 - - - 
28 - - - 81 - - - 
29 - - - 82 - - - 
30 - - - 83 - - - 
31 - - - 84 - - - 
32 - - - 85 - - - 
33 - - - 86 - - - 
34 - + - 87 - - - 
35 - - - 88 - - - 
36 - - - 89 - - - 
37 - - - 90 - - - 
38 - - - 91 - - - 
39 - - - 92 - - - 
40 - - - 93 - - - 
41 - - - 94 - - - 
42 - - - 95 - - - 
43 - - - 96 - - - 
44 - - - 97 - - - 
45 - - - 98 - - - 
46 - - - 99 - - - 
47 - - - 100 - - - 
48 - - - 101 - - - 
49 - - - 102 - - - 
50 - - - 103 - - - 
51 - - - 104 - - - 
52 - - - 105 - - - 
53 - - - 106 - - - 
*Although there was amplification of the multiple ESBL-associated resistance genes, some were feint and only 
weakly positive but are still noted above in table. 
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The genes BEL-1 CTX-MU, AmpC and CS Integrons are not presented as all isolates 
were PCR negative for these markers.   
 
 
Multiplex Polymerase Chain Reaction (PCR) Assays 
 
Following the initial multiplex PCR (refer to Chapter 2 for Methods and Results as 
detailed above) on all 106 isolates for the previously described genes it was 
concluded that the results of the multiplex PCR were not as clear to interpret as had 
been expected. Many multiple faint positive bands or unexplained banding were 
present in some isolates interfering with the reading of results.  The primers chosen 
were mostly previously used for Enterobacteriacea isolates by the VDL and 
experience of their use with P.aeruginosa isolates was more limited.  As there was 
insufficient time and further funding on this project for carrying out repeated PCRs 
with alternative gene primers or for performing a multitude of gradient PCRs to 
refine PCR conditions, it was decided to repeat all as simplex PCRs but for a smaller 
subset of isolates which had the potential to carry resistance genes based on their 
susceptibility phenotype. The selection of this smaller subset of 32 isolates is 
detailed below and listed in Table 4.13 (the results of these simplex PCRs on this 
subset of isolates are presented under the section of work entitled: Findings from 
Simplex Polymerase Chain Reaction (PCR) Assays).  
 
Although the initial screening of 106 isolates via multiplex PCR for the TEM, SHV and 
OXA set of genes did show some fairly clear positive/weak positive amplicons, for 
the remainder of genes screened, the results were not easily interpretable due to 
multiple non-specific banding (Figure 4.14).   
 
An example of a gel that yielded potential unconfirmed positive amplicons is shown 
in Figure 4.14. 
 
 148 
 
Figure 4.14 PCR assay using primers to detect blaVIM gene performed on isolates from VDL, 
Leahurst. Multiple isolates (86, 87, 89, 92, 94, 95) appear to show strong amplification of 
blaVIM shown with the positive control and negative controls and multiple bands. The DNA 
loading dye DNA/BsuRI (HaeIII) Marker 9, 50 mg (0.5 μg/μl)(ThermoScientific Molecular 
Biology), was placed on each gel run.  
 
 
 
This was thought to be due to multiplex PCR and so it was repeated but as simplex 
presuming that this would improve the clarity of results.  However, the resultant gel 
images on the simplex PCRs that were repeated on the same 106 isolates the results 
were generally overall difficult to interpret. The screening of all of the described 
genes were then repeated but only on the narrowed down sample size of 32 
isolates (as described earlier, along with how they were selected) and their DNA 
extraction method was improved (refer to Materials and Methods; DNA Extraction), 
due to time and cost constraints for this study this had to be limited.  Improved 
results were achieved following gradient PCRs to adjust the thermocycler conditions 
for optimisation (conditions used as detailed in Table 4.13). 
 
 
It is suggested that multiple or non specific PCR products can occur due to the 
following potential reasons  
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Table 4.13 Potential causes of non specific PCR product 
 
 
Possible causes of non 
specific product 
Possible adjustments Any method adjustments 
made after gradient PCRs 
for optimisation  
Premature replication Use a hot start polymerase, such as 
OneTaq Hot Start DNA Polymerase 
 
Set up reactions on ice using chilled 
components and add samples to 
thermocycler preheated to the 
denaturation temperature 
 
N/A 
 
 
 
Already done in method 
Primer annealing 
temperature too low 
Increase annealing temperature 
 
Annealing temperature 
increased 
 
Incorrect Mg++ 
concentration 
Adjust Mg++ in 0.2–1 mM increments 
 
N/A as within a compound 
polymerase mastermix 
solution Firepol® so Mg non 
adjustable 
Poor primer Check specific product literature for 
recommended primer design 
 
Verify that primers are non-
complementary, both internally and to 
each other 
 
Increase length of primer 
 
Avoid GC-rich 3´ ends 
 
N/A Insufficient 
time/funding to reorder 
alternative primers to trial 
Excess primer Primer concentration can range from 
0.05–1 µM in the reaction. Please see 
specific product literature for ideal 
conditions. 
Primer concentrations were 
reduced  
Contamination with 
exogenous DNA 
Use positive displacement pipettes or 
non-aerosol tips 
 
Set-up dedicated work area and pipettor 
for reaction setup 
 
Wear gloves during reaction setup 
 
All of this was already in 
place 
Template conc too high For low complexity templates (i.e. 
plasAmid, lambda, BAC DNA), use 1 pg–
10 ng of Dper 50 µl re 
 
A lower conc dna used 
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Findings from Simplex Polymerase Chain Reaction (PCR) Assays 
 
This further narrowed down subset of 32 isolates (Table 4.14) from the 106 were 
selected on the basis of the criteria of being either ESBL positive phenotypes and/or 
those that were resistant to ceftazidime (a third generation cephalosporin) plus any 
of the antibiotics; aztreonam, meropenam (carbapenems), cefepime (fourth 
generation cephalosporin), piperacillin or piperacllin/tazobactam (ESBLs).  These 
isolates underwent PCR following repeat subculture and DNA extraction using an 
alternative extraction method (as referenced in Materials and Methods section - 
Wizard® Genomic DNA Purification Kit Method). Resultant PCR products were 
electrophoresed (in 1% agarose gels containing PeqGREEN® dye). 
 
 
Table 4.14  A further narrowed down selection of isolates (n=32) from the 106 
that were used for the characterisation study. 
 
Isolate  Source 
4 
6 
22 
28 
33 
42 
43 
44 
45 
46 
47 
48 
52 
53 
54 
55 
63 
64 
69 
70 
74 
72 
81 
82 
Abdominal fluid 
Vulval swab 
Wound swab 
Right ear swab 
Right ear swab 
Wound 
Right ear swab 
Tracheal 
Left ear 
Right ear swab 
Tissue 
Right ear swab 
Urine 
Urine catheter 
Right ear swab 
PEG tube Stoma wound 
Wound 
Right anal sac swab 
Right ear swab 
Wound serous discharge and fat tissue 
Right and Left BAL 
Tissue 
Tissue 
Vulval fluid swab 
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84 
86 
87 
88 
93 
95 
99 
100 
 
Skin  
Right ear swab 
Ear swab 
Right ear swab 
Urine 
Ear swab 
Ear swab 
Vaginal swab 
 
 
Of the positive amplicons obtained for each resistant determinant presented in the 
Tables 4.9-4.12) only a small selection were subsequently sequenced due to time 
and cost constraints (sequenced amplicons and sequencing results are listed in 
Table 4.15) 
 
Table 4.15. Selected isolates and results of the simplex PCR sequenced isolates of 
ESBL-associated resistance genes from veterinary panel of P. aeruginosa  
Isolate sent for 
sequencing 
Positive amplicon Results of sequencing 
13 TEM Confirmed as 
TEM1/TEM 188/ 
71 TEM Confirmed as TEM1 
54 SHV Confirmed as SHV 12 
58 SHV Confirmed as SHV 
1/11/148/149/150/33 
70 OXA Confirmed as OXA 1 - 
100% 
42 PER Non specific 
amplification 
6 VIM Non specific 
amplification 
80 VIM Non specific 
amplification 
33 KPC Non specific 
amplification 
70 KPC Non specific 
amplification 
91 KPC Non specific 
amplification 
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The ESBL-associated resistance genes which generated a weak amplicon were not 
included for sequencing.   
The table below (Table 4.16) summarises the findings of isolates within the smaller 
subset selected that were confirmed PCR positive and sequenced along with the 
results of phenotypic antibacterial resistance testing for these isolates. 
Table 4.16. Summary of the isolates and resistance genes confirmed by simplex 
PCR and sequencing for selected veterinary P. aeruginosa isolates associated with 
ESBL resistance (n=32)  
Gene Simplex PCR 
positive 
isolates  
Isolates confirmed by 
sequencing  
Results of additional 
phenotypic 
antibacterial resistance 
to testing 
blaTEM 6 isolates 
 
(43, 44, 45, 54, 55, 
93)  
Isolate 71 (canine urine) 
=blaTEM-1,  
 
 
 
 
Isolate 13 (canine ear 
swab)=blaTEM1/188 
71 =  Intermediate 
Resistance to aztreonam. 
Intermediate Resistant to 
enrofloxacin. 
* 
 
13= Intermediate Resistance 
to aztreonam. 
Intermediate Resistance to 
enrofloxacin. 
* 
 
Susceptible to others. 
 
blaSHV 4 isolates 
 
(43, 44, 54, 55) 
Isolate 58 (canine tissue 
swab) = SHV 
1/148/149/150/33 
 
 
 
Isolate 54 (canine ear swab) 
=SHV 12 
Intermediate Resistant to 
aztreonam. 
Intermediate Resistant to 
enrofloxacin. 
* 
 
Resistant to aztreonam, 
cefepime, piperacillin, 
pip/taz. 
Intermediate Resistant to 
Meropenam. 
Intermediate Resistant to 
Gentamicin. 
Resistant to enrofloxacin and 
Marbofloxacin. 
* 
 
blaOXA 3 isolates 
 
(70, 71, 72) 
Isolate 70 (canine wound 
serous discharge and fat 
tissue) = OXA-1 
Intermediate Resistant to 
aztreonam. 
Resistant to cefepime, 
piperacillin, pip/taz. 
Intermediate Resistant to 
enrofloxacin. 
* 
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Resistance to aminoglycoside antibiotics 
In order to determine the resistance to aminoglycosides, MICs to two clinically used 
aminoglycoside antibiotics; amikacin and gentamicin were performed.  From the 
panel of 106 isolates, seven were found to be resistant to amikacin with an MIC of 
≥16 mcg/ml. Nine isolates displayed intermediate resistance and 90 were found to 
be susceptible. Of the seven amikacin resistant isolates, six were of canine origin 
with one from equine origin. Of the 11 gentamicin resistant isolates, 10 were from 
canine infections and one from equine (Table 4.17 and Table 4.18). 
 
 
 
MIC resistance levels for amikacin and gentamicin were found to be at similar 
levels, at 6.6% and 10.4% respectively (Table 4.17).  
 
 
Table 4.17. Minimum inhibitory concentration testing of P. aeruginosa from  
companion animal (n=106) isolates to aminogycosides  
 
Antimicrobial       
 
Breakpoint 
mcg/L 
                               MIC mcg/mL   
0.25     0.5     1      2      4       8     16    32     64     >64 
MIC50 
         
MIC90 
         
Resistant strains (%) 
  
Amikacin S≤4, I=8, R≥16                                     90       9      6                          1 4 4 6.6  [3, 13] 
Gentamicin S≤2, I=4, R≥8 
 
                     25    54   16       6      5 
  
2 
 
 
4 
 
10.4  [0.176, 0.059] 
 
 
Confidence intervals are 95% {Lower, Upper) Wilson method 
Other antibacterials (amoxicillin/clavulanic acid, ampicillin, cefazolin, cefovecin, cefoxtine, cefpodoxime, chloramphenicol, 
clindamycin, doxycycline, erythromycin, oxacillin, +2%NaCl, penicillin, rifampicin, trimethoprim sulfamethoxazole) included 
in the Trek COMPAN1F plate were also tested but are not reported due to intrinsic P.aeruginosa resistance. 
 
 
There were seven isolates that were resistant to amikacin and 11 were resistant to 
gentamicin. One of these isolates (isolate 43, from canine ear swab) was confirmed 
by sequencing as carrying the qnrB resistance gene (Table 4.22).  Of the seven 
amikacin resistant isolates six were similarly resistant to gentamicin.  These 
consisted of five isolates from canine infections and one from an equine sample.  
 154 
The majority were sourced from ear swabs (10), with remainder being from wound 
swab (1) and from tissue swab (1) (Table 4.18). 
 
 
Table 4.18. Clinical veterinary bacterial isolates from companion animals resistant 
to both aminoglycosides, amikacin and gentamicin 
Isolate Ref 
number 
   Description                                                                      Species                                
16 
43 
48 
49 
72 
75 
86 
87 
89 
94 
95 
105 
  
Left ear swab Canine 
Right ear swab Canine 
Right ear swab Canine 
Right ear swab Canine 
Tissue Canine 
Left ear swab Canine 
Right ear swab Canine 
Ear swab Canine 
Ear swab Canine 
Midline swab Equine 
Ear swab Canine 
Right Ear Swab Canine 
 
 
 
Resistance to Fluoroquinolones 
 
In order to determine the resistance to fluoroquinolones, MICs to two widely used 
fluroquinolone antibiotics; enrofloxacin and marbofloxacin were performed.  From 
the panel of 106 isolates, 38 were found to be resistant to enrofloxacin with an MIC 
of 4 mcg/ml. 55 isolates displayed intermediate resistance and 13 were found to be 
susceptible. Of the 38 enrofloxacin resistant isolates, all were of canine origin.  For 
marbofloxacin 29 were found to be resistant with a MIC of 4mcg/ml.  21 isolates 
displayed intermediate resistance and 55 were found to be susceptible.  Of the 29 
resistant isolates, all were of canine origin (Table 4.19). 
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Table 4.19. Minimum inhibitory concentration tests to show antimicrobial 
resistance of P. aeruginosa in companion animal (n=106) isolates to fluroquinolone 
veterinary antimicrobials 
 
Antimicrobial       
 
Breakpoint 
mg/L 
                               MIC mg/mL   
0.25     0.5     1      2      4       8     16    32     64     >64 
MIC50 
         
MIC90 
         
Resistant strains (%) 
  
Enrofloxacin S<1, I ≥1 ≤2, 
R>4 
  3        10     43    12    38                                   0.5 4  35.8 [27.4, 45.3] 
Marbofloxacin 
 
S<1, I ≥1 ≤2, 
R>4 
 
 16       39    14      7     29    
  
1 
 
 
4 
 
27.4 [19.8, 36.5] 
 
 
Confidence intervals are 95% {Lower, Upper) Wilson method 
Other antibacterials (amoxicillin/clavulanic acid, ampicillin, cefazolin, cefovecin, cefoxtine, cefpodoxime, chloramphenicol, 
clindamycin, doxycycline, erythromycin, oxacillin, +2%NaCl, penicillin, rifampicin, trimethoprim sulfamethoxazole) included 
in the Trek COMPAN1F plate were also tested but are not reported due to intrinsic P.aeruginosa resistance. 
 
 
 
MIC resistance levels for enrofloxacin were notably slightly higher at a level of 
35.8% compared to 27.3% in marbofloxacin.  There were 38 isolates that were 
resistant to enrofloxacin and 29 were resistant to marbofloxacin.  All 29 isolates 
that were resistant to marbofloxacin were also resistant to enrofloxacin.  These 
were isolates all of canine origin and the majority were sourced from ear swabs 
(17), with remainder being from wound swabs (3), from tissue swabs (2), from 
vulva/vaginal swab (2), from other skin sites (neck/lip folds) (2), from urine (1) and 
abdominal fluid (1) (Table 4.20). 
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Table 4.20.  Clinical veterinary bacterial isolates from companion animals resistant 
to both fluroquinolones, enrofloxacin and marbofloxacin. 
Isolate Ref 
number 
   Description                                                                      Species                                
3 
4 
14 
18 
26 
28 
32 
33 
34 
35 
42 
43 
45 
46 
52 
54 
56 
63 
68 
72 
85 
86 
87 
89 
95 
97 
99 
104 
105 
  
Skin swab Canine 
Abdominal fluid Canine 
Right ear swab Canine 
Left ear swab Canine 
Neck swab Canine 
Right ear swab Canine 
Vaginal swab Canine 
Right ear swab Canine 
Lip fold Canine 
Right ear swab Canine 
Wound Canine 
Right ear swab Canine 
Left ear swab Canine 
Right ear swab Canine 
Urine Canine 
Right ear swab Canine 
Left ear swab Canine 
Wound swab Canine 
Tissue Canine 
Tissue Canine 
Left ear swab Canine 
Right ear swab Canine 
Ear swab Canine 
Ear swab Canine 
Ear swab Canine 
Vulval swab Canine 
Ear swab Canine 
Wound swab Canine 
Right Ear Swab Canine 
 
 
 
In order to determine whether the resistance phenotypes observed via MIC assays 
were associated with the presence of fluroquinolone resistance determinants, PCR 
for the genes qnrA, qnrB, qnrS and aac 6’lb-cr were performed.  Six isolates showed 
positive amplifications for resistance determinants qnrA (one – isolate 57) and qnrB 
(five – isolates 42, 43, 44, 57, 70, 72) – refer to Figures 4.14 and 4.15.  Of these 
isolates three (isolates 42, 43, 72) were resistant to both fluroquinolones 
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enrofloxacin and marbofloxacin, one (isolate 57) was resistant to just enrofloxacin 
alone and two demonstrated intermediate resistance to enrofloxacin (but were 
susceptible to marbofloxacin). 16 isolates showed positive amplicons for resistance 
determinants qnrS (Figure 4.21) and seven positive to aac(6′)-Ib -cr (Figure 4.22). 
However, of these amplicons several were feint and considered only weakly 
potential positives (detailed in Table 4.21).  (begins on p158) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 158 
Table 4.21 Results of the PCR screening of fluroquinolone-associated resistance 
genes within the larger veterinary panel of P. aeruginosa 
Isolate qnrA qnrB qnrS aac(6’)-lb-
cr 
Isolate qnrA qnrB qnrS aac(6′)-Ib 
-cr 
1 - - - - 54 + - - - 
2 - - - - 55 - - + - 
3 - - - - 56 - - - - 
4 - - - - 57 + - - - 
5 - - - - 58 - - + - 
6 - - - - 59 - - - - 
7 - - - - 60 - - + - 
8 - - - - 61 - - - - 
9 - - + - 62 - - - - 
10 - - - - 63 - - + - 
11 - - + - 64 - - - - 
12 - - - - 65 - - - - 
13 - - - - 66 - - - - 
14 - - - - 67 - - - - 
15 - - - - 68 - - - - 
16 - - - - 69 - - - - 
17 - - + - 70 - + - + 
+ 
+ 
18 - - - - 71 - - - 
19 - - - - 72 - + - 
20 - - - - 73 - - - - 
21 - - - - 74 - - + - 
22 - - - - 75 - - - - 
23 - - - - 76 - - - - 
24 - - + - 77 - - - - 
25 - - - - 78 - - - - 
26 - - - - 79 - - + - 
27 - - - - 80 - - - - 
28 - - - - 81 - - - + 
29 - - + 
+ 
- 82 - - - - 
30 - - - 83 - - - - 
31 - - - - 84 - - - - 
32 - - - - 85 - - - - 
33 - - - - 86 - - - - 
34 - - - - 87 - - - - 
35 - - - - 88 - - - - 
36 - - - - 89 - - - - 
37 - - - + 90 - - - - 
38 - - - - 91 - - + - 
39 - - - - 92 - - - - 
40 - - + - 93 - - - - 
41 - - - - 94 - - - - 
42 - + 
+ 
+ 
- + 
+ 
+ 
95 - - - - 
43 - - 96 - - - - 
44 - - 97 - - - - 
45 - - - - 98 - - - - 
46 - - - - 99 - - + - 
47 - - - - 100 - - - - 
48 - - - - 101 - - - - 
49 - - - - 102 - - + - 
50 - - - - 103 - - - - 
51 - - - - 104 - - - - 
52 - - + - 105 - - - - 
53 - - - - 106 - - - - 
*Although there was amplification of the multiple fluroquinolone-associated resistance genes, some were feint and only 
weakly positive but are still noted above in table. 
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The figures below depict some of the PCR gel results for the qnrA gene, qnrB, qnrS, 
aac(6′)-Ib-cr genes as reported. 
 
(a) 
 
 
(b) 
 
Figure 4.15  Simplex PCR assay using primers to detect qnrA gene performed on isolates 
from VDL, Leahurst. An isolate (54) appears to show strong amplification of qnrA shown on 
the first gel image (a), the second gel image (b) shows the positive control with positive 
result. The DNA loading dye DNA/BsuRI (HaeIII) Marker 9, 50 mg (0.5 
μg/μl)(ThermoScientific Molecular Biology), was placed on each gel run.  
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Figure 4.16  Simplex PCR assay using primers to detect qnrB gene performed on isolates 
from VDL, Leahurst. Here isolates 42,43 and 44 appear to show strong amplification.  The 
PCR products were electrophoresed in 1% agarose gels containing PeqGREEN® dye (VWR 
International Ltd, Leicestershire, England). The DNA fragments were imaged with UV 
transilluminator and UViProMW software documentation system.  The DNA loading dye 
DNA/BsuRI (HaeIII) Marker 9, 50 mg (0.5 μg/μl)(ThermoScientific Molecular Biology), was 
placed on each gel run.  
 
 
 
 
 
Figure 4.17   Simplex PCR assay using primers to detect qnrS gene performed on isolates 
from VDL, Leahurst. An isolate (99) appears to show strong amplification of qnrS shown on 
the gel image.  The DNA loading dye DNA/BsuRI (HaeIII) Marker 9, 50 mg (0.5 
μg/μl)(ThermoScientific Molecular Biology), was placed on each gel run.  
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(a) 
 
(b) 
 
(c) 
 
Figure 4.18  Simplex PCR assay using primers to detect aac(6′)-Ib -cr gene performed on 
isolates from VDL, Leahurst. Three isolates (70, 71, 72) appear to show strong amplification 
of aac(6′)-Ib -cr shown on the first gel image (a), the second gel image (b) shows the 
positive control, the third gel image (c) shows 3 isolates (42, 43,44 showing strong 
amplification of the aac(6′)-Ib -cr gene – the positive control is also identified. The DNA 
loading dye DNA/BsuRI (HaeIII) Marker 9, 50 mg (0.5 μg/μl)(ThermoScientific Molecular 
Biology), was placed on each gel run.  
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To verify the sequence identity a small selection (due to time and cost limitations) 
of the amplified bands were sent for sequencing for each fluroquinolone-associated 
resistance determinant, these are detailed in  (Table 4.22) along with the result of 
sequencing.   
 
Table 4.22  Selected isolates and results of the PCR sequenced isolates of 
fluroquinolone-associated resistance genes from veterinary panel of P. aeruginosa  
Isolate sent for 
sequencing 
Positive amplicon Results of 
sequencing 
54 qnr A Confirmed as qnrA1 
43 qnrB Confirmd as qnrB2 
70 qnrB Non specific 
amplification 
99 qnrS Didn’t reproduce a 
strong positive 
amplicon therefore 
not sent 
72 aac -6’lb-cr Confirmed as  
acetyltransferase 
AAC(6')-Ib-cr 
(aac(6')-Ib-cr) 
*However this 
result was excluded 
because the initial 
Simplex PCR 
showed positive 
amplicon but the 
subsequent simplex 
PCR on the smaller 
selection of isolates 
did not produce 
positive PCR.   
81 aac -6’lb -cr Non specific 
amplification 
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Detailed in Table 4.23 are the molecular and phenotypic characteristics of the 
specific isolates with fluroquinolone associated resistance determinants as 
confirmed via sequencing along with the number of positive amplicons identified on 
PCR from the smaller subset (n 32) of veterinary P.aeruginosa isolates. 
 
 
Table 4.23. Summary of the confirmed PCR positive and sequenced isolates 
associated with fluroquinolone resistance within the smaller (n 32) subset of 
P.aeruginosa veterinary isolates combined with the phenotypic characteristics 
 
 Gene Number of 
positive PCR 
isolates  
Sequencing 
confirmed positive 
isolates 
Results of additional 
phenotypic 
antibacterial 
resistance to testing 
 
qnrA 2 isolates 
 
(54 and 55) 
Isolate 54 (canine ear 
swab) = qnrA1 
Intermediate Resistant to 
aztreonam. 
Resistant to cefepime, 
piperacillin, pip/taz. 
Intermediate Resistant to 
enrofloxacin. 
* 
qnrB 2 isolates 
 
(43 and 44) 
Isolate 43 (canine ear 
swab) = qnrB 
Intermediate Resistant to 
aztreonam. 
Intermediate Resistant to 
Gentamicin. 
Resistant to enrofloxacin 
and marbofloxacin.  
 
aac(6')-Ib-cr 7 isolates 
 
(4 stronger 
positive 
amplicons 43, 44, 
45,100 and 3 
weakly positive 
amplicons 42, 48, 
54) 
Isolate 72 (canine tissue 
swab) – aac 6’lb -cr 
Resistant to aztreonam. 
Resistant to ticarcallin and 
ticacillin/clavulanate 
Resistant to enrofloxacin 
and marbofloxacin, 
Resistant to gentamicin. 
* 
* Other antibacterials (amoxicillin/clavulanic acid, ampicillin, cefazolin, cefovecin, cefoxtine, cefpodoxime, chloramphenicol, 
clindamycin, doxycycline, erythromycin, oxacillin, +2%NaCl, penicillin, rifampicin, trimethoprim sulfamethoxazole) included in 
the Trek COMPAN1F plate were also tested but are not reported due to intrinsic P.aeruginosa resistance. 
(Nikaido 1994) 
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Multidrug resistance (MDR) in isolates from companion animals. 
 
The PCR amplicons confirmed by DNA sequencing to encode for the screened 
genes, originated from 8 different Pseudomonas isolates, with 5 of these isolates 
harbouring more than one of the investigated resistance genes.   
 
Isolates 43 (canine ear swab) and 44 (canine tracheal swab) were found to carry the 
blaTEM, blaSHV and qnrB genes.  Isolate 45 (canine ear swab) was found to carry both 
the blaTEM and blaOXA genes.  Isolate 54 (canine ear swab) and 55 (canine PEG tube 
stoma wound) was found to carry the blaTEM, blaSHV and qnrA genes.  Isolate 93 
(canine urine) was found to carry just the blaTEM gene and isolates 84 (canine skin 
swab) and 99 (canine ear swab) were both found to carry only the blaOXA gene. 
 
Isolate 71 (canine urine sample) was found to be carrying TEM-1 gene with 
intermediate resistance to aztreonam and enrofloxacin.  Isolate 13 (canine ear 
swab) was found to be carrying TEM-1/188 gene and similarly with intermediate 
resistance to aztreonam and enrofloxacin. Isolate 58 (canine tissue sample) was 
found to be carrying SHV-1/148/149/150/33 gene also with intermediate resistance 
to aztreonam and enrofloxacin.  Isolate 70 (canine wound sample) was found to be 
carrying OXA-1 gene with resistance to cefepime, piperacillin and 
pipercillin/tazobactam, along with intermediate resistance to aztreonam and 
enrofloxacin.  One particularly interesting isolate was isolate 54, from a canine ear 
swabs and showing multidrug resistance characteristics.  Isolate 54 was found to be 
carrying SHV-12 gene and qnrA1 with resistance to aztreonam, enrofloxacin, to both 
piperacillin and piperacillin/tazobactam and also to the 4th generation 
cephalosporin cefepime, as such making it multidrug resistant (MDR).  It also 
demonstrated intermediate resistance to meropenam and gentamicin.  Isolate 43 
(canine ear swab) was found to harbour qnrB gene with resistance to enrofloxacin 
and marbofloxacin. It also demonstrated intermediate resistance to aztreonam and 
gentamicin. 
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Isolate 72 (canine tissue swab) was found to be carrying the aac(6′)-Ib -cr variant 
resistant determinant by sequencing and was resistant to aztreonam, ticarcacillin, 
ticacillin/clavulanate, enrofloxacin, marbofloxacin and gentamicin and therefore 
was multidrug resistant.  However, although this sequencing result is reported (in 
Table 4.22) there was disparity in the PCR results for the isolate.  Isolate 72 showed 
a positive band on the PCR in the original simplex PCR (Table 4.21) but was then 
negative in repeated simplex PCR for the smaller subset of isolates.  As such this 
isolate is being considered as negative for this gene in this isolate.  There is the 
potential possibility contamination may have resulted in misleading results in this 
case. 
 
 
4.4 Discussion  
 
The true extent and importance of AMR in companion animals is not entirely 
understood and limited surveillance contributes to this (P. H. Jones et al., 2014; 
Radford et al., 2011; Scott Weese, 2008).  As discussed previously in Chapter 1, 
potential for interspecies human-animal transmission exists. Studies have 
demonstrated that AMR is problematic in a number of important pathogens and 
commensals, such as Staphylococci, Enterococci, E. coli and Salmonella, although in 
P. aeruginosa this appears less well reported in animals as compared to humans. 
Much of the literature has focussed on AMR in food producing animals. This area 
may be a reservoir and source of AMR genes that could be transmitted to the 
human population (Arnold et al., 2016; Weese, 2008).  Studies have shown that 
antimicrobial use in food animals contributes to the selection of antimicrobial 
resistance and poses risks to humans due to transmission of resistant zoonotic 
bacteria via the food chain and indirect transfer of resistance genes from animals to 
humans (Aarestrup et al., 1998; Smith et al., 2002; Tang et al,. 2017; van Den 
Bogaard & Stobberingh, 2000).   
 
Companion animals are another potential reservoir source for AMR to develop and 
is less well studied.  The pet population is ever growing (PFMA, 2017) and in 2017 it 
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is estimated that 12m (44%) of households have pets giving a pet population of 
around 54 million.  24% of households owning dogs and 17% of households owning 
cats (PFMA, 2017).  Several reports have highlighted the presence of resistance 
genes in both farm (Timofte et al., 2014) and companion animals (Schmidt et al., 
2015; Timofte et al., 2011) including equines (Ahmed et al., 2012; Maddox et al., 
2011). Cats and dogs in particular, represent a potential source of spread of 
antimicrobial resistance due to the extensive use of antimicrobial agents in these 
animals and their close contact with humans.  There are several studies looking at 
AMR in companion animals (mainly in that of dogs and horses), predominantly 
involving E.coli (Schmidt et al., 2015; Wedley et al., 2011).  However, fewer studies 
of AMR and P. aeruginosa isolates exist.  
 
A number of antimicrobial classes are frequently used in small animal veterinary 
medicine including penicillins, cephalosporins, macrolides, lincosamides, fusidic 
acid, tetracyclines, chloramphenicol, potentiated sulphonamides, aminoglycosides 
and fluoroquinolones. The most frequent causes of antimicrobial treatment in dogs 
and cats are skin and wound infections, otitis externa, respiratory infections, and 
urinary tract infections (UTI) (Radford et al., 2011; Singleton et al., 2017). 
 
Due to the presence of several drug efflux systems and porins, P. aeruginosa is 
intrinsically resistant to a wide range of antimicrobials. The results here confirmed 
the intrinsic resistance to antibacterials amoxicillin/clavulanic acid, ampicillin, 
cefazolin, cefovecin, cefoxitine, cefpodoxime, chloramphenicol, clindamycin, 
doxycycline, erythromycin, oxacillin, +2%NaCl, penicillin, rifampicin, trimethoprim 
sulfamethoxazole (these were included in the Trek COMPAN1F plate and were also 
tested but results not reported). 
There was high occurrence of resistance to the third generation cephalosporin 
ceftiofur (98.1% resistant).  Although the prevelance of resistance to fourth 
generation cephalosporin, cefepime was found to be 9.4%.  Beta-latam resistance 
to piperacillin, piperacillin/tazobactam, ticarcillin and ticacillin/clavulanate were 
17%, 17.9%, 9.6% and 5.6% respectively.  Of the carbapenems; meropenam 
resistance was particularly low (3.7%) and also low for imipenem (8.5%), although 
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slightly higher in aztreonam (11%).  Resistance to aminoglycosides was low (6.6% 
for amikacin and 10.4% for gentamicin).   
 
The fluoroquinolones are some of the most commonly prescribed effective 
antimicrobials against P. aeruginosa infections, in recent years bacterial resistance 
to fluroquinolones has been promoted with overuse of these antibacterials (Jacoby, 
2005) and as such, the monitoring of antimicrobial susceptibility is important for 
selecting effective antimicrobial agents in the treatment of this disease. 
Quinolones enter bacteria through porins or directly through the lipid and 
cytoplasmic membrane and target DNA topoisomerases (Jacoby et al., 2008)  
achieving their bactericidal effects through the inhibition of DNA gyrase and 
topoisomerase IV.  There are three plasmid-mediated quinolone resistance 
determinants discussed in the literature.  The qnr genes (qnrA, qnrB, qnrS), aac(6′)-
Ib -cr, and qepA. Qnr proteins are known to be a part of the pentapeptide repeat 
family and protect DNA gyrase and topoisomerase IV from quinolone inhibition (Ma 
et al., 2009).  The aac(6′)-Ib-cr is a variant of aac(6′)-Ib. AAC (6')-Ib is an enzyme that 
causes aminoglycoside resistance through acetylation, and a variant of this enzyme, 
aac (6')-Ib-cr, is deemed responsible for plasmid-mediated quinolone resistance 
(Ma et al., 2009). 
Studies have largely shown that resistance to the fluroquinolones is mainly due to: 
(i) the point mutations in the DNA gyrase (gyrA and gyrB) and topoisomerase IV 
(parC and parE) genes, (ii) the presence of transferable plasmid-mediated quinolone 
resistance (PMQR) determinants, and (iii) mutations in genes regulating the 
expression of efflux pumps and decreased expression of outer membrane porins (D. 
Lin et al., 2012).  Plasmid-associated resistance to fluroquinolones can be mediated 
by the production of qnr proteins, which preserve DNA gyrase and topoisomerase 
IV from inhibition by quinolones (Strahilevitz et al., 2009a). The fluoroquinolones 
are approved for indications such as respiratory tract, urinary tract infections and 
soft tissue infections and in dogs and cats along with colibacillosis in poultry 
(chickens and turkeys). Fluoroquinolone use is licenced for conditions such as 
canine otitis externa and in rabbits, small mammals and reptiles for alimentary and 
respiratory tract infections. The fluroquinolones are also licensed for veterinary use 
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in treatment of acute mastitis and respiratory infections in bovines and neonatal E. 
coli gastroenteritis in calves. Other indications for which the fluoroquinolones have 
been used in animal health include deep-seated infections, prostatitis, and other 
bacterial infections resistant to standard antimicrobial therapy (Brown, 1996).  In 
this study, P. aeruginosa isolates showed 36% resistance to enrofloxacin and 27% to 
marbofloxacin.  With increasing utilization of fluoroquinolones in both human and 
veterinary medicine, emerging resistance has become a significant concern (Cattoir 
et al., 2007; Hong et al., 2009; Strahilevitz et al., 2009a; Sumrall et al, 2014). 
 
A study of a University Hospital in North eastern Poland looked at a relatively small 
number of P.aeruginosa human isolates (from 2002-2009) and reported 20% (5/25) 
isolates had detectable qnrB by PCR (Michalska et al., 2014).  The same study did 
also identify aac(6′)-Ib in 28% (7/25) of isolates. Compared to none found in the 
results of this work. Among Enterobacteriaceae screened for production of plasmid-
mediated fluoroquinolone resistance determinants, qnrB was reported as the most 
prevalent gene (Kim et al 2009).  However there is not a similar longitudinal study 
to date to compare prevalence in P.aeruginosa or in veterinary isolates (for 
comparison to human isolates).  However, plasmid mediated quinolone resisatnce 
(PMQR) genes (qnrA, qnrB, qnrS, qnrD and qepA) have been reported in veterinary 
clinical isolates in China (Yang et al., 2015; Zhao et al., 2010). The qnrA1 and qnrB 
determinants identified in P. aeruginosa isolates of this study are novel findings in 
UK in companion animal isolates.  Plasmid mediated quinolone resistance (PMQR) 
determinants have been demonstrated among a variety of animal sources in the 
Enterobactereaceae bacteria.  A number of studies have reported presence of the 
qnr genes in faeces from healthy animals or clinical isolates, including in chicken 
faeces from poultry production systems, cattle faeces, pig farms, other food 
production animals and companion animals (Ajayi et al, 2012; Huang et al., 2009; 
Kuo et al., 2009; Ma et al., 2009) and appears to be distributed throughout the 
world.  Fluroquinolone resistance genes qnrA and qnrB are reported in P. putida in 
isolates from imported shrimp (Tran et al, 2011) and in P. fluoroscens although none 
currently reported in animal P. aeruginosa isolates.  Cayci et al (Cayci et al., 2014), 
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performed screening for plasmid mediated quinolone resistance genes in P. 
aeruginosa clinical (human) isolates, although no qnr genes were identified. 
The qnrB1 has been reported present in an ESBL producing E.coli isolates from 
Tunisia and in E.coli isolates from human and poultry origin in Ecuador based study 
(Armas-Freire et al., 2015). In a study of AMR resistance risk factors in E.coli in 
healthy Labrador retrievers (Schmidt et al., 2015) the qnr genes were not detected 
in the sample set investigated in that study. 
Bacterial resistance to fluroquinolones results from mutations in the quinolone 
resistance determining regions of the drug targets, over expression of efflux pumps 
and/or the more recently identified plasmid mediated low level resistance 
mechanism (Cayci, Y.T 2014; Strahilevitz et al., 2009a). 
 
In this study, whilst qnr determinants where confirmed, the aac(6′)-Ib-cr 
determinants were not.  The qnr and aac(6′)-Ib-cr determinants are widely reported 
in human clinical isolates of Enterobacteriaceae with a worldwide distribution (Hong 
et al., 2009; Ma et al., 2009; Park et al., 2006; Robicsek et al., 2006; Rodríguez-
Martínez et al., 2011; Sumrall et al., 2014; Xiao et al., 2012).  There is suggestion of 
transferability of resistant bacteria or mobile resistance determinants between 
animals and humans potentially via the food chain or direct contact (Fey et al., 
2000; Manian, 2003).  The quinolones are an antibacterial with widespread use in 
livestock veterinary care and in treatment of companion animals in some countries, 
including the UK. However, few reports on the occurrence of plasmid-mediated 
quinolone resistant (PMQR) determinants among bacteria from companion animals 
and food-producing animals have been published.  Quinolones and β-lactams are 
among the most commonly used antimicrobials in both human and veterinary 
clinical medicine.  
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4.5 Conclusions  
 
The findings in this work have identified several resistance genes including those 
relating to ESBLs production (blaTEM, blaSHV and blaOXA) and those relating to 
fluroquinolone resistance (qnr).  In particular, the identification of qnrA and qnrB 
genes in P.aeruginosa isolates of companion animal origin is a novel finding with no 
known reports to current date in the UK.  Whilst reports demonstate their 
prevelance worldwide and in Enterobacteriaceae, reports on P aeruginosa of 
companion animal origin remain non reported in literature.  It would be 
advantageous to have further time and funds on this study to be able to expand 
upon the study sample size and also investigate the transmissibility of these 
identified genes through conjugation studies and to further define the mechanisms 
of resistance.  In addition, genotyping of the resistant isolates to determine their 
relative distribution within the wider P.aeruginosa population would be beneficial. 
 
This study further confirms the likelihood that companion animals are an 
understudied source of antimicrobial resistant P. aeruginosa isolates and merit 
sustained surveillance of the veterinary niche as a potential reservoir for resistant, 
clinically-relevant bacteria. 
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Chapter 5: General Discussion and Future Studies 
 
Antimicrobial resistance is a multifactorial and complex issue affecting healthcare 
worldwide. It is an escalating concern as a developing public health crisis and 
European and International bodies have highlighted AMR as a global public health 
issue of imperative importance.  The World Health Organisation (WHO), the 
European Centre Disease Prevention and Control (ECDPC) and Infectious Diseases 
Society of America (IDSA) have included within their concerns and priorities, 
emerging antimicrobial resistance mechanisms, surveillance and antibiotic 
stewardship, applicable to both the veterinary and medical communities. 
AMR is not only a concern in human health but also animal health.  The close 
interface between people, pets, food production animals and the environment 
exemplifies the importance that these two areas of health should not be considered 
as entirely independent factions, particularly in relation to AMR.  Adopting a ‘one-
health’ approach in combatting this global problem is of great importance in 
understanding and potentially controlling the advances of resistance among the 
microbial population.   
 
P. aeruginosa is one of the so-named ESKAPE pathogens by the IDSA and is 
categorized by the CDC as a serious level of threat (CDC, 2013).  It was also named 
recently by the WHO as in the top three bacteria for which there is an urgent need 
for new antibiotics for therapy (WHO, Feb 2017).  The WHO specified in particular 
carbapenem resistant P. aeruginosa in the WHO priority pathogens list for R&D of 
new antibiotics as Priority 1 - Critical (WHO 2017; Important & Priority, 2017). 
Increased resistance has resulted in limited therapeutic options.  ESKAPE pathogens 
are highlighted as being of ever-growing relevance to antimicrobial chemotherapy 
in future years (Boucher et al., 2009; Santajit & Indrawattana, 2016).  P. aeruginosa 
is a formidable pathogen due to its innate resistant making it naturally insensitive to 
many classes of antimicrobials, alongside its ability to acquire further resistance 
mechanisms (Henrichfreise et al., 2007; Lambert, 2002).  In addition to these 
factors, it is known to form and survive in biofilms and is ubiquitous and 
opportunistic nature. 
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This thesis reports the levels of antibacterial resistance in a panel of P. aeruginosa 
isolates from companion animals including a high number of resistant isolates from 
canine ear infections.  It was shown that resistance to polymyxins (a class of 
antimicrobials of particular importance in the management of P. aeruginosa lung 
infections in patients with CF), particularly polymyxin B was significantly higher in 
the panel of P. aeruginosa isolates taken from companion animals as compared to 
that of a human panel.  This study highlighted the importance of sustained 
surveillance of the veterinary niche as source of antibacterial resistance.   
 
Whole genome sequencing of a selection of polymyxin B resistant isolates from 
animal sources was performed.  These were found to be a unique and an interesting 
source of genomic data.  The sequencing revealed some of these resistant isolates 
to be incredibly diverse.  Notably isolate 856 (sample from an equine abdominal 
incision) was diverse from the main population and was located on a distinct arm of 
the phylogenetic tree (refer to Chapter 3, Figure 3.6). This genome had 125303 
SNPs and 1884 indels compared to PAO1 and 130312 SNPs and 1985 indels in 
comparison to PA14 (refer to Chapter 3, Figure 3.8).  This was double the number of 
SNPs and indels than any other isolate sequenced. 
 
An abundance of P. aeruginosa genome sequencing data information already exists, 
compiled predominantly from human isolates and environmental sources.  P. 
aeruginosa isolates derived from animal infections are currently under-represented 
and this study highlights the importance of including such isolates. Increased 
sequencing and analysis of veterinary-associated P. aeruginosa isolates may add 
important additional data to the P. aeruginosa pan genome and population level 
analyses. Using the Clondiag Tube Array, a commercially available strain typing 
system, it was demonstrated that strain types identified from these companion 
animals had also been associated with human infections and therefore there may 
be a potential for transmission of infection through close contact. Indeed, there 
have been case studies reporting this between human and  animal (Deora et al, 
2013; Ferreira et al., 2011; Mohan et al., 2008b; Register et al., 2012; Wannet et al, 
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2005) however this area is understudied and therefore the true risk is unknown.  By 
characterising and WGS a sample set of veterinary isolates in future studies it would 
be potentially possible to offer novel findings in this area contributing to knowledge 
of the P. aeruginosa population diversity in an understudied, under represented 
field and potentially identifying it as a reservoir of antimicrobial resistance. 
 
The results from this study suggest that a larger study is warranted. In such a study, 
samples could be obtained on a random basis from a commercial UK veterinary 
reference diagnostic laboratory (for example Idexx Veterinary Diagnostic 
Laboratories – a commercial laboratory utilised by many veterinary practices) and 
would therefore be from a variety of UK geographic areas, different species and 
sites of origin. Characterisation through genomics and phenoptypic studies 
(including virulence factor production, biofilm formation and antimicrobial 
susceptibility testing) would provide a wealth of information which could both 
contribute to knowledge of P. aeruginosa population biology as well as providing a 
full characterisation of the features of isolates capable of causing infections in 
particular species of animals. This information could contribute to appropriate 
therapeutic choices and veterinary management of animals therefore ultimately 
providing a rationale and basis for treatment for veterinary practitioners.   
 
It is acknowledged that there are limitations in the interpreting the results of this 
thesis.  For instance, whilst the results of Chapter 3 showed the polymyxin 
resistance to be higher in the veterinary clinical isolates as compared to the human 
isolates and this was statistically significant (p < 0.05 – refer to Chapter 3 Results) 
however these results being from a relatively small sample set may not necessarily 
extrapolate to the wider population.  It is also acknowledged that the two sample 
sets used (animal versus human) were not of equal size.  In further studies it would 
be advantageous to acquire additional ‘background’ information such as that of the 
clinical history from the cases isolates were sampled from.  This may help to better 
understand and postulate mechanisms of resistance development in the isolates.  In 
this work, the samples were those sent in from a referral university 
practice/external veterinary practices directly to a Diagnostic Laboratory for 
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Microbiological assessment and then stored there, hence no clinical history would 
be available.  To know if any of the patients from which the isolates originated had 
been previously treated with antibiotics would add value to understanding the full 
significance of the levels of antibiotic resistance reported from this work.  To collate 
this prior clinical history in future study would be of benefit.  
Limitations of the methods used, in particular that of the multiplex versus simplex 
pcr where identified during the study.  However, it is understood that part of these 
issues may have been due to using some primers that were designed for use in 
Enterobactereaccea and thermocycler protocols published for these, it is 
acknowledged that to carry out prior optimisation PCRs to refine the conditions and 
to have Pseudomonas specific designed primers for the regions being targeted 
would have been an improvement that may have overcome these issues 
encountered.  Further improvements would have been to use WGS to identify 
resistance detrminants, if funding would allow.   
Whilst the larger sample set of 106 (Results reported in Chapter 4) is a statistically 
better sample size, ultimately there was a reduced sample size of 32 used for 
refining the results.  These were chosen on basis of being ‘interesting’ isolates from 
the initial screening ie they had identified some resistance in specific antibitics or 
ESBL positive, however it is understood some bias would result in doing this.  It is 
also noted that the inconsistencies of utilising human clinical breakpoints ion 
isolates of animla origin would not be ideal.  However, some antibiotics especially 
those not routinely used in veterinary medicine do not have established veterinary 
breakpoints to use.  VetCAST (a subcommittee of EUCAST) has been formed in 2015 
and provides some guidance on this area of using available breakpoints. 
 
Other findings as a result of the work performed within this thesis, has identified 
several resistance genes including those relating to ESBLs production (blaTEM, 
blaSHV and blaOXA) and those relating to fluroquinolone resistance (qnr) from P. 
aeruginosa isolates of veterinary origin.  In particular the identification of qnrA and 
qnrB genes in P.aeruginosa isolates of companion animal origin is a novel finding 
with no known reports to current date in the UK.  Whilst reports demonstate their 
prevelance worldwide and in Enterobacteriaceae, reports in P. aeruginosa of 
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companion animal origin remain non reported in literature, to the best of my 
knowledge.  These findings would suggest that further exploration of isolates of 
animal origin could provide sources of resistant bacteria. That may have 
implications as a niche reservoir of resistant bacteria to provide a source of cross-
resistance to human bacteria and also have implications in animal welfare and 
disease treatment as well as human health.   In addition further genotyping of 
resistant animal isolates may provide novel information regarding their relative 
distribution within the wider P.aeruginosa population. 
 
There are studies in the literature, for example that by Haenni et al., (Haenni et al., 
2015), looking at population structure and antimicrobial susceptibility of P. 
aeruginosa from animal infections in France. They found resistance phenotypes 
were much more frequent in dogs (as compared to cows and horses), and multidrug 
resistant P. aeruginosa appeared to emerge mainly in those suffering from otitis. 
However, they noted such multidrug phenotypes are comparatively rare in other 
animal species.  It would be of interest to further expand this study to include a 
greater number of P.aeruginosa isolates from a greater variety of animal species. 
 
P. aeruginosa in the veterinary setting is a clinically relevant pathogen and a known 
to be associated with disease. In companion animals, P. aeruginosa can cause 
pyoderma, chronic otitis, ulcerative keratitis, wound infections, respiratory tract 
infections and urinary tract infections in a number of species.  A number of other 
diseases involving P. aeruginosa in animals are known, including that of equine 
metritis and in chronic equine wounds where the ability of P. aeruginosa to form 
and survive within protective biofilms has been reported (Percival et al., 2015; 
Westgate et al., 2011).  Canine chronic otitis is a common presentation in small 
animal veterinary medicine and a challenging infection to treat.  Much is already 
known regarding P. aeruginosa in human disease, in particular that of cystic fibrosis 
(CF).  From the extensive research carried out in the area of CF whereby these 
patients suffer from long-term chronic lung infections caused by P. aeruginosa.  It is 
known that these are complicated and difficult to treat with routine antimicrobials.  
This is, in part, attributed to the complex behaviour of P. aeruginosa in chronic 
 176 
infections.  During these chronic infections the bacteria diversify, leading to 
populations with mixed levels of resistance or susceptibility to drugs. Further 
complicated by the ability of P. aeruginosa to form complex biofilm communities 
and coexist with many other bacterial species. The use of some antimicrobials may 
even drive diversification and increased resistance to drugs. It is unknown if these 
diverse populations occur in chronic infection of other species. Therefore, it would 
be insightful to study the population biology and dynamics in chronic P. aeruginosa 
infections of the canine ear by analysis of ear swab samples taken during therapy.  
This could improve current knowledge of microbial population dynamics within 
microbial communities in such infections and may inform diagnostic practice such 
as testing “sweeps” of P. aeruginosa from a samples rather than a single isolate 
when testing for antimicrobial susceptibility.  By studying populations of P. 
aeruginosa from animal infections it would be possible to assess the impact of 
treatment strategies, fluctuations in the bacterial population biology and diversity, 
and potential drivers of antimicrobial resistance.  Cross resistance of antimicrobial 
classes and transmission of resistant isolates between human and animal P. 
aeruginosa are major issues and therefore merit continued study. 
 
Little is known about P. aeruginosa carriage in seemingly healthy companion 
animals and their owners. Suggested future avenues of study would be to 
determine the levels of P. aeruginosa carriage in the human owners/contact animal 
handlers of companion animals, particularly those canine patients with otitis. This 
would allow the study of potential cross transmission routes between species.  A US 
study by Ferreira et al (Ferreira et al., 2011) looked at Methicillin-resistant 
Staphylococcus aureus (MRSA) transmission between companion animals and 
infected human patients presenting to outpatient medical care facilities. MRSA was 
isolated from at least one companion animal in 4/49 (8.2%) households of MRSA-
infected outpatients compared to none of the pets of the 50 uninfected human 
controls. Using PFGE, patient-pets MRSA isolates were identical for three pairs and 
discordant for one pair. The results of this study suggest that companion animals of 
MRSA-infected patients can be culture-positive for MRSA, thus representing a 
potential source of infection or re-infection for humans. However, there is the 
 177 
possibility that both parts became infected from different sources and direction of 
transmission also cannot be determined.  Weese et al (Weese et al., 2006) studied 
the transmission of MRSA in veterinary clinics and in the households, after the 
identification of a MRSA positive animal. The authors described six cases. MRSA was 
isolated from 16% (14/88) of household contacts or veterinary personnel and in all 
of the 6 cases it was possible to find at least one human isolate identical to the 
animal (initial) one (Weese et al., 2006). Faires et al (Faires et al, 2009) evaluated 
both the rate of MRSA transmission from infected animals to humans and vice-
versa. When the MRSA-infected animal was initially identified, at least one MRSA-
colonized person was identified in over one-quarter (6/22; 27.3%) of the study 
households. By contrast, only one of the 8 (12.5%) study households of MRSA-
infected humans contained an MRSA-colonised pet (Faires et al, 2009).  The high 
prevalence of concurrent MRSA colonization as well as identification of 
indistinguishable strains in humans and pet dogs and cats in the same household 
suggested that interspecies transmission of MRSA is possible. Longitudinal studies 
are required to identify factors associated with interspecies transmission.  Similar 
studies for investigation of such occurrence and factors involved for P.aeruginosa 
would be similarly useful. 
 
The close nature of contact of animals and humans in both the home and working 
environments can allow for an opportunity of transmission of infection from human 
to animal and vice versa.  This is an area where relatively few studies exist (Deora et 
al, 2013; Ferreira et al., 2011; Mohan et al., 2008b; Register et al., 2012; Wannet et 
al, 2005).  There is potential to expand this study by collating samples from 
owners/handlers in contact with the corresponding pets for which canine chronic 
ear swab samples are collected from a Small Animal Teaching Hospital could 
provide a further interesting body of work.  Potential results from such data could 
help to identify risk factors and interventions with the aim of improving the health 
of both humans and animals. 
 
Antimicrobials are highly valuable in the prevention and treatment of infectious 
diseases in dogs and cats, and the occurrence of antimicrobial resistance threatens 
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their efficacy and utility.  Overuse of antimicrobials is an important contributor to 
the occurrence of antimicrobial resistance.  Few studies describing antimicrobial 
use in small animal practice have been published, in particular the off license use of 
antimicrobials. From the available evidence, antimicrobial use is common in small 
animal practice, although the overall quantity prescribed to small animals is often 
much smaller than in humans or food animal species (DANMAP 2015).  In one 
veterinary teaching hospital, the rate of antimicrobial prescriptions ranged from 
168 to 235 prescriptions per 1,000 admissions to the hospital (Weese et al., 2006).  
There is no specific recording scheme of the usage of antimicrobials for veterinary 
use per country but the European Medicines Agency reports (EMA, 2016) sales of 
antimicrobial agents in 29 European countries. Several epidemiological studies in 
dogs have demonstrated that prior antimicrobial exposure was associated with 
antimicrobial resistance in a number of bacterial species including E. coli isolates 
from faeces (Murphy et al., 2009; Ogeer-Gyles et al., 2006; Schmidt et al., 2015; 
Wedley et al., 2011) and opportunistic pathogens.  Antimicrobial use needs to be 
appropriate and prudent, considering factors such as when to use antimicrobials, 
length of therapy and antimicrobial selection. Several veterinary professional 
organizations have published guidelines on the prudent use of antimicrobials 
(BSAVA 2017a).  The PROTECT message developed out of an initiative of Small 
Animal Medicine Society (SAMSoc) to review and promote responsible antibacterial 
prescribing. This led to the PROTECT poster (BSAVA 2016b), produced by BSAVAs 
(British Small Animal Veterinary Association) and SAMSoc.  A 2017 study (Singleton 
et al., 2017) describes antimicrobial agent prescription patterns over a 2 year period 
in small animal veterinary practices involved in a real time surveillance network 
scheme.  The importance of guidelines or policies promoting responsible antibiotic 
use was identified as being important in guiding practitioner prescribing (Singleton 
et al., 2017).   
 
There are documented areas within prescribing for small animal veterinary practice 
that antimicrobial use by veterinary surgeons could be improved (Coyne et al., 
2016; Hughes et al., 2012; Mateus et al, 2014). These include eliminating the 
common use of antimicrobials in elective, routine neutering procedures (eg. 
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ovariohysterectomy, castration) and reducing antimicrobial use in other clean 
surgical procedures However, a study by Pratesi et al (Pratesi et al, 2015) looked at 
the efficacy of postoperative antimicrobial use for clean orthopedic implant surgery 
in dogs (a prospective randomized study in 100 consecutive cases) and showed that 
overall postoperative infection rate was 12.9%. Infection occurred in 2 cases (4.3%) 
administered postoperative oral antimicrobials and in 10 cases (21.3%) not 
administered postoperative antimicrobials.  Use of postoperative antimicrobials 
was associated with a significant reduction in the risk of infection by 84% and risk of 
infection was increased by 2% for each minute increase in anesthesia time. The 
authors of the study concluded that administration of oral postoperative 
antimicrobials had a protective effect.  The BSAVA provides guidance in the use of 
prophylaxis use of antibiotics and selection based on classification of wounds and 
surgical wounds (BSAVA, 2017). Antimicrobial use could likely be reduced for 
diseases such as feline lower urinary tract disease (FLUTD), feline upper respiratory 
tract disease (URT) and canine infectious tracheobronchitis.  These are three 
particular conditions fairly commonly presented in veterinary first opinion practice 
and, although in some instances may involve primary or secondary bacterial 
pathogens, they are typically not primarily bacterial in origin. Traditional empirical 
practice in the afore mentioned conditions has frequently been to ‘cover’ these 
presentations with antibiotics.   
 
Certain regulatory bodies already offer advice and protocols/prescribing pipeline for 
antimicrobial use in veterinary practice, notably the BVA (BVA 2017) and the 
BSAVA.  The BSAVA provides guidelines to practicing veterinary surgeons (BSAVA 
2017).  PROTECT encourages a practice policy for empirical prescribing (whilst 
awaiting cultures) that can optimize therapy, and minimize inappropriate use of 
antibacterials.  There are very strong arguments that antibaterials with restricted 
use in human medicine (eg. imipenem, vancomycin) should not be used in animals.  
These include amikacin, 3rd and 4th generation cephalosporins (except cefovecin) 
and fluroquinolones.  These antibacterials should only be used when other agents 
are inappropriate and or ineffective and culture and sensitivity testing indicates that 
they will be effective.  Following the veterinary prescribing Cascade is advocated.  
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Using antimicrobials only when appropriate is important, as is antimicrobial 
selection and application.  A better understanding of the links between antibiotic 
resistance in animals and humans and its transmission and relevant selection 
pressures and drivers would also help guide the use of antibiotics within the 
veterinary industry. 
 
Overall it is apparent that resistance of many antibacterials and limited new 
therapeutic options create a challenge in therapeutics of conditions in both humans 
and animals.  The potential for animals as a reservoir for the development of these 
resistance antimicrobial genes has been eluded to earlier in this discussion but 
there is also the capability and potential for rapid spread of these resistance genes 
within this niche reservoir and furthermore the significant potential for 
transmissibility including between humans and animals.  Antimicrobial resistance in 
animal P. aeruginosa should be closely monitored in the future, in line with possible 
animal-to-human transfers between pets and owners. Among other conditions this 
may be especially important for patients with cystic fibrosis, which often results 
from unique P. aeruginosa strains acquired in the environment of the patient.  
Animal welfare is of prime importance and whilst we need to preserve the 
availability of antibiotics for treating animal infections, this needs to be done 
responsibly to ensure that we do not promote further antimicrobial resistance.  
 
In summary the findings of this work suggest that P. aeruginosa veterinary isolates 
maybe an understudied reservoir of antibacterial resistance.  The identification of 
some novel findings using these two sets veterinary isolates studied in this body of 
work demonstrate this.  Whilst the study using the larger sample set has not been 
exhaustive in its methods and further work (as discussed earlier in Chapter 3.2) 
could have expanded upon these findings if time constraints had not limited this.  A 
further conclusion from this thesis has been that that any results should be verified 
via multiple methods for clarity and confirmation purposes.  In that whilst PCR 
technique was used as a screening tool for identification of resistance determinants 
present or absent in the sample sets, whole genome sequencing on all positive 
amplicons (detailed in Results Chapter 4) would have been the’gold standard’ 
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approach.  As WGS becomes more widely available and affordable, it is hoped that 
further funding will be secured in order to continue this work. 
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